U.S. patent application number 10/718328 was filed with the patent office on 2004-07-01 for heterocyclic glycyl beta-alanine derivatives.
This patent application is currently assigned to G. D. Searle & Co.. Invention is credited to Chandrakumar, Nizal Samuel, Desai, Bipinchandra Nanubhai, Devadas, Balekudru, Gasiecki, Alan Frank, Huff, Renee, Khanna, Ish K., Malecha, James W., Miyashiro, Julie M., Rao, Shashidhar N., Rico, Joseph Gerace, Rogers, Thomas Edward, Ruminski, Peter Gerrard, Russell, Mark Andrew, Yu, Yi.
Application Number | 20040127477 10/718328 |
Document ID | / |
Family ID | 30772408 |
Filed Date | 2004-07-01 |
United States Patent
Application |
20040127477 |
Kind Code |
A1 |
Chandrakumar, Nizal Samuel ;
et al. |
July 1, 2004 |
Heterocyclic glycyl beta-alanine derivatives
Abstract
The present invention relates to a class of compounds
represented by the Formula I 1 or a pharmaceutically acceptable
salts thereof, pharmaceutical compositions containing such
compounds and methods of treating conditions mediated by the
.alpha..sub.V.beta..sub.3 integrin.
Inventors: |
Chandrakumar, Nizal Samuel;
(Vernon Hills, IL) ; Desai, Bipinchandra Nanubhai;
(Vernon Hills, IL) ; Devadas, Balekudru;
(Chesterfield, MO) ; Gasiecki, Alan Frank; (Vernon
Hills, IL) ; Huff, Renee; (Park Ridge, IL) ;
Khanna, Ish K.; (Vernon Hills, IL) ; Malecha, James
W.; (Libertyville, IL) ; Miyashiro, Julie M.;
(Skokie, IL) ; Rao, Shashidhar N.; (Mundelein,
IL) ; Rico, Joseph Gerace; (Ballwin, MO) ;
Rogers, Thomas Edward; (Ballwin, MO) ; Ruminski,
Peter Gerrard; (Dardenne Prairie, MO) ; Russell, Mark
Andrew; (Gurnee, IL) ; Yu, Yi; (Skokie,
IL) |
Correspondence
Address: |
Pharmacia Corporation
Global Patent Department
P. O. Box 1027
St. Louis
MO
63006
US
|
Assignee: |
G. D. Searle & Co.
Chicago
IL
|
Family ID: |
30772408 |
Appl. No.: |
10/718328 |
Filed: |
November 20, 2003 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10718328 |
Nov 20, 2003 |
|
|
|
09289140 |
Apr 8, 1999 |
|
|
|
6689754 |
|
|
|
|
60081394 |
Apr 10, 1998 |
|
|
|
Current U.S.
Class: |
514/183 ;
514/217.11; 514/227.5; 514/237.5; 514/255.01; 514/317; 514/370;
514/374; 514/377; 514/398; 514/423; 544/162; 544/382; 544/59;
546/306; 548/190; 548/230; 548/531 |
Current CPC
Class: |
A61K 38/00 20130101;
C07D 417/12 20130101; C07D 401/12 20130101; C07D 409/12 20130101;
C07K 5/0202 20130101; C07D 403/12 20130101; C07D 491/10 20130101;
C07D 213/82 20130101 |
Class at
Publication: |
514/183 ;
514/217.11; 514/227.5; 514/237.5; 514/255.01; 514/317; 514/370;
514/374; 514/377; 514/398; 514/423; 544/059; 544/162; 544/382;
546/306; 548/190; 548/230; 548/531 |
International
Class: |
A61K 031/54; A61K
031/537; A61K 031/495; A61K 031/44; A61K 031/426; A61K 031/421;
A61K 031/401 |
Claims
What is claimed is:
1. A compound of the formula 222or a pharmaceutically acceptable
salt thereof, wherein 223is a 5-8 membered monocyclic heterocyclic
ring, optionally, unsaturated, containing 1 to 4 heteroatoms,
selected from the group consisting of O, N or S; wherein X.sup.1 is
selected from the group consisting of CH, CH.sub.2, N, NH, O and S;
A is 224 wherein Y.sup.1 is selected from the group consisting of
N--R.sup.2, O, and S; R.sup.2 is selected from the group consisting
of H; alkyl; aryl; hydroxy; alkoxy; cyano; nitro; amino; alkenyl;
alkynyl; amido; alkylcarbonyl; arylcarbonyl; alkoxycarbonyl;
aryloxycarbonyl; haloalkylcarbonyl; haloalkoxycarbonyl;
alkylthiocarbonyl; arylthiocarbonyl; acyloxymethoxycarbonyl; alkyl
optionally substituted with one or more substituent selected from
lower alkyl, halogen, hydroxyl, haloalkyl, cyano, nitro, carboxyl,
amino, alkoxy, aryl or aryl optionally substituted with one or more
halogen, haloalkyl, lower alkyl, alkoxy, cyano, alkylsulfonyl,
alkylthio, nitro, carboxyl, amino, hydroxyl, sulfonic acid,
sulfonamide, aryl, fused aryl, monocyclic heterocycles, or fused
monocyclic heterocycles; aryl optionally substituted with one or
more substituent selected from halogen, haloalkyl, hydroxy, lower
alkyl, alkoxy, methylenedioxy, ethylenedioxy, cyano, nitro,
alkylthio, alkylsulfonyl, sulfonic acid, sulfonamide, carboxyl
derivatives, amino, aryl, fused aryl, monocyclic heterocycles and
fused monocyclic heterocycle; monocyclic heterocycles; and
monocyclic heterocycles optionally substituted with one or more
substituent selected from halogen, haloalkyl, lower alkyl, alkoxy,
amino, nitro, hydroxy, carboxyl derivatives, cyano, alkylthio,
alkylsulfonyl, sulfonic acid, sulfonamide, aryl or fused aryl; or
R.sup.2 taken together with R.sup.7 forms a 4-12 membered
dinitrogen containing heterocycle optionally substituted with one
or more substituent selected from the group consisting of lower
alkyl, thioalkyl, alkylamino, hydroxy, keto, alkoxy, halo, phenyl,
amino, carboxyl/carboxyl ester, spirodioxolane, and fused phenyl;
or R.sup.2 taken together with R.sup.7 forms a 4-12 membered
heterocycle, optionally unsaturated, containing one or more
heteroatom selected from O, N and S; or R.sup.2 taken together with
R.sup.7 forms a 5-9 membered heteroaromatic ring optionally
substituted with one or more substituent selected from lower alkyl,
phenyl, alkoxy and hydroxy; or R.sup.2 taken together with R.sup.7
forms a 5 membered heteroaromatic ring fused with a aryl or
heteroaryl ring; R.sup.7 (when not taken together with R.sup.2) and
R.sup.8 are independently selected from the group consisting of H;
alkyl; alkenyl; alkynyl; aralkyl; amino; alkylamino; hydroxy;
alkoxy; arylamino; amido, alkylcarbonyl, arylcarbonyl;
alkoxycarbonyl; aryloxy; aryloxycarbonyl; haloalkylcarbonyl;
haloalkoxycarbonyl; alkylthiocarbonyl; arylthiocarbonyl;
acyloxymethoxycarbonyl; cycloalkyl; bicycloalkyl; aryl; acyl;
benzoyl; alkyl optionally substituted with one or more substituent
selected from lower alkyl, halogen, hydroxy, haloalkyl, cyano,
nitro, carboxyl derivatives, amino, alkoxy, thio, alkylthio,
sulfonyl, aryl, aralkyl, aryl optionally substituted with one or
more substituent selected from halogen, haloalkyl, lower alkyl,
alkoxy, methylenedioxy, ethylenedioxy, alkylthio, haloalkylthio,
thio, hydroxy, cyano, nitro, carboxyl derivatives, aryloxy, amido,
acylamino, amino, alkylamino, dialkylamino, trifluoroalkoxy,
trifluoromethyl, sulfonyl, alkylsulfonyl, haloalkylsulfonyl,
sulfonic acid, sulfonamide, aryl, fused aryl, monocyclic
heterocycles, fused monocyclic heterocycles; aryl optionally
substituted with one or more substituent selected from halogen,
haloalkyl, lower alkyl, alkoxy, methylenedioxy, ethylenedioxy,
alkylthio, haloalkylthio, thio, hydroxy, cyano, nitro, carboxyl
derivatives, aryloxy, amido, acylamino, amino, alkylamino,
dialkylamino, trifluoroalkoxy, trifluoromethylsulfonyl,
alkylsulfonyl, sulfonic acid, sulfonamide, aryl, fused aryl,
monocyclic heterocycles, or fused monocyclic heterocycles;
monocyclic heterocycles; monocyclic heterocycles optionally
substituted with one or more substituent selected from halogen,
haloalkyl, lower alkyl, alkoxy, aryloxy, amino, nitro, hydroxy,
carboxyl derivatives, cyano, alkylthio, alkylsulfonyl, aryl, fused
aryl; monocyclic and bicyclic heterocyclicalkyls;
--SO.sub.2R.sup.10 wherein R.sup.10 is selected from the group
consisting of alkyl, aryl and monocyclic heterocycles, all
optionally substituted with one or more substituent selected from
the group consisting of halogen, haloalkyl, alkyl, alkoxy, cyano,
nitro, amino, acylamino, trifluoroalkyl, amido, alkylaminosulfonyl,
alkylsulfonyl, alkylsulfonylamino, alkylamino, dialkylamino,
trifluoromethylthio, trifluoroalkoxy, trifluoromethylsulfonyl,
aryl, aryloxy, thio, alkylthio, and monocyclic heterocycles; and
225 wherein R.sup.10 is defined above; or NR.sup.7 and R.sup.8
taken together form a 4-12 membered mononitrogen containing
monocyclic or bicyclic ring optionally substituted with one or more
substituent selected from lower alkyl, carboxyl derivatives, aryl
or hydroxy and wherein said ring optionally contains a heteroatom
selected from the group consisting of O, N and S; R.sup.5 is
selected from the group consisting of H, alkyl, alkenyl, alkynyl,
benzyl, and phenethyl; or A is 226 wherein Y.sup.2 is selected from
the group consisting of alkyl; cycloalkyl; bicycloalkyl; aryl;
monocyclic heterocycles; alkyl optionally substituted with aryl
which can also be optionally substituted with one or more
substituent selected from halo, haloalkyl, alkyl, nitro, hydroxy,
alkoxy, aryloxy, aryl, or fused aryl; aryl optionally substituted
with one or more substituent selected from halo, haloalkyl,
hydroxy, alkoxy, aryloxy, aryl, fused aryl, nitro, methylenedioxy,
ethylenedioxy, or alkyl; alkynyl; alkenyl; --S--R.sup.9 and
--O--R.sup.9 wherein R.sup.9 is selected from the group consisting
of H; alkyl; aralkyl; aryl; alkenyl; and alkynyl; or R.sup.9 taken
together with R.sup.7 forms a 4-12 membered mononitrogen and
monosulfur or monooxygen containing heterocyclic ring optionally
substituted with lower alkyl, hydroxy, keto, phenyl, carboxyl or
carboxyl ester, and fused phenyl; or R.sup.9 taken together with
R.sup.7 is thiazole; oxazole; benzoxazole; or benzothiazole; and
R.sup.5 and R.sup.7 are as defined above; or Y.sup.2 (when Y.sup.2
is carbon) taken together with R.sup.7 forms a 4-12 membered
mononitrogen or dinitrogen containing ring optionally substituted
with alkyl, aryl, keto or hydroxy; or A is 227 where R.sup.2 and
R.sup.7 taken together form a 5-8 membered dinitrogen containing
heterocycle optionally substituted with one or more substituent
selected from the group consisting of lower alkyl, hydroxy, alkoxy,
keto, phenyl, or carboxyl derivatives; and R.sup.8 is selected from
the group consisting of alkylcarbonyl, arylcarbonyl,
alkoxycarbonyl, aryloxycarbonyl, haloalkylcarbonyl,
haloalkoxycarbonyl, alkylthiocarbonyl, arylthiocarbonyl, or
acyloxymethoxycarbonyl; and R.sup.5 is defined as above or R.sup.2
and R.sup.7 taken together form a membered heteroaromatic ring such
as imidazole or pyrimidone; or A is 228 where R.sup.2 and R.sup.7
taken together form a 5-8 membered dinitrogen containing
heterocycle optionally substituted with hydroxy, keto, phenyl, or
alkyl; and R.sup.8 are both selected from the group consisting of
alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aryloxycarbonyl,
haloalkylcarbonyl, haloalkoxycarbonyl, alkylthiocarbonyl,
arylthiocarbonyl and acyloxymethoxycarbonyl; Z.sup.1 is one or more
substituent selected from the group consisting of H; alkyl;
hydroxy; alkoxy; aryloxy; halogen; haloalkyl; haloalkoxy; nitro;
amino; alkylamino; acylamino; dialkylamino; cyano; alkylthio;
alkylsulfonyl; carboxyl derivatives; trihaloacetamide; acetamide;
acyl; aryl; fused aryl; cycloalkyl; thio; monocyclic heterocycles;
fused monocyclic heterocycles; and A, wherein A is defined above; V
is selected from the group consisting of --N--(R.sup.6)-- wherein
R.sup.6 is selected from the group consisting of H; lower alkyl;
cycloalkyl; aralkyl; aryl; and monocyclic heterocycles; or R.sup.6
taken together with Y, forms a 4-12 membered mononitrogen
containing ring; Y, Y.sup.3, Z and Z.sup.3 are independently
selected from the group consisting of hydrogen; alkyl; aryl; and
cycloalkyl; or Y and Z taken together form a cycloalkyl; or Y.sup.3
and Z.sup.3 taken together form a cycloalkyl; n is an integer 1, 2,
or 3; t is an integer 0, 1, or 2; p is an integer 0, 1, 2, or 3; R
is X--R.sup.3 wherein X is selected from the group consisting of O,
S and NR.sup.4, wherein R.sup.3 and R.sup.4 are independently
selected from the group consisting of hydrogen; alkyl; alkenyl;
alkynyl; haloalkyl; aryl; arylalkyl; sugars; steroids;
polyalkylethers; alkylamido; alkyl N,N-dialkylamido;
pivaloyloxymethyl; and in the case of the free acid, all
pharmaceutically acceptable salts thereof; R.sup.1 is selected from
the group consisting of hydrogen; alkyl; alkenyl; alkynyl; aryl;
carboxyl derivatives; haloalkyl; cycloalkyl; monocyclic
heterocycles; monocyclic heterocycles optionally substituted with
alkyl, halogen, haloalkyl, cyano, hydroxy, aryl, fused aryl, nitro,
alkoxy, aryloxy, alkylsulfonyl, arylsulfonyl, sulfonamide, thio,
alkylthio, carboxyl derivatives, amino, amido; alkyl optionally
substituted with one or more of halo, haloalkyl, hydroxy, alkoxy,
aryloxy, thio, alkylthio, alkynyl, alkenyl, alkyl, arylthio,
alkylsulfoxide, alkylsulfonyl, arylsulfoxide, arylsulfonyl, cyano,
nitro, amino, alkylamino, dialkylamino, alkylsulfonamide,
arylsulfonamide, acylamide, carboxyl derivatives, sulfonamide,
sulfonic acid, phosphonic acid derivatives, phosphinic acid
derivatives, aryl, arylthio, arylsulfoxide, or arylsulfone all
optionally substituted on the aryl ring with halo, alkyl,
haloalkyl, cyano, nitro, hydroxy, carboxyl derivatives, alkoxy,
aryloxy, amino, alkylamino, dialkylamino, amido, aryl, fused aryl,
monocyclic heterocycles; and fused monocyclic heterocycles,
monocyclic heterocyclicthio, monocyclic heterocyclicsulfoxide, and
monocyclic heterocyclic sulfone, which can be optionally
substituted with halo, haloalkyl, nitro, hydroxy, alkoxy, fused
aryl, or alkyl; alkylcarbonyl, haloalkylcarbonyl, and arylcarbonyl;
aryl optionally substituted in one or more positions with halo,
haloalkyl, alkyl, alkoxy, aryloxy, methylenedioxy, ethylenedioxy,
alkylthio, haloalkylthio, thio, hydroxy, cyano, nitro, acyloxy,
carboxyl derivatives, carboxyalkoxy; amido, acylamino, amino,
alkylamino, dialkylamino, trifluoroalkoxy, trifluoromethylsulfonyl,
alkylsulfonyl, sulfonic acid, sulfonamide, aryl, fused aryl,
monocyclic heterocycles and fused monocyclic heterocycles; and 229
wherein R.sup.7 and R.sup.8 are as defined above and provided that
taken together with the nitrogen, R.sup.7 and R.sup.8 comprise an
amino acid; and R.sup.11 is selected from the group consisting of
H, alkyl, aralkyl, alkenyl, alkynyl, haloalkyl or haloalkynyl or
R.sup.11 taken together with Y forms a 4-12 membered mononitrogen
containing ring; or a pharmaceutically acceptable salt thereof.
2. A compound according to claim 1 of the formula 230wherein
231wherein R.sup.32 is H, alkyl, alkoxyalkyl, aminoalkyl,
dialkylamino alkyl, wherein the alkyl group is optionally
substituted by one or more substituent selected from the group
consisting of hydroxy, alkoxy, amino, alkylamino, dialkylamino,
aryl- or alkyl-sulfonyl, carboxyl, and carboxyl derivatives.
3. A compound according to claim 2 wherein the compound is selected
from the group consisting of 232233234
4. A compound according to claim 1 of the formula 235wherein
236
5. A compound according to claim 4 wherein the compound is selected
from the group consisting of 237238239240
6. A compound according to claim 1 of the formula 241wherein
242
7. A compound according to claim 6 selected from the group
consisting of 243244
8. A compound according to claim 1 wherein the compound is of the
formula 245wherein 246
9. A compound according to claim 8 of the formula 247
10. A compound according to claim 1 of the formula 248wherein
249
11. A compound according to claim 10 of the formula 250
12. A pharmaceutical composition comprising a therapeutically
effective amount of a compound according to claim 1, 2, 3, 4, 5, 6,
7, 8, 9, 10 or 11 and a pharmaceutically acceptable carrier.
13. A method for treating conditions mediated by the
.alpha..sub.V.beta..sub.3 integrin in a mammal in need of such
treatment comprising administering a therapeutically effective
.alpha..sub.V.beta..sub.3 inhibiting amount of a compound according
to claim 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11.
14. A method according to claim 13 wherein the condition treated is
tumor metastasis.
15. A method according to claim 13 wherein the condition treated is
solid tumor growth.
16. A method according to claim 13 wherein the condition treated is
angiogenesis.
17. A method according to claim 13 wherein the condition treated is
osteoporosis.
18. A method according to claim 13 wherein the condition treated is
humoral hypercalcemia of malignancy.
19. A method according to claim 13 wherein the condition treated is
smooth muscle cell migration.
20. A method according to claim 13 wherein restenosis is
inhibited.
21. A method according to claim 13 wherein the condition treated is
rheumatoid arthritis.
22. A method according to claim 13 wherein the condition treated is
macular degeneration.
Description
[0001] The present application claims priority under 35 USC
.sctn.119(e) of U.S. provisional patent application Serial No.
60/081,394, filed April 10, 1998.
FIELD OF THE INVENTION
[0002] The present invention relates to pharmaceutical agents
(compounds) which are useful as .alpha..sub.V.beta..sub.3 integrin
antagonists and as such are useful in pharmaceutical compositions
and in methods for treating conditions mediated by
.alpha..sub.V.beta..sub.3 by inhibiting or antagonizing
.alpha..sub.V.beta..sub.3 integrins.
BACKGROUND OF THE INVENTION
[0003] Integrins are a group of cell surface glycoproteins which
mediate cell adhesion and therefore are useful mediators of cell
adhesion interactions which occur during various biological
processes. Integrins are heterodimers composed of noncovalently
linked .alpha. and .beta. polypeptide subunits. Currently eleven
different .alpha. subunits have been identified and six different
.beta. subunits have been identified. The various .alpha. subunits
can combine with various .beta. subunits to form distinct
integrins.
[0004] The integrin identified as .alpha..sub.V.beta..sub.3 (also
known as the vitronectin receptor) has been identified as an
integrin which plays a role in various conditions or disease states
including tumor metastasis, solid tumor growth (neoplasia),
osteoporosis, Paget's disease, humoral hypercalcemia of malignancy,
angiogenesis, including tumor angiogenesis, retinopathy including
macular degeneration, arthritis, including rheumatoid arthritis,
periodontal disease, psoriasis and smooth muscle cell migration
(e.g. restenosis). Additionally, it has been found that such agents
would be useful as antivirals, antifungals and antimicrobials.
Thus, compounds which selectively inhibit or antagonize
.alpha..sub.V.beta..sub.3 would be beneficial for treating such
conditions.
[0005] It has been shown that the .alpha..sub.V.beta..sub.3
integrin and other .alpha..sub.Vcontaining integrins bind to a
number of Arg-Gly-Asp (RGD) containing matrix macromolecules.
Compounds containing the RGD sequence mimic extracellular matrix
ligands so as to bind to cell surface receptors. However, it is
also known that RGD peptides in general are non-selective for RGD
dependent integrins. For example, most RGD peptides which bind to
.alpha..sub.V.beta..sub.3 also bind to .alpha..sub.V.beta..sub.5,
.alpha..sub.V.beta. .sub.1 and .alpha..sub.IIb.beta..sub.3.
Antagonism of platelet (.alpha..sub.IIb.beta..sub.3 (also known as
the fibrinogen receptor) is known to block platelet aggregation in
humans. In order to avoid bleeding side-effects when treating the
conditions or disease states associated with the integrin
.alpha..sub.V.beta..sub.3, it would be beneficial to develop
compounds which are selective antagonists of
.alpha..sub.V.beta..sub.3 as opposed to
.alpha..sub.IIb.beta..sub.3.
[0006] Tumor cell invasion occurs by a three step process: 1) tumor
cell attachment to extracellular matrix; 2) proteolytic dissolution
of the matrix; and 3) movement of the cells through the dissolved
barrier. This process can occur repeatedly and can result in
metastases at sites distant from the original tumor.
[0007] Seffor et al. (Proc. Natl. Acad. Sci. USA, Vol. 89 (1992)
1557-1561) have shown that the .alpha..sub.V.beta..sub.3 integrin
has a biological function in melanoma cell invasion. Montgomery et
al., (Proc. Natl. Acad. Sci. USA, Vol. 91 (1994) 8856-60) have
demonstrated that the integrin .alpha..sub.V.beta..sub.3 expressed
on human melanoma cells promotes a survival signal, protecting the
cells from apoptosis. Mediation of the tumor cell metastatic
pathway by interference with the .alpha..sub.V.beta..sub.3 integrin
cell adhesion receptor to impede tumor metastasis would be
beneficial.
[0008] Brooks et al. (Cell, Vol. 79 (1994)1157-1164) have
demonstrated that antagonists of .alpha..sub.V.beta..sub.3 provide
a therapeutic approach for the treatment of neoplasia (inhibition
of solid tumor growth) since systemic administration of
.alpha..sub.V.beta..sub.3 antagonists causes dramatic regression of
various histologically distinct human tumors.
[0009] The adhesion receptor integrin .alpha..sub.V.beta..sub.3 was
identified as a marker of angiogenic blood vessels in chick and man
and therefore such receptor plays a critical role in angiogenesis
or neovascularization. Angiogenesis is characterized by the
invasion, migration and proliferation of smooth muscle and
endothelial cells. Antagonists of .alpha..sub.V.beta..sub.3 inhibit
this process by selectively promoting apoptosis of cells in
neovasculature. The growth of new blood vessels, or angiogenesis,
also contributes to pathological conditions such as diabetic
retinopathy including macular degeneration (Adamis et al., Amer. J.
Ophthal., Vol. 118, (1994) 445-450) and rheumatoid arthritis
(Peacock et al., J. Exp. Med., Vol. 175, (1992), 1135-1138).
Therefore, .alpha..sub.V.beta..sub.3 antagonists would be useful
therapeutic agents for treating such conditions associated with
neovascularization (Brooks et al., Science, Vol. 264, (1994),
569-571). It has been reported that the cell surface receptor
.alpha..sub.V.beta..sub.3 is the major integrin on osteoclasts
responsible for attachment to bone. Osteoclasts cause bone
resorption and when such bone resorbing activity exceeds bone
forming activity it results in osteoporosis (loss of bone), which
leads to an increased number of bone fractures, incapacitation and
increased mortality. Antagonists of .alpha..sub.V.beta..sub.3 have
been shown to be potent inhibitors of osteoclastic activity both in
vitro [Sato et al., J. Cell. Biol., Vol. 1-11 (1990) 1713-1723] and
in vivo [Fisher et al., Endocrinology, Vol. 132 (1993) 1411-1413].
Antagonism of .alpha..sub.V.beta..sub.3 leads to decreased bone
resorption and therefore restores a normal balance of bone forming
and resorbing activity. Thus it would be beneficial to provide
antagonists of osteoclast .alpha..sub.V.beta..sub.3 which are
effective inhibitors of bone resorption and therefore are useful in
the treatment or prevention of osteoporosis.
[0010] The role of the .alpha..sub.V.beta..sub.3 integrin in smooth
muscle cell migration also makes it a therapeutic target for
prevention or inhibition of neointimal hyperplasia which is a
leading cause of restenosis after vascular procedures (Choi et al.,
J. Vasc. Surg. Vol. 19(1) (1994) 125-34). Prevention or inhibition
of neointimal hyperplasia by pharmaceutical agents to prevent or
inhibit restenosis would be beneficial.
[0011] White (Current Biology, Vol. 3(9)(1993) 596-599) has
reported that adenovirus uses (.alpha..sub.V.beta..sub.3 for
entering host cells. The integrin appears to be required for
endocytosis of the virus particle and may be required for
penetration of the viral genome into the host cell cytoplasm. Thus
compounds which inhibit .alpha..sub.V.beta..sub.3 would find
usefulness as antiviral agents.
SUMMARY OF THE INVENTION
[0012] The present invention relates to a class of compounds
represented by the Formula I 2
[0013] or a pharmaceutically acceptable salt thereof, wherein 3
[0014] is a 5-8 membered monocyclic heterocyclic ring, optionally
unsaturated, containing 1 to 4 heteroatoms, selected from the group
consisting of O, N or S, wherein X.sup.1 is selected from the group
consisting of CH, CH.sub.2, N, NH, O and S;
[0015] A is 4
[0016] wherein
[0017] Y.sup.1 is selected from the group consisting of N--R.sup.2,
O, and S;
[0018] R.sup.2 is selected from the group consisting of H; alkyl;
aryl; hydroxy; alkoxy; cyano; nitro; amino; alkenyl; alkynyl;
amido; alkylcarbonyl; arylcarbonyl; alkoxycarbonyl;
aryloxycarbonyl; haloalkylcarbonyl; haloalkoxycarbonyl;
alkylthiocarbonyl; arylthiocarbonyl; acyloxymethoxycarbonyl; alkyl
optionally substituted with one or more substituent selected from
lower alkyl, halogen, hydroxyl, haloalkyl, cyano, nitro, carboxyl,
amino, alkoxy, aryl or aryl optionally substituted with one or more
halogen, haloalkyl, lower alkyl, alkoxy, cyano, alkylsulfonyl,
alkylthio, nitro, carboxyl, amino, hydroxyl, sulfonic acid,
sulfonamide, aryl, fused aryl, monocyclic heterocycles, or fused
monocyclic heterocycles; aryl optionally substituted with one or
more substituent selected from halogen, haloalkyl, hydroxy, lower
alkyl, alkoxy, methylenedioxy, ethylenedioxy, cyano, nitro,
alkylthio, alkylsulfonyl, sulfonic acid, sulfonamide, carboxyl
derivatives, amino, aryl, fused aryl, monocyclic heterocycles and
fused monocyclic heterocycle; monocyclic heterocycles; and
monocyclic heterocycles optionally substituted with one or more
substituent selected from halogen, haloalkyl, lower alkyl, alkoxy,
amino, nitro, hydroxy, carboxyl derivatives, cyano, alkylthio,
alkylsulfonyl, sulfonic acid, sulfonamide, aryl or fused aryl;
or
[0019] R.sup.2 taken together with R.sup.7 forms a 4-12 membered
dinitrogen containing heterocycle optionally substituted with one
or more substituent selected from the group consisting of lower
alkyl, thioalkyl, alkylamino, hydroxy, keto, alkoxy, halo, phenyl,
amino, carboxyl or carboxyl ester, and fused phenyl;
[0020] R.sup.2 taken together with R.sup.7 forms a 4-12 membered
heterocycle containing one or more heteroatom selected from O, N
and S optionally unsaturated;
[0021] R.sup.2 taken together with R.sup.7 forms a 5-9 membered
heteroaromatic ring optionally substituted with one or more
substituent selected from lower alkyl, phenyl, alkoxy and
hydroxy;
[0022] R.sup.2 taken together with R.sup.7 forms a 5 membered
heteroaromatic ring fused with a aryl or heteroaryl ring;
[0023] R.sup.7 (when not taken together with R.sup.2) and R.sup.8
are independently selected from the group consisting of H; alkyl;
alkenyl; alkynyl; aralkyl; amino; alkylamino; hydroxy; alkoxy;
arylamino; amido, alkylcarbonyl, arylcarbonyl; alkoxycarbonyl;
aryloxy; aryloxycarbonyl; haloalkylcarbonyl; haloalkoxycarbonyl;
alkylthiocarbonyl; arylthiocarbonyl; acyloxymethoxycarbonyl;
cycloalkyl; bicycloalkyl; aryl; acyl; benzoyl; alkyl optionally
substituted with one or more substituent selected from lower alkyl,
halogen, hydroxy, haloalkyl, cyano, nitro, carboxyl derivatives,
amino, alkoxy, thio, alkylthio, sulfonyl, aryl, aralkyl, aryl
optionally substituted with one or more substituent selected from
halogen, haloalkyl, lower alkyl, alkoxy, methylenedioxy,
ethylenedioxy, alkylthio, haloalkylthio, thio, hydroxy, cyano,
nitro, carboxyl derivatives, aryloxy, amido, acylamino, amino,
alkylamino, dialkylamino, trifluoroalkoxy, trifluoromethyl,
sulfonyl, alkylsulfonyl, haloalkylsulfonyl, sulfonic acid,
sulfonamide, aryl, fused aryl, monocyclic heterocycles, fused
monocyclic heterocycles; aryl optionally substituted with one or
more substituent selected from halogen, haloalkyl, lower alkyl,
alkoxy, methylenedioxy, ethylenedioxy, alkylthio, haloalkylthio,
thio, hydroxy, cyano, nitro, carboxyl derivatives, aryloxy, amido,
acylamino, amino, alkylamino, dialkylamino, trifluoroalkoxy,
trifluoromethylsulfonyl, alkylsulfonyl, sulfonic acid, sulfonamide,
aryl, fused aryl, monocyclic heterocycles, or fused monocyclic
heterocycles; monocyclic heterocycles; monocyclic heterocycles
optionally substituted with one or more substituent selected from
halogen, haloalkyl, lower alkyl, alkoxy, aryloxy, amino, nitro,
hydroxy, carboxyl derivatives, cyano, alkylthio, alkylsulfonyl,
aryl, fused aryl; monocyclic and bicyclic heterocyclicalkyls;
--SO.sub.2R.sup.10 wherein R.sup.10 is selected from the group
consisting of alkyl, aryl and monocyclic heterocycles, all
optionally substituted with one or more substituent selected from
the group consisting of halogen, haloalkyl, alkyl, alkoxy, cyano,
nitro, amino, acylamino, trifluoroalkyl, amido, alkylaminosulfonyl,
alkylsulfonyl, alkylsulfonylamino, alkylamino, dialkylamino,
trifluoromethylthio, trifluoroalkoxy, trifluoromethylsulfonyl,
aryl, aryloxy, thio, alkylthio, and monocyclic heterocycles; and
5
[0024] wherein R.sup.10 is defined above;
[0025] or NR.sup.7 and R.sup.8 taken together form a 4-12 membered
mononitrogen containing monocyclic or bicyclic ring optionally
substituted with one or more substituent selected from lower alkyl,
carboxyl derivatives, aryl or hydroxy and wherein said ring
optionally contains a heteroatom selected from the group consisting
of O, N and S;
[0026] R.sup.5 is selected from the group consisting of H, alkyl,
alkenyl, alkynyl, benzyl, and phenethyl;
[0027] or
[0028] A is 6
[0029] wherein Y.sup.2 is selected from the group consisting of
alkyl; cycloalkyl; bicycloalkyl; aryl; monocyclic heterocycles;
alkyl optionally substituted with aryl which can also be optionally
substituted with one or more substituent selected from halo,
haloalkyl, alkyl, nitro, hydroxy, alkoxy, aryloxy, aryl, or fused
aryl; aryl optionally substituted with one or more substituent
selected from halo, haloalkyl, hydroxy, alkoxy, aryloxy, aryl,
fused aryl, nitro, methylenedioxy, ethylenedioxy, or alkyl;
alkynyl; alkenyl; --S--R.sup.9 and --O--R.sup.9 wherein R.sup.9 is
selected from the group consisting of H; alkyl; aralkyl; aryl;
alkenyl; and alkynyl; or R.sup.9 taken together with R.sup.7 forms
a 4-12 membered mononitrogen and monosulfur or monooxygen
containing heterocyclic ring optionally substituted with lower
alkyl, hydroxy, keto, phenyl, carboxyl or carboxyl ester, and fused
phenyl; or R.sup.9 taken together with R.sup.7 is thiazole;
oxazole; benzoxazole; or benzothiazole; and
[0030] R.sup.5 and R.sup.7 are as defined above;
[0031] or Y.sup.2 (when Y.sup.2 is carbon) taken together with
R.sup.7 forms a 4-12 membered mononitrogen or dinitrogen containing
ring optionally substituted with alkyl, aryl, keto or hydroxy;
[0032] or A is 7
[0033] where R.sup.2 and R.sup.7 taken together form a 5-8 membered
dinitrogen containing heterocycle optionally substituted with one
or more substituent selected from the group consisting of lower
alkyl, hydroxy, alkoxy, keto, phenyl, or carboxyl derivatives; and
R.sup.8 is selected from the group consisting of alkylcarbonyl,
arylcarbonyl, alkoxycarbonyl, aryloxycarbonyl, haloalkylcarbonyl,
haloalkoxycarbonyl, alkylthiocarbonyl, arylthiocarbonyl, or
acyloxymethoxycarbonyl; and
[0034] R.sup.5 is defined as above
[0035] or R.sup.2 and R.sup.7 taken together form a heteroaromatic
ring such as imidazole or pyrimidone;
[0036] or A is 8
[0037] where R.sup.2 and R.sup.7 taken together form a 5-8 membered
dinitrogen containing heterocycle optionally substituted with
hydroxy, keto, phenyl, or alkyl; and
[0038] R.sup.8 are both selected from the group consisting of
alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aryloxycarbonyl,
haloalkylcarbonyl, haloalkoxycarbonyl, alkylthiocarbonyl,
arylthiocarbonyl and acyloxymethoxycarbonyl;
[0039] Z.sup.1 is one or more substituent selected from the group
consisting of H; alkyl; hydroxy; alkoxy; aryloxy; halogen;
haloalkyl; haloalkoxy; nitro; amino; alkylamino; acylamino;
dialkylamino; cyano; alkylthio; alkylsulfonyl; carboxyl
derivatives; trihaloacetamide; acetamide; acyl; aryl; fused aryl;
cycloalkyl; thio; monocyclic heterocycles; fused monocyclic
heterocycles; and A, wherein A is defined above;
[0040] V is selected from the group consisting of --N--(R.sup.6)--
wherein R.sup.6 is selected from the group consisting of H; lower
alkyl; cycloalkyl; aralkyl; aryl; and monocyclic heterocycles; or
R.sup.6 taken together with Y, forms a 4-12 membered mononitrogen
containing ring;
[0041] Y, Y.sup.3, Z and Z.sup.3 are independently selected from
the group consisting of hydrogen; alkyl; aryl; and cycloalkyl; or Y
and Z taken together form a cycloalkyl; or Y.sup.3 and Z.sup.3
taken together form a cycloalkyl;
[0042] n is an integer 1, 2, or 3;
[0043] t is an integer 0, 1, or 2;
[0044] p is an integer 0, 1, 2, or 3;
[0045] R is X--R.sup.3 wherein X is selected from the group
consisting of O, S and NR.sup.4) wherein R.sup.3 and R.sup.4 are
independently selected from the group consisting of hydrogen;
alkyl; alkenyl; alkynyl; haloalkyl; aryl; arylalkyl; sugars;
steroids; polyalkylethers; alkylamido; alkyl N,N-dialkylamido;
pivaloyloxymethyl; and in the case of the free acid, all
pharmaceutically acceptable salts thereof;
[0046] R.sup.1 is selected from the group consisting of hydrogen;
alkyl; alkenyl; alkynyl; aryl; carboxyl derivatives; haloalkyl;
cycloalkyl; monocyclic heterocycles; monocyclic heterocycles
optionally substituted with alkyl) halogen, haloalkyl, cyano,
hydroxy, aryl, fused aryl, nitro, alkoxy, aryloxy, alkylsulfonyl,
arylsulfonyl, sulfonamide, thio, alkylthio, carboxyl derivatives,
amino, amido;
[0047] alkyl optionally substituted with one or more of halo,
haloalkyl, hydroxy, alkoxy, aryloxy, thio, alkylthio, alkynyl,
alkenyl, alkyl) arylthio, alkylsulfoxide, alkylsulfonyl,
arylsulfoxide, arylsulfonyl, cyano, nitro, amino, alkylamino,
dialkylamino, alkylsulfonamide, arylsulfonamide, acylamide,
carboxyl derivatives, sulfonamide, sulfonic acid, phosphonic acid
derivatives, phosphinic acid derivatives, aryl, arylthio,
arylsulfoxide, or arylsulfone all optionally substituted on the
aryl ring with halo, alkyl, haloalkyl, cyano, nitro, hydroxy,
carboxyl derivatives, alkoxy, aryloxy, amino, alkylamino,
dialkylamino, amido, aryl, fused aryl, monocyclic heterocycles; and
fused monocyclic heterocycles, monocyclic heterocyclicthio,
monocyclic heterocyclicsulfoxide, and monocyclic heterocyclic
sulfone, which can be optionally substituted with halo, haloalkyl,
nitro, hydroxy, alkoxy, fused aryl, or alkyl;
[0048] alkylcarbonyl, haloalkylcarbonyl, and arylcarbonyl;
[0049] aryl optionally substituted in one or more positions with
halo, haloalkyl, alkyl, alkoxy, aryloxy, methylenedioxy,
ethylenedioxy, alkylthio, haloalkylthio, thio, hydroxy, cyano,
nitro, acyloxy, carboxyl derivatives, carboxyalkoxy; amido,
acylamino, amino, alkylamino, dialkylamino, trifluoroalkoxy,
trifluoromethylsulfonyl, alkylsulfonyl, sulfonic acid, sulfonamide,
aryl, fused aryl, monocyclic heterocycles and fused monocyclic
heterocycles; and 9
[0050] wherein R.sup.7 and R.sup.8 are as defined above and
provided that taken together with the nitrogen, R.sup.7 and R.sup.8
comprise an amino acid;
[0051] and
[0052] R.sup.11 is selected from the group consisting of H.sub.1
alkyl, aralkyl, alkenyl, alkynyl, haloalkyl or haloalkynyl or
R.sup.11 taken together with Y forms a 4-12 membered mononitrogen
containing ring.
[0053] It is another object of the invention to provide
pharmaceutical compositions comprising compounds of the Formula I.
Such compounds and compositions are useful in selectively
inhibiting or antagonizing the .alpha..sub.V.beta..sub.3 integrin
and therefore in another embodiment the present invention relates
to a method of selectively inhibiting or antagonizing the
.alpha..sub.V.beta..sub.3 integrin. The invention further involves
treating or inhibiting pathological conditions associated therewith
such as osteoporosis, humoral hypercalcemia of malignancy, Paget's
disease, tumor metastasis, solid tumor growth (neoplasia),
angiogenesis, including tumor angiogenesis, retinopathy including
macular degeneration and diabetic retinopathy, arthritis, including
rheumatoid arthritis, periodontal disease, psoriasis, smooth muscle
cell migration and restenosis in a mammal in need of such
treatment. Additionally, such pharmaceutical agents are useful as
antiviral agents, and antimicrobials.
DETAILED DESCRIPTION
[0054] The present invention relates to a class of compounds
represented by the Formula I, described above.
[0055] A preferred embodiment of the present invention is a
compound of the Formula II 10
[0056] wherein 11
[0057] wherein R.sup.32 is H, alkyl, alkoxyalkyl, aminoalkyl,
dialkylamino alkyl, wherein the alkyl group is optionally
substituted by one or more substituent selected from the group
consisting of hydroxy, alkoxy, amino, alkylamino, dialkylamino,
aryl- or alkyl-sulfonyl, carboxyl, and carboxyl derivatives and the
other variables are as described in Formula I.
[0058] Another preferred embodiment of the present invention is a
compound of the Formula III 12
[0059] wherein 13
[0060] optionally substituted and the other variables are as
defined above in Formula I.
[0061] Another preferred embodiment of the present invention is a
compound of the Formula IV 14
[0062] wherein 15
[0063] optionally substituted and the other variables are as
defined above in Formula I.
[0064] Another preferred embodiment of the present invention is a
compound of the Formula V 16
[0065] wherein 17
[0066] optionally substituted and the other variables are as
defined above in Formula I.
[0067] Another preferred embodiment of the present invention is a
compound of the Formula VI 18
[0068] wherein 19
[0069] optionally substituted and the other variables are as
defined above in Formula I.
[0070] The invention further relates to pharmaceutical compositions
containing therapeutically effective amounts of the compounds of
Formulas I-VI.
[0071] The invention also relates to a method of selectively
inhibiting or antagonizing the .alpha..sub.V.beta..sub.3 integrin
and more specifically relates to a method of inhibiting bone
resorption, periodontal disease, osteoporosis, humoral
hypercalcemia of malignancy, Paget's disease, tumor metastasis,
solid tumor growth (neoplasia), angiogenesis, including tumor
angiogenesis, retinopathy including macular degeneration and
diabetic retinopathy, arthritis, including rheumatoid arthritis,
smooth muscle cell migration and restenosis by administering a
therapeutically effective amount of a compound of the Formula I-VI
to achieve such inhibition together with a pharmaceutically
acceptable carrier.
[0072] The following is a list of definitions of various terms used
herein:
[0073] As used herein, the terms "alkyl" or "lower alkyl" refer to
a straight chain or branched chain hydrocarbon radicals having from
about 1 to about 10 carbon atoms, and more preferably 1 to about 6
carbon atoms. Examples of such alkyl radicals are methyl, ethyl,
n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, pentyl,
neopentyl, hexyl, isohexyl, and the like.
[0074] As used herein the terms "alkenyl" or "lower alkenyl" refer
to unsaturated acyclic hydrocarbon radicals containing at least one
double bond and 2 to about 6 carbon atoms, which carbon-carbon
double bond may have either cis or trans geometry within the
alkenyl moiety, relative to groups substituted on the double bond
carbons. Examples of such groups are ethenyl, propenyl, butenyl,
isobutenyl, pentenyl, hexenyl and the like.
[0075] As used herein the terms "alkynyl" or "lower alkynyl" refer
to acyclic hydrocarbon radicals containing one or more triple bonds
and 2 to about 6 carbon atoms. Examples of such groups are ethynyl,
propynyl, butynyl, pentynyl, hexynyl and the like.
[0076] The term "cycloalkyl" as used herein means saturated or
partially unsaturated cyclic carbon radicals containing 3 to about
8 carbon atoms and more preferably 4 to about 6 carbon atoms.
Examples of such cycloalkyl radicals include cyclopropyl,
cyclopropenyl, cyclobutyl, cyclopentyl, cyclohexyl,
2-cyclohexen-1-yl, and the like.
[0077] The term "aryl" as used herein denotes aromatic ring systems
composed of one or more aromatic rings. Preferred aryl groups are
those consisting of one, two or three aromatic rings. The term
embraces aromatic radicals such as phenyl, pyridyl, naphthyl,
thiophene, furan, biphenyl and the like.
[0078] As used herein, the term "cyano" is represented by a radical
of the formula 20
[0079] The terms "hydroxy" and "hydroxyl" as used herein are
synonymous and are represented by a radical of the formula 21
[0080] The radical of the formula 22
[0081] refers to a 5-10 membered monocyclic or bicyclic
heterocyclic ring, optionally containing unsaturation, containing 1
to 3 hetero atoms selected from the group consisting of O, N and S;
wherein X.sup.1 is CH, N, O or S.
[0082] Representative examples of the radical include pyridones,
pyridines, pyrimidines, imidazoles, oxazoles, isoxazoles,
thiazoles, pyridazines, thiophenes, furans, pyrazoles and bicyclic
heterocyclics such as benzimidazole, imidazopyridine, benzofuran
and the like.
[0083] The term "lower alkylene" or "alkylene" as used herein
refers to divalent linear or branched saturated hydrocarbon
radicals of 1 to about 6 carbon atoms.
[0084] As used herein the term "alkoxy" refers to straight or
branched chain oxy containing radicals of the formula --OR.sup.20,
wherein R.sup.20 is an alkyl group as defined above. Examples of
alkoxy groups encompassed include methoxy, ethoxy, n-propoxy,
n-butoxy, isopropoxy, isobutoxy, sec-butoxy, t-butoxy and the
like.
[0085] As used herein the terms "arylalkyl" or "aralkyl" refer to a
radical of the formula 23
[0086] wherein R.sup.21 is aryl as defined above and R.sup.22 is an
alkylene as defined above. Examples of aralkyl groups include
benzyl, pyridylmethyl, naphthylpropyl, phenethyl and the like.
[0087] As used herein the term "nitro" is represented by a radical
of the formula 24
[0088] As used herein the term "halo" or "halogen" refers to bromo,
chloro, fluoro or iodo.
[0089] As used herein the term "haloalkyl" refers to alkyl groups
as defined above substituted with one or more of the same or
different halo groups at one or more carbon atom. Examples of
haloalkyl groups include trifluoromethyl, dichloroethyl,
fluoropropyl and the like.
[0090] As used herein the term "carboxyl" or "carboxy" refers to a
radical of the formula --COOH.
[0091] As used herein the term "carboxyl ester" refers to a radical
of the formula --COOR.sup.23 wherein R.sup.23 is selected from the
group consisting of H, alkyl, aralkyl or aryl as defined above.
[0092] As used herein the term "carboxyl derivative" refers to a
radical of the formula 25
[0093] wherein Y.sup.6 and Y.sup.7 are independently selected from
the group consisting of O, N or S and R.sup.23 is selected from the
group consisting of H, alkyl, aralkyl or aryl as defined above.
[0094] As used herein the term "amino" is represented by a radical
of the formula --NH.sub.2.
[0095] As used herein the term "alkylsulfonyl" or "alkylsulfone"
refers to a radical of the formula 26
[0096] wherein R.sup.24 is alkyl as defined above.
[0097] As used herein the term "alkylthio" refers to a radical of
the formula --SR.sup.24 wherein R.sup.24 is alkyl as defined
above.
[0098] As used herein the term "sulfonic acid" refers to a radical
of the formula 27
[0099] wherein R.sup.25 is alkyl as defined above.
[0100] As used herein the term "sulfonamide" refers to a radical of
the formula 28
[0101] wherein R.sup.7 and R.sup.8 are as defined above.
[0102] As used herein the term "fused aryl" refers to an aromatic
ring such as the aryl groups defined above fused to one or more
phenyl rings. Embraced by the term "fused aryl" is the radical
naphthyl and the like.
[0103] As used herein the terms "monocyclic heterocycle" or
"monocyclic heterocyclic" refer to a monocyclic ring containing
from 4 to about 12 atoms, and more preferably from 5 to about 10
atoms, wherein 1 to 3 of the atoms are heteroatoms selected from
the group consisting of oxygen, nitrogen and sulfur with the
understanding that if two or more different heteroatoms are present
at least one of the heteroatoms must be nitrogen. Representative of
such monocyclic heterocycles are imidazole, furan, pyridine,
oxazole, pyran, triazole, thiophene, pyrazole, thiazole,
thiadiazole, and the like.
[0104] As used herein the term "fused monocyclic heterocycle"
refers to a monocyclic heterocycle as defined above with a benzene
fused thereto. Examples of such fused monocyclic heterocycles
include benzofuran, benzopyran, benzodioxole, benzothiazole,
benzothiophene, benzimidazole and the like.
[0105] As used herein the term "methylenedioxy" refers to the
radical 29
[0106] and the term "ethylenedioxy" refers to the radical 30
[0107] As used herein the term "4-12 membered dinitrogen containing
heterocycle refers to a radical of the formula 31
[0108] wherein m is 1 or 2 and R.sup.19 is H, alkyl, aryl, or
aralkyl and more preferably refers to 4-9 membered ring and
includes rings such as imidazoline.
[0109] As used herein the term "5-membered optionally substituted
heteroaromatic ring" includes for example a radical of the formula
32
[0110] and "5-membered heteroaromatic ring fused with a phenyl"
refers to such a "5-membered heteroaromatic ring" with a phenyl
fused thereto. Representative of such 5-membered heteroaromatic
rings fused with a phenyl is benzimidazole.
[0111] As used herein the term "bicycloalkyl" refers to a bicyclic
hydrocarbon radical containing 6 to about 12 carbon atoms which is
saturated or partially unsaturated.
[0112] As used herein the term "acyl" refers to a radical of the
formula 33
[0113] wherein R.sup.26 is alkyl, alkenyl, alkynyl, aryl or aralkyl
and optionally substituted thereon as defined above. Encompassed by
such radical are the groups acetyl, benzoyl and the like.
[0114] As used herein the term "thio" refers to a radical of the
formula 34
[0115] As used herein the term "sulfonyl" refers to a radical of
the formula 35
[0116] wherein R.sup.27 is alkyl, aryl or aralkyl as defined
above.
[0117] As used herein the term "haloalkylthio" refers to a radical
of the formula --S--R.sup.28 wherein R.sup.28 is haloalkyl as
defined above.
[0118] As used herein the term "aryloxy" refers to a radical of the
formula 36
[0119] wherein R.sup.29 is aryl as defined above.
[0120] As used herein the term "acylamino" refers to a radical of
the formula 37
[0121] wherein R.sup.30 is alkyl, aralkyl or aryl as defined
above.
[0122] As used herein the term "amido" refers to a radical of the
formula 38
[0123] As used herein the term "alkylamino" refers to a radical of
the formula --NHR.sup.32 wherein R.sup.32 is alkyl as defined
above.
[0124] As used herein the term "dialkylamino" refers to a radical
of the formula --NR.sup.33R.sup.34 wherein R.sup.33 and R.sup.34
are the same or different alkyl groups as defined above.
[0125] As used herein the term "trifluoromethyl" refers to a
radical of the formula 39
[0126] As used herein the term "trifluoroalkoxy" refers to a
radical of the formula 40
[0127] wherein R.sup.35 is a bond or an alkylene as defined
above.
[0128] As used herein the term "alkylaminosulfonyl" refers to a
radical of the formula 41
[0129] wherein R.sup.36 is alkyl as defined above.
[0130] As used herein the term "alkylsulfonylamino" refers to a
radical of the formula 42
[0131] wherein R is alkyl as defined above.
[0132] As used herein the term "trifluoromethylthio" refers to a
radical of the formula 43
[0133] As used herein the term "trifluoromethylsulfonyl" refers to
a radical of the formula 44
[0134] As used herein the term "4-12 membered mono-nitrogen
containing monocyclic or bicyclic ring" refers to a saturated or
partially unsaturated monocyclic or bicyclic ring of 4-12 atoms and
more preferably a ring of 4-9 atoms wherein one atom is nitrogen.
Such rings may optionally contain additional heteroatoms selected
from nitrogen, oxygen or sulfur. Included within this group are
morpholine, piperidine, piperazine, thiomorpholine, pyrrolidine,
proline, azacycloheptene and the like.
[0135] As used herein the term "benzyl" refers to the radical
45
[0136] As used herein the term "phenethyl" refers to the radical
46
[0137] As used herein the term "4-12 membered mono-nitrogen
containing monosulfur or monooxygen containing heterocyclic ring"
refers to a ring consisting of 4 to 12 atoms and more preferably 4
to 9 atoms wherein at least one atom is a nitrogen and at least one
atom is oxygen or sulfur. Encompassed within this definition are
rings such as thiazoline and the like.
[0138] As used herein the term "arylsulfonyl" or "arylsulfone"
refers to a radical of the formula 47
[0139] wherein R.sup.37 is aryl as defined above.
[0140] As used herein the terms "alkylsulfoxide" or "arylsulfoxide"
refer to radicals of the formula 48
[0141] wherein R.sup.38 is, respectively, alkyl or aryl as defined
above.
[0142] As used herein the term "phosphonic acid derivative" refers
to a radical of the formula 49
[0143] wherein R.sup.39 and R.sup.40 are the same or different H,
alkyl, aryl or aralkyl.
[0144] As used herein the term "phosphinic acid derivatives" refers
to a radical of the formula 50
[0145] wherein R.sup.41 is H, alkyl, aryl or aralkyl as defined
above.
[0146] As used herein the term "arylthio" refers to a radical of
the formula 51
[0147] wherein R.sup.42 is aryl as defined above.
[0148] As used herein the term "monocyclic heterocycle thio" refers
to a radical of the formula 52
[0149] wherein R.sup.43 is a monocyclic heterocycle radical as
defined above.
[0150] As used herein the terms "monocyclic heterocycle sulfoxide"
and "monocyclic heterocycle sulfone" refer, respectively, to
radicals of the formula 53
[0151] and 54
[0152] wherein R.sup.43 is a monocyclic heterocycle radical as
defined above.
[0153] As used herein the term "alkylcarbonyl" refers to a radical
of the formula 55
[0154] wherein R.sup.50 is alkyl as defined above.
[0155] As used herein the term "arylcarbonyl" refers to a radical
of the formula 56
[0156] wherein R.sup.51 is aryl as defined above.
[0157] As used herein the term "alkoxycarbonyl" refers to a radical
of the formula 57
[0158] wherein R.sup.52 is alkoxy as defined above.
[0159] As used herein the term "aryloxycarbonyl" refers to a
radical of the formula 58
[0160] wherein R.sup.51 is aryl as defined above.
[0161] As used herein the term "haloalkylcarbonyl" refers to a
radical of the formula 59
[0162] wherein R.sup.53 is haloalkyl as defined above.
[0163] As used herein the term "haloalkoxycarbonyl" refers to a
radical of the formula 60
[0164] wherein R.sup.53 is haloalkyl as defined above.
[0165] As used herein the term "alkylthiocarbonyl" refers to a
radical of the formula 61
[0166] wherein R.sup.50 is alkyl as defined above.
[0167] As used herein the term "arylthiocarbonyl" refers to a
radical of the formula 62
[0168] wherein R.sup.51 is aryl as defined above.
[0169] As used herein the term "acyloxymethoxycarbonyl" refers to a
radical of the formula 63
[0170] wherein R.sup.54 is acyl as defined above.
[0171] As used herein the term "arylamino" refers to a radical of
the formula R.sup.51--NH-- wherein R.sup.51 is aryl as defined
above.
[0172] As used herein the term "polyalkylether" refers to commonly
used glycols such as triethyleneglycol, tetraethylene glycol,
polyethylene glycol and the like.
[0173] As used herein the term "alkylamido" refers to a radical of
the formula 64
[0174] wherein R.sup.50 is alkyl as defined above.
[0175] As used herein the term "N,N-dialkylamido" refers to a
radical of the formula 65
[0176] wherein R.sup.50 is the same or different alkyl group as
defined above.
[0177] As used herein the term "pivaloyloxymethyl" refers to a
radical of the formula 66
[0178] As used herein the term "acyloxy" refers to a radical of the
formula R.sup.55--O-- wherein R.sup.55 is acyl as defined
above.
[0179] The term "composition" as used herein means a product which
results from the mixing or combining of more than one element or
ingredient.
[0180] The term "pharmaceutically acceptable carrier", as used
herein means a pharmaceutically acceptable material, composition or
vehicle, such as a liquid or solid filler, diluent, excipient,
solvent or encapsulating material, involved in carrying or
transporting a chemical agent.
[0181] The term "therapeutically effective amount" shall mean that
amount of drug or pharmaceutical agent that will elicit the
biological or medical response of a tissue, system or animal that
is being sought by a researcher or clinician.
[0182] The following is a list of abbreviations and the
corresponding meanings as used interchangeably herein:
[0183] .sup.1H-NMR=proton nuclear magnetic resonance
[0184] AcOH=acetic acid
[0185] Ar=argon
[0186] BH.sub.3-THF=borane-tetrahydrofuran complex
[0187] Bn=benzyl
[0188] BOC=tert-butoxycarbonyl
[0189] ButLi=butyl lithium
[0190] Cat.=catalytic amount
[0191] CDMT=2-chloro-4,6-dimethoxytriazine
[0192] CH.sub.2Cl.sub.2=dichloromethane
[0193] CH.sub.3CN=acetonitrile
[0194] CH.sub.31=iodomethane
[0195] CHN analysis=carbon/hydrogen/nitrogen elemental analysis
[0196] CHNCl analysis=carbon/hydrogen/nitrogen/chlorine
elemental
[0197] analysis
[0198] CHNS analysis=carbon/hydrogen/nitrogen/sulfur elemental
[0199] analysis
[0200] DAST=diethylaminosulfur trifluoride
[0201] DCC=1,3-dicyclohexylcarbodiimide
[0202] DCM=dichloromethane
[0203] DIBAL=diisobutylaluminum hydride
[0204] DIEA=diisopropylethylamine
[0205] DI water=deionized water
[0206] DMA=N,N-dimethylacetamide
[0207] DMAC=N,N-dimethylacetamide
[0208] DMAP=4-(N,N-dimethylamino)pyridine
[0209] DMF=N,N-dimethylformamide
[0210] DSC=disuccinyl carbonate
[0211] EDCI=1-(3-dimethylaminopropyl)-3-ethylcarbodiimide
[0212] hydrochloride
[0213] Et=ethyl
[0214] Et.sub.2O=diethyl ether
[0215] Et.sub.3N=triethylamine
[0216] EtOAc=ethyl acetate
[0217] EtOH=ethanol
[0218] FAB MS=fast atom bombardment mass spectroscopy
[0219] g=gram(s)
[0220] GIHA=meta-guanidinohippuric acid
[0221] GIHA HCl=meta-guanidinohippuric acid hydrochloride
[0222] Gly=glycine
[0223] HMPA=hexamethylphosphoramide
[0224] HOBT=1-hydroxybenzotriazole hydrate
[0225] HPLC=high performance liquid chromatography
[0226] IBCF=isobutylchloroformate
[0227] i-Pr=isopropyl
[0228] i-Prop isopropyl
[0229] K.sub.2CO.sub.3=potassium carbonate
[0230] KMnO.sub.4=potassium permanganate
[0231] KOH=potassium hydroxide
[0232] KSCN=potassium thiocyanate
[0233] L=Liter
[0234] LIOH=lithium hydroxide
[0235] MCPBA=m-chloroperoxybenzoic acid or m-chloroperbenzoic
acid
[0236] Me=methyl
[0237] MeI=methyl iodide
[0238] MeOH=methanol
[0239] MEMCl=methoxyethoxy methyl chloride
[0240] MesCl=methanesulfonylchloride
[0241] mg=milligram
[0242] MgSO.sub.4=magnesium sulfate
[0243] ml=milliliter
[0244] mL=milliliter
[0245] MS mass spectroscopy
[0246] MTBE=methyl t-butyl ether
[0247] N.sub.2=nitrogen
[0248] NaCNBH.sub.3=sodium cyanoborohydride
[0249] NaH--sodium hydride
[0250] NaHCO.sub.3=sodium bicarbonate
[0251] NaOH=sodium hydroxide
[0252] NaOMe=sodium methoxide
[0253] Na.sub.2PO.sub.4=sodium phosphate
[0254] Na.sub.2SO.sub.4=sodium sulfate
[0255] NEt.sub.3=triethylamine
[0256] NH.sub.4HCO.sub.3=ammonium bicarbonate
[0257] NH.sub.4.sup.+HCO.sub.2.sup.-=ammonium formate
[0258] NH.sub.4OH=ammonium hydroxide
[0259] NMM=N-methylmorpholine
[0260] NMP=1-methyl-2-pyrrolidinone
[0261] NMR=nuclear magnetic resonance
[0262] Pd/C=palladium on carbon
[0263] Ph=phenyl
[0264] Pt/C=platinum on carbon
[0265] RPHPLC=reverse phase high performance liquid
[0266] chromatography
[0267] RT=room temperature
[0268] t-BOC=tert-butoxycarbonyl
[0269] TFA=trifluoroacetic acid
[0270] THF=tetrahydrofuran
[0271] TLC--thin layer chromatography
[0272] TMEDA=tetramethylethylenediamine
[0273] TMS=trimethylsilyl
[0274] .DELTA.=heating the reaction mixture
[0275] The compounds as shown in Formulas I-VI can exist in various
isomeric forms and all such isomeric forms are meant to be
included. Tautomeric forms are also included as well as
pharmaceutically acceptable salts of such isomers and
tautomers.
[0276] In the structures and formulas herein, a bond drawn across a
bond of a ring can be to any available atom on the ring.
[0277] The term "pharmaceutically acceptable salt" refers to a salt
prepared by contacting a compound of Formula I with an acid whose
anion is generally considered suitable for human consumption.
Examples of pharmacologically acceptable salts include the
hydrochloride, hydrobromide, hydroiodide, sulfate, phosphate,
acetate, propionate, lactate, maleate, malate, succinate, tartrate
salts and the like. All of the pharmacologically acceptable salts
may be prepared by conventional means. (See Berge et al., J. Pharm.
Sci, 66(1), 1-19 (1977) for additional examples of pharmaceutically
acceptable salts.)
[0278] For the selective inhibition or antagonism of
.alpha..sub.V.beta..sub.3 integrins, compounds of the present
invention may be administered orally, parenterally, or by
inhalation spray, or topically in unit dosage formulations
containing conventional pharmaceutically acceptable carriers,
adjuvants and vehicles. The term parenteral as used herein
includes, for example, subcutaneous, intravenous, intramuscular,
intrasternal, infusion techniques or intraperitonally.
[0279] The compounds of the present invention are administered by
any suitable route in the form of a pharmaceutical composition
adapted to such a route, and in a dose effective for the treatment
intended. Therapeutically effective doses of the compounds required
to prevent or arrest the progress of or to treat the medical
condition are readily ascertained by one of ordinary skill in the
art using preclinical and clinical approaches familiar to the
medicinal arts.
[0280] Accordingly, the present invention provides a method of
treating conditions mediated by selectively inhibiting or
antagonizing the .alpha..sub.V.beta..sub.3 cell surface receptor
which method comprises administering a therapeutically effective
amount of a compound selected from the class of compounds depicted
in Formulas I-VI, wherein one or more compounds of the Formulas
I-VI is administered in association with one or more non-toxic,
pharmaceutically acceptable carriers and/or diluents and/or
adjuvants (collectively referred to herein as "carrier" materials)
and if desired other active ingredients. More specifically, the
present invention provides a method for inhibition of the
.alpha..sub.V.beta..sub.3 cell surface receptors. Most preferably
the present invention provides a method for inhibiting bone
resorption, treating osteoporosis, inhibiting humoral hypercalcemia
of malignancy, treating Paget's disease, inhibiting tumor
metastasis, inhibiting neoplasia (solid tumor growth), inhibiting
angiogenesis including tumor angiogenesis, treating retinopathy
including macular degeneration and diabetic retinopathy, inhibiting
arthritis, psoriasis and periodontal disease, and inhibiting smooth
muscle cell migration including restenosis.
[0281] Based upon standard laboratory experimental techniques and
procedures well known and appreciated by those skilled in the art,
as well as comparisons with compounds of known usefulness, the
compounds of Formula I can be used in the treatment of patients
suffering from the above pathological conditions. One skilled in
the art will recognize that selection of the most appropriate
compound of the invention is within the ability of one with
ordinary skill in the art and will depend on a variety of factors
including assessment of results obtained in standard assay and
animal models.
[0282] Treatment of a patient afflicted with one of the
pathological conditions comprises administering to such a patient
an amount of compound of the Formula I which is therapeutically
effective in controlling the condition or in prolonging the
survivability of the patient beyond that expected in the absence of
such treatment. As used herein, the term "inhibition" of the
condition refers to slowing, interrupting, arresting or stopping
the condition and does not necessarily indicate a total elimination
of the condition. It is believed that prolonging the survivability
of a patient, beyond being a significant advantageous effect in and
of itself, also indicates that the condition is beneficially
controlled to some extent.
[0283] As stated previously, the compounds of the invention can be
used in a variety of biological, prophylactic or therapeutic areas.
It is contemplated that these compounds are useful in prevention or
treatment of any disease state or condition wherein the
.alpha..sub.V.beta..sub.3 integrin plays a role.
[0284] The dosage regimen for the compounds and/or compositions
containing the compounds is based on a variety of factors,
including the type, age, weight, sex and medical condition of the
patient; the severity of the condition; the route of
administration; and the activity of the particular compound
employed. Thus the dosage regimen may vary widely. Dosage levels of
the order from about 0.01 mg to about 1000 mg per kilogram of body
weight per day are useful in the treatment of the above-indicated
conditions.
[0285] The active ingredient administered by injection is
formulated as a composition wherein, for example, saline, dextrose
or water may be used as a suitable carrier. A suitable daily dose
would typically be about 0.01 to 10 mg/kg body weight injected per
day in multiple doses depending on the factors listed above.
[0286] For administration to a mammal in need of such treatment,
the compounds in a therapeutically effective amount are ordinarily
combined with one or more adjuvants appropriate to the indicated
route of administration. The compounds may be admixed with lactose,
sucrose, starch powder, cellulose esters of alkanoic acids,
cellulose alkyl esters, talc, stearic acid, magnesium stearate,
magnesium oxide, sodium and calcium salts of phosphoric and
sulphuric acids, gelatin, acacia, sodium alginate,
polyvinylpyrrolidone, and/or polyvinyl alcohol, and tableted or
encapsulated for convenient administration. Alternatively, the
compounds may be dissolved in water, polyethylene glycol, propylene
glycol, ethanol, corn oil, cottonseed oil, peanut oil, sesame oil,
benzyl alcohol, sodium chloride, and/or various buffers. Other
adjuvants and modes of administration are well and widely known in
the pharmaceutical art.
[0287] The pharmaceutical compositions useful in the present
invention may be subjected to conventional pharmaceutical
operations such as sterilization and/or may contain conventional
pharmaceutical adjuvants such as preservatives, stabilizers,
wetting agents, emulsifiers, buffers, etc.
[0288] The general synthetic sequences for preparing the compounds
useful in the present invention are outlined in Schemes 1-15. Both
an explanation of, and the actual procedures for, the various
aspects of the present invention are described where appropriate.
The following Schemes and Examples are intended to be merely
illustrative of the present invention, and not limiting thereof in
either scope or spirit. Those with skill in the art will readily
understand that known variations of the conditions and processes
described in the Schemes and Examples can be used to synthesize the
compounds of the present invention.
[0289] Unless otherwise indicated all starting materials and
equipment employed were commercially available. 67 68 69
[0290] Schemes 1-3 are illustrative of methodology useful for
preparing the guanidinopyridine/cycloguanidino pyridine carboxylic
acid portions of the present invention which are used for coupling
to the gly-.beta.-amino acid portion. This can be accomplished
using other appropriate guanidating reagents known to those skilled
in the art. The methodologies of Schemes 1-3 can be modified using
conventional techniques and methods to prepare alternate compounds
useful for coupling to the gly-.beta.-amino acid portion. 70
[0291] Scheme 4 is illustrative of methodology used for preparing
the guanidinothiazole carboxylic acid portion of the present
invention which is used for coupling to the gly-.alpha.-amino acid
portion. The methodology of Scheme 4 can be modified using
conventional techniques known to those skilled in the art to
prepare this and alternate compounds useful for coupling to the
gly-.alpha.-amino acid portion. 71
[0292] Scheme 5 illustrates methodology useful for preparing the
ethyl N-gly-amino-3-(3,5-dihalo-2-hydroxy)phenyl propionate portion
of the compounds of the present invention. Briefly, 3,5-halo
substituted salicylaldehydes (halo
substituted-2-hydroxybenzaldehydes) were prepared by direct
halogenation. For example, 5-bromosalicylaldehyde is slurried in
acetic acid and an equivalent or more of chlorine is added to
produce 3-chloro-5-bromo-2-hydroxybenzaldehyde.
[0293] Some product precipitates and is recovered by filtration.
The remainder is recovered by diluting the filtrate with water and
isolating the precipitate. Combining the solids and drying gives
3-chloro-5-bromo-2-hydroxybenzaldehyde.
3-iodo-5-chlorosalicylaldehyde was prepared by reacting
5-chlorosalicylaldehyde with N-iodosuccinimide in DMF and
subjecting the reaction mixture to conventional work-up conditions.
3-iodo-5-bromosalicylaldehyde can be prepared by reacting
5-bromosalicylaldehyde in acetonitrile with potassium iodide and
chloramine T. Conventional work-up gives a material that when
treated with hexanes gives the desired
3-iodo-5-chlorosalicylaldehyde.
[0294] Coumarins are readily prepared from salicylaldehydes using a
modified Perkin reaction (e.g., Vogel's Textbook of Practical
Organic Chemistry, 5th Ed., 1989, p.1040). The halo-substituted
coumarins were converted to 3-aminohydrocoumarins (see J. G. Rico,
Tett. Let., 1994, 35, 6599-6602) which were readily opened in
acidic alcohol to give 3-amino-3-(3,5-halo-2-hydroxy)phenyl
propanoic acid esters.
[0295] 3-amino-3-(3,5-halo-2-hydroxy)phenyl propanoic acid esters
were converted to N-gly-3-amino-3-(3,5-halo-2hydroxy)phenyl
propanoic acid esters by reaction of Boc-N-gly-N-hydroxysuccinimide
to give Boc-N-gly-3-amino-3-(3,5-halo-2-hydroxy)phenyl propanoic
acid esters that were converted to HX salts of
N-gly-3-amino-3-(3,5-halo-2-hydroxy)phenyl propanoic acid esters
(wherein X is Cl, Br or I). 72
[0296] Scheme 6 illustrates methodology useful for coupling the
heterocyclic acid portion (A1-A13) to the gly-.alpha.-amino portion
(C) of the present invention.
[0297] Synthesis of A1-A13 is illustrated in Schemes 14 and
synthesis of (C) is illustrated in Scheme 5 (where X and Y were
halogen, same or different).
[0298] Such methodology can be modified using conventional methods
known to those with ordinary skill in the art. 73
[0299] Scheme 7 illustrates methodology for preparing the
gly-.beta.-amino acid portion of the molecule (F) in a general
manner.
[0300] Aldehydes (R'CHO) used in this methodology are either
commercially available or can be prepared from commercially
available reagents using methodologies for the preparation of
aldehydes which are commonly known to those with ordinary skill in
the art.
[0301] All other reagents are commercially available or can be
readily synthesized by one skilled in the art.
[0302] Such methodologies and conditions can be further modified
using conventional techniques to produce similar desired
intermediates, 74
[0303] Scheme 8 illustrates methodology useful for coupling the
heterocyclic acid portion (A1-13) to a gly-.beta.-amino acid
portion (F) to prepare compounds of the present invention.
[0304] The synthesis of A1-13 is illustrated in Schemes 14 and the
synthesis of (F) is illustrated in Scheme 7.
[0305] Such methodology can be modified using conventional methods
known to those with ordinary skill in the art.
[0306] Schemes 9-12 illustrate general methodology for preparing
compounds of the present invention. 75
[0307] Scheme 9 illustrates the general methodology for the
synthesis of the heterocycle derived gly-.beta.-amino acid coupled
target compounds. The reaction of the heterocyclic carboxylic acid
with gly-.beta.-amino acid under peptide coupling conditions gives
the intermediate (2). Reduction of the nitro group using catalytic
hydrogenation (e.g. Pt/C, H.sub.2) gives the amino intermediate
(3). This transformation may also be carried out chemically using
SnCl.sub.2. The amino group can be elaborated to guanidino or other
functional groups of Formula I using the methodologies discussed
above. 76
[0308] Alternatively, the target compounds may be synthesized by
building the left hand portion of the molecule prior to coupling
with the gly-.alpha.-amino acid (Scheme 10). The amino
functionality of the heterocycle amine (1) is functionalized to the
guanidine or other groups (A, Formula I) and then coupled to the
gly-.beta.-amino acid under standard coupling conditions. 77
[0309] Scheme 11 shows a general synthesis of substituted pyridines
and pyridone derived target compounds. Nitration of
6-hydroxynicotinic acid followed by chlorination gives
6-chloro-5-nitronicotinic acid. Coupling of the intermediate 3 with
the gly-.beta.-amino acid gives the product 4. The chloro group in
versatile intermediate 4 can be readily displaced by a variety of
nucleophiles to give 5. Reduction of the nitro group on 4 or 5 and
further elaboration of the amino group as discussed in Scheme 9
gives the target compounds. 78
[0310] Scheme 12 shows the synthesis of substituted pyridine and
pyridone derived target compounds starting with
2-amino-6-hydroxypridine-4-carboxy- lic acid. The starting material
1 used in the scheme may be prepared by reacting commercially
available 2-chloro-6-methoxy-pyridine-4-carboxylic acid with
ammonium hydroxide under high pressure conditions. Elaboration of
the amino group followed by coupling to the gly-.beta.-amino acid
as discussed in Scheme 10 gives the target compounds. 79
[0311] Scheme 13 shows the synthesis of isomeric pyridines and
pyridones starting with 6-amino-4-methoxy-picolinic acid. The
starting material 1 used in the Scheme 13 may be prepared as
described in the literature (J. Am. Chem. Soc., 78, 4130, 1956).
Functionalization of the amino group in 1 followed by coupling
reaction and hydrolysis (as in Scheme 10) gives the target
compounds. 80
[0312] The isomeric pyridine and pyridone derived compounds may be
prepared using the methodology shown in Scheme 14. The key
intermediate 4 may be prepared by starting with 6-chloro-picolinic
acid. Oxidation followed by nitration gives the 4-nitropyridine
derivative (3). Deoxygenation of the N-oxide, reduction of the
nitro group and nucleophilic displacement of chloro group gives the
intermediate 4. The methodology discussed in Scheme 10 may be
applied to achieve the synthesis of target compounds. 81
[0313] The methodology shown in Scheme 10 can also be used for the
synthesis of pyrimidine derived target compounds (Scheme 15). The
isomeric pyrimidine derivatives 1 and 2 may be synthesized by
following the literature preparations (J. Org. Chem., 26, 2755,
1961).
EXAMPLE A
[0314] Preparation of 82
[0315] 5-aminonicotinic acid (4.0 g, 0.021 mole) (Helv. Chim. Acta,
47, 363 (1964); JACS, 70, 2381 [1948]), 1
H-pyrazole-1-carboxamidine hydrochloride (4.6 g, 0.031 mole),
diisopropylethylamine (8.0 g, 0.062 mole), dioxane (14 mL) and
H.sub.2O (7 mL) were heated at reflux for 2 days. The reaction was
cooled to room temperature, the precipitate was filtered, washed
with H.sub.2O/dioxane (50:50) and dried. The precipitate was
slurried in H.sub.2O and made acidic with 2N HCl. The solvent was
removed under vacuum to yield the above compound as a white solid
(750 mg).
[0316] MS and .sup.1H-NMR were consistent with the desired
structure.
EXAMPLE B
[0317] Preparation of 83
[0318] Step 1
[0319] To 3,4,5,6-tetrahydro-2-pyrimidine thiol (10 g, 0.086 mole)
(Aldrich) in absolute ethanol (75 ml) is added MeI (12.2 g, 0.086
mole). The reaction was stirred at reflux for 2.5 hours. The
solvent was removed under vacuum and the product dried to yield
2-methyl thio-3,4,5,6-tetrahydro-2-pyrimidine hydroiodide as a
white solid (22 g).
[0320] MS and .sup.1H-NMR were consistent with the desired
structure.
[0321] Step 2
[0322] To the product from Step 1 above (5.3 g, 0.021 mole) and
triethylamine (2.07 g, 0.021 mole) in CH.sub.2Cl.sub.2 (25 mL) was
added BOC anhydride (4.5 g, 0.021 mole) at ice bath temperature.
The reaction was then stirred at room temperature for 2 days. The
CH.sub.2Cl.sub.2 was washed with H.sub.2O (3.times.), dried over
MgSO.sub.4, and removed under vacuum to yield
N-Boc-2-methylthio-3,4,5,6-tetrahydro-2-pyrimidine (4.14 g).
[0323] MS and .sup.1H-NMR were consistent with the desired
structure.
[0324] Step 3
[0325] The product from Step 2 above (3.08 g, 0.0134 mole),
5-aminonicotinic acid (1.8 g, 0.0134 mole) in DMA (12 mL) was
heated at 80-85.degree. C. for 2 weeks. The reaction mixture was
diluted with CH.sub.3CN, the precipitate was filtered, washed with
CH.sub.3CN and dried. The precipitate was slurried in H.sub.2O and
the pH was lowered to 1-2 with concentrated HCl. The solution was
frozen and lyopholized to yield the desired product as a light
brown solid (1.2 g). MS and .sup.1H-NMR were consistent with the
desired structure.
EXAMPLE C
[0326] Preparation of 84
[0327] Step 1
[0328] To 2-methylthio-2-imidazoline hydroiodide (20 g, 0.082 mole)
(Aldrich), and triethylamine (8.28 g, 0.082 mole) in
CH.sub.2Cl.sub.2 (100 mL) was added BOC anhydride (17.9 g, 0.082
mole) at ice bath temperature. The reaction was stirred overnight
at room temperature. The CH.sub.2Cl.sub.2 was washed with H.sub.2O
(2.times.), dried over MgSO.sub.4 and removed under vacuum to yield
N-BOC-2-methylthio-2-imidazo- line as a viscous oil turned waxy
white solid (15.93 g).
[0329] MS and .sup.1H-NMR were consistent with the desired
structure.
[0330] Step 2
[0331] The product from Step 1 above (15.93 g, 0.0737 mole),
5-aminonicotinic acid (9.6 g, 0.07 mole), and triethylamine (7.1 g,
0.07 mole) in DMA (60 mL) was heated at 100.degree. C. for 2 days,
then at 130.degree. C. for 1 day, and at 150.degree. C. for 2
additional days. After cooling and diluting the reaction mixture
with CH.sub.3CN, the precipitate was filtered, washed with ether
and dried (zwitterion yield is 10.16 g). This was slurried in
H.sub.2O and made acidic with TFA (pH 1-2). The solution was frozen
and lyophilized to yield the desired product as a light yellow
solid (20.15 g).
[0332] MS and .sup.1H-NMR were consistent with the desired
structure.
EXAMPLE D
[0333] Preparation of 85
[0334] Step 1
[0335] Preparation of 86
[0336] To a 2 L round bottom flask fitted with a mechanical stirrer
and condenser was placed 3,5-dichlorosalicylaldehyde (200.0 g, 1.05
mol, 1 equivalent), acetic anhydride (356 g, 3.49 mol) and
triethylamine (95.0 g, 0.94 mol, 0.90 equivalent). The reaction
solution was heated at reflux overnight. The dark brown reaction
mixture was cooled to 50.degree. C. and water (1 L) added with
stirring. After one hour the mixture was filtered and the filtrate
combined with EtOH (1 L). This mixture was heated to 45.degree. C.
for one hour, cooled to room temperature, filtered and the solid
(fraction A) washed with EtOH (0.5 L). The combined EtOH solutions
were concentrated by rotary evaporation to produce an oil (fraction
B). The solid from fraction A was dissolved in methylene chloride
(1.5 L) and the resulting solution passed through a pad of silica
gel (1300 mL volume). The resulting dark brown solution was
concentrated to an oil that was triturated with hexanes (1.3 L) to
give a solid that was isolated by filtration and washed (hexanes)
to give substantially pure 6,8-dichlorocoumarin (163 g). An
additional 31 g of product was obtained by treating the oil
(fraction B) in a similar fashion; the oil was dissolved in
methylene chloride (0.5 L) passed through a silica pad (0.5 L
volume) and triturated with hexanes. The total isolated yield is
194 g or 86% of the brown solid.
[0337] MS and .sup.1H-NMR were consistent with the desired
product.
[0338] Step 2
[0339] Preparation of 87
[0340] To a 3-neck 2 L round bottom flask fitted with a mechanical
stirrer was placed 6,8-dichlorocoumarin (160 g, 0.74 mol) prepared
in Step 1 and dry THF (375 mL, Aldrich Sure Seal). The resulting
mixture was cooled to -40.degree. C. (dry ice-acetone bath) and
lithium bis(trimethylsilyl)amid- e (0.80 mol, 800 mL of 1M in THF)
added while maintaining the temperature below -40.degree. C. Upon
completion of the addition the cooling bath was removed. After 0.5
hour the mixture was warmed to -5.degree. C. The reaction was
quenched by addition of a solution of HCl (0.5 L of 4M in dioxane)
in EtOH (1.25 L). The temperature was maintained below 0.degree. C.
overnight. The reaction mixture was concentrated to about one-half
its original volume and partitioned between EtOAc (3 L) and water
(2 L). The organic layer was washed with aqueous HCl (3.times.1 L,
0.5 N HCl). The pH of the combined water layers was adjusted to
about 7 by addition of 10% aqueous NaOH and extracted with
methylene chloride (3.times.2 L). The combined organic layers were
dried (MgSO.sub.4), filtered, and HCl (210 mL of 4M in dioxane)
added with stirring. Upon completion of precipitation the solid was
removed by filtration. The filtrate was concentrated to a small
volume and methyl t-butyl ether added. The solid obtained was
combined with the initially formed solid and the combined product
was washed with methyl t-butyl ether, isolated by filtration and
dried (vacuum oven over a weekend) to obtain the desired product
(172 g, 74% yield).
[0341] MS and .sup.1H-NMR were consistent with the desired
product.
[0342] Step 3
[0343] Preparation of 88
[0344] To a flame-dried round bottom flask (0.5 L) equipped with
magnetic stir bar was added N-t-Boc-glycine N-hydroxysuccinimide
ester (Sigma, 15.0 g, 0.055 mol), dry DMF (Aldrich Sure Seal, 200
mL) and the product from Step 2 (21.67 g, 0.055 mol) under an inert
atmosphere (Ar). The reaction mixture was cooled to approximately
0.degree. C. (salt-ice bath) and N-methyl morpholine (5.58 g, 0.056
mole) and a catalytic amount of DMAP added. The reaction was
allowed to proceed overnight. The reaction mixture was concentrated
to a slush, and partitioned between EtOAc (0.4 L) and aqueous base
(2.times.0.2 L, aqueous saturated NaHCO.sub.3). The organic layer
was washed consecutively with aqueous citric acid (2.times.0.2 L,
10% w/v), with aqueous sodium bicarbonate (2.times.0.2 L), brine
and dried (Na.sub.2SO.sub.4). Volatiles were removed under vacuum
at 55.degree. C. to give an oil (22.5 g, 92% yield) that solidified
on standing.
[0345] MS and .sup.1H-NMR were consistent with the desired
product.
[0346] Step 4
[0347] Preparation of 89
[0348] The product obtained in Step 3 was deprotected to give the
amine hydrochloride salt using the following procedure. To the
product obtained in Step 3 (14.0 g, 0.032 mole) in a flame-dried
round bottom flask (0.1 L) with stir bar was added dry dioxane (40
mL). To this solution was added HCl (4.0 N in dioxane, 2
equivalents, 6.32 mL) at 0.degree. C. The reaction was allowed to
proceed until gas evolution ceased and the reaction was complete.
Volatiles were removed under vacuum and the residue triturated with
diethyl ether (50 mL). Solids were collected by filtration, washed
with ether and dried to give the desired product (12.5 g).
[0349] MS and .sup.1H-NMR were consistent with the desired
product.
EXAMPLE E
[0350] Preparation of 90
[0351] Step 1
[0352] Preparation of
[0353] To a suspension of 3-bromo-5-chlorosalicylaldehyde (175 g,
743.2 mmol) in acetic anhydride (280.5 mL, 3 mol) was added
triethylamine (103.6 mL, 743.2 mmol). The reaction solution was
heated at reflux for 4.5 hours. The solution was cooled and
concentrated in vacuo. The brown residue was added to absolute
ethanol (730 mL). The mixture was stored at 0.degree. C. for 14
hours. The brown solid was collected by filtration and washed with
cold ethanol. The solid was dried in vacuo to give the desired
product (123 g, 64% yield). .sup.1H-NMR was consistent with the
proposed structure.
[0354] Step 2
[0355] Preparation of 91
[0356] To a suspension of the coumarin produced in Step 1 (40.0 g,
154.1 mmol) in THF (400 mL) at -76.degree. C. was added dropwise
with stirring lithium bis(trimethylsilyl)amide (154.1 mL of a 1M
solution in THF). The addition was completed in 10 minutes. The
reaction mixture was then stirred for 5 minutes, warmed to
-20.degree. C. and stirred for 15 minutes. To this solution was
added acetic acid (9.25 g, 154.1 mmol) in THF (28 mL) over 5
minutes. The mixture was warmed to room temperature and volatiles
were removed in vacuo. The residue was dissolved in ether (850 mL),
washed with saturated aqueous NaHCO.sub.3 (2.times.100 mL), brine
(2.times.40 mL) and dried (MgSO.sub.4). The ether solution was
concentrated to about 160 mL, and cooled to 0.degree. C. To this
suspension was added HCl (4 M in dioxane, 56.3 mL, 225 mmol) and
the mixture was stirred at 0.degree. C. for 30 minutes. The
suspension was filtered and the filter cake exhaustively washed
with ether. The solid was dried in vacuo to give the desired
product as the HCl salt, dioxane solvate (45 g). .sup.1H-NMR was
consistent with the proposed structure.
[0357] Step 3
[0358] Preparation of 92
[0359] To a suspension of the lactone produced in Step 2 (142.2 g,
354.5 mmol) in absolute ethanol (533 mL) was added HCl (4M in
dioxane, 157.8 mL, 631.1 mmol) over 10 minutes. The reaction
mixture was stirred at room temperature for 2.5 hours. Volatiles
were removed in vacuo. The residue was dissolved in ethyl acetate
(450 mL) and the solution kept at 0.degree. C. for 15 hours. The
tan precipitate was collected by filtration and washed with cold
ethyl acetate. The solid was dried in vacuo to give the desired
product as the hydrochloride salt (100.4 g, 79% yield). .sup.1H-NMR
was consistent with the proposed structure.
[0360] Step 4
[0361] Preparation of 93
[0362] To a flame-dried round bottom flask (0.1 L) equipped with
magentic stir bar was added N-t-Boc-glycine N-hydroxysuccinimide
ester (Sigma, 2.72 g, 0.010 mol), dry THF (Aldrich Sure Seal, 50
mL) and the product of Step 3 (3.10 g, 0.01 mole, vacuum desiccated
overnight over P.sub.2O.sub.5) under an inert atmosphere (Ar). The
reaction mixture was cooled to approximately 0.degree. C. (salt-ice
bath) and triethylamine (1.01 g, 0.010 mole) was added. The
reaction was allowed to proceed overnight. The reaction mixture was
concentrated to a semi-solid and worked up in a fashion similar to
Example A, Step 3. Volatiles were removed from the organic layer
under vacuum at 55.degree. C. to give an oil (4.0 g, 83% yield)
that solidified on standing.
[0363] MS and .sup.1H-NMR were consistent with the desired
product.
[0364] Step 5
[0365] Preparation of 94
[0366] The product obtained in Step 4 was deprotected to give the
hydrochloride salt using the following procedure. To the product
obtained in Step 4 (4.0 g, 0.0084 mole) in a flame-dried round
bottom flask (0.1 L) with stir bar was added dry dioxane (20 mL).
To this was added HCl (4N in dioxane, mL) and the reaction allowed
to proceed until gas evolution ceased and the reaction was complete
(about 1 hour). Volatiles were removed under vacuum and the residue
triturated with diethyl ether (50 mL). Solids were collected by
filtration, washed with ether and dried to give a light brown solid
(2.7 g, 78% yield).
[0367] MS and .sup.1H-NMR were consistent with the desired
product.
EXAMPLE F
[0368] Preparation of 95
[0369] Step 1
[0370] Preparation of 3-iodo-5-chlorosalicylaldehyde 96
[0371] N-Iodosuccinimide (144.0 g, 0.641 mole) was added to a
solution of 5-chlorosalicylaldehyde (100 g, 0.638 mole) in
dimethylformamide (400 mL). The reaction mixture was stirred for 2
days at room temperature. Additional N-iodosuccinimide (20.0 g) was
added and the stirring was continued for additional 2 days. The
reaction mixture was diluted with ethyl acetate (1 L), washed with
hydrochloric acid (300 mL, 0.1 N), water (300 mL), sodium
thiosulfate (5%, 300 mL), brine (300 mL), dried (MgSO.sub.4) and
was concentrated to dryness to afford the desired aldehyde as a
pale yellow solid (162 g, 90% yield).
[0372] .sup.1H-NMR and MS were consistent with the desired
product.
[0373] Step 2
[0374] Preparation of 6-chloro-8-iodocoumarin 97
[0375] A mixture of 3-iodo-5-chlorosalicylaldehyde (100 g, 0.354
mole), acetic anhydride (300 mL) and triethylamine (54 mL) was
heated at reflux for 18 hours. Upon cooling, the desired coumarin
precipitated as a dark brown crystalline material. The precipitate
was filtered, washed with hexane/ethyl acetate (4:1, 200 mL), and
air dried. [Yield: 60 g (55% yield)]. Additional quantities of the
desired product (10 g, 9% yield) can be obtained from the filtrate,
upon storage.
[0376] .sup.1H-NMR and MS indicated this to be the desired
product.
[0377] Step 3
[0378] Preparation of
(R,S)-4-amino-3,4-dihydro-6-chloro-8-iodocoumarin hydrochloride
98
[0379] Lithium hexamethyldisilazane (21.62 mL, 1M, 21.62 mmol) was
added to a solution of 6-chloro-8-iodocoumarin (6.63 g, 21.62 mmol)
in tetrahydrofuran (100 mL) at -78.degree. C. The reaction mixture
was stirred at this temperature for 30 minutes, then at 0.degree.
C. for 1 hour. Acetic acid (1.3 g, 21.62 mmol) was added to the
reaction mixture. The reaction mixture was poured into an ethyl
acetate (300 mL) and saturated sodium carbonate (200 mL) solution.
The organic layer was separated, washed with brine (200 mL)
followed by dioxane/HCl (4N, 30 mL) at 0.degree. C. The reaction
mixture was stirred for 1 hour at room temperature, filtered, and
was dried in vacuo to afford the desired product as a powder (4.6
g, 59% yield). (rphplc: Rf 6.8 minutes; Gradient 10%
acetonitrile-90% acetonitrile over 15 minutes then to 100%
acetonitrile over the next 6 minutes. Both water and acetonitrile
contain 0.1% TFA. Vydac C18 protein peptide column, 2 mL/min flow
rate, monitored at 254 nm).
[0380] .sup.1H-NMR and MS were consistent with the desired
product.
[0381] Step 4
[0382] Preparation of (R,S)-ethyl
3-amino-3-(5-chloro-2-hydroxy-3-iodo)phe- nyl propionate
hydrochloride 99
[0383] Hydrogen chloride gas was bubbled into a solution of
4-amino-3,4-dihydro-6-chloro-8-iodocoumarin hydrochloride (22.0 g,
61.09 mmol) in ethanol (250 mL) keeping the reaction mixture at
0-10.degree. C. until saturation. After 6 hours at reflux, most of
the solvent was removed by distillation. The cooled residue was
added to anhydrous ether and was stirred for 2 hours. The initial
gum turned in to a crystalline material. The crystalline product
was filtered and was dried to afford the desired product as an
off-white crystalline powder (20 g, 81% yield). (Rf. 7.52 min,
conditions as Step 3).
[0384] .sup.1H-NMR and MS were consistent with the desired
product.
[0385] Step 5
[0386] Preparation of (R,S)-ethyl
3-(N-BOC-gly)-amino-3-(5-chloro-2-hydrox- y-3-iodo)phenyl
propionate 100
[0387] A mixture of BOC-gly (2.16 g, 12.31 mmol), HOBT (1.67 g,
12.31), EDCl (2.36 g, 12.31 mmol) and DMF (50 mL) was stirred at
0.degree. C. for 1 hour. Ethyl
3-amino-3-(5-chloro-2-hydroxy-3-iodo)propionate hydrochloride (5.0
g, 12.31 mmol) was added to the reaction mixture followed by
triethylamine (3.5 mL). The reaction mixture was stirred for 18
hours at room temperature. DMF was removed in vacuo and the residue
was partitioned between ethyl acetate (300 mL) and sodium
bicarbonate (200 mL). The organic layer was washed with
hydrochloric acid (1N, 100 mL), brine (200 mL), dried (MgSO.sub.4)
and was concentrated to afford the desired product as a solid (6 g,
93% yield).
[0388] .sup.1H-NMR and MS were consistent with the desired
product.
[0389] Step 6
[0390] Preparation of (R,S)-ethyl
3-(N-gly)-amino-3-(5-chloro-2-hydroxy-3-- iodo)phenyl propionate
hydrochloride 101
[0391] Dioxane/HCl (4N, 20 mL) was added to ethyl
3-(N-BOC-gly)-amino-3-(5- -chloro-2-hydroxy-3-iodo)propionate (6.0
g, 11.30 mmol) at 0.degree. C. and was stirred at room temperature
for 3 hours. The reaction mixture was concentrated, and
concentrated once more after addition of toluene (100 mL). The
residue obtained was suspended in ether, was filtered and dried to
afford the desired product as a crystalline powder (5.0 g, 95%
yield). (rphplc: Rf 8.3 min. conditions as Step 3).
[0392] .sup.1H-NMR and MS were consistent with the desired
product.
EXAMPLE G
[0393] Preparation of 102
[0394] Step 1
[0395] Preparation of Reformatski Reagent
BrZnCH.sub.2CO.sub.2-t-Bu
[0396] A 4-L flask fitted with a condenser, temperature probe and
mechanical stirrer was charged with Zn metal (180.0 g, 2.76 mol,
30-100 mesh) and THF (1.25 L). While stirring 1,2-dibromoethane
(4.74 mL, 0.06 mol) was added via syringe [alternatively, TMS Cl
(0.1 eq.) at room temperature for one hour may be substituted].
After inert gas purge (3 N.sub.2/vacuum cycles) the suspension of
zinc in THF was heated to reflux (65.degree. C) and maintained at
this temperature for 1 hour. The mixture was cooled to 50.degree.
C. before charging tert-butyl bromoacetate (488 g, 369 mL, 2.5 mol)
via 50 mL syringe and syringe pump (delivery set to 4.1 mL/min)
over 1.5 hours. Reaction temperature of 50.degree.+/-5.degree. C.
was maintained throughout the addition. The reaction mixture was
allowed to stir at 50.degree. C. for one hour after the addition
was complete. Subsequently, the mixture was allowed to cool to
25.degree. C. and the precipitated product allowed to settle. The
THF mother liquor is decanted into a 2-L round bottom flask using a
coarse fritted filter stick and partial vacuum transfer (20 mm Hg).
This removed about 65% of the THF from the mixture.
1-Methyl-2-pyrrolidinone (NMP, 800 mL) was added and agitation
resumed for 5 minutes. The reaction mixture can be filtered to
remove any remaining zinc. Analysis indicated a titer of desired
Reformatski reagent of 1.57 M with a molar yield of 94%.
Alternatively, the solid reagent can be isolated by filtration from
the original reaction mixture. The cake was washed with THF until a
white solid was obtained and dried under N.sub.2 to obtain the
desired product as a mono THF solvate that may be stored at
-20.degree. C. (desicated) for extended periods. Typical recoveries
are 85-90%.
[0397] Step 2
[0398] A. Preparation of 103
[0399] Potassium carbonate (powder, oven dried at 100.degree. C.
under vacuum, 8.82 g, 60 mmoles) was added to a solution of
3,5-dichlorosalicylaldehyde (11.46 g, 60 moles) in DMF (40 mL) at
room temperature to give a bright yellow slurry. MEMCI (neat, 7.64
g, 61 mmoles) was then added while maintaining the bath temperature
at 20.degree. C. The mixture was stirred at 22.degree. C. for 6
hours and MEMCI (0.3 g, 2.4 mmoles) was added. The mixture was
stirred for another 0.5 hour and the reaction mixture poured into
cold water (200 mL) to precipitate the product. The slurry was
filtered on a pressure filter and the cake was washed with water
(2.times.50 mL) and dried under N.sub.2/vacuum to afford the
product as an off white solid (14.94 g, 89% yield).
[0400] .sup.1H-NMR (CDCl.sub.3, TMS) 3.37 (s, 3H), 3.54 to 3.56 (m,
2H), 3.91 to 3.93 (m, 2H), 5.30 (s, 2H), 7.63 (d, 1H), 7.73 (d,
1H), 10.30 (s, 1H); .sup.13C NMR (CDCl.sub.3, TMS) .delta. (ppm):
59.03, 70.11, 99.57, 126.60, 129.57, 130.81, 132.07, 135.36,
154.66, 188.30. DSC: 48.24.degree. C. (endo 90.51 J/g).
[0401] Microanalytical: calculated for
C.sub.11H.sub.12Cl.sub.2O.sub.4: C, 47.33%; H, 4.33%; Cl, 25.40%
Found: C, 47.15%; H, 4.26%; Cl, 25.16%.
[0402] B. Preparation of 104
[0403] The product from Step 2A (35.0 g, 0.125 mol) was charged in
a 1-L 3-neck round bottom flask fitted with a mechanical stirrer
and an addition funnel followed by addition of THF (200 mL). The
solution was stirred at 22.degree. C. and (S)-phenylglycinol (17.20
g, 0.125 mol) was added at once. After 30 minutes at 22.degree. C.,
MgSO.sub.4 (20 g) was added. The mixture was stirred for 1 hour at
22.degree. C., and filtered on a coarse fritted filter. The
filtrate was concentrated under reduced pressure. No further
purification was performed and the crude imine was used directly in
the coupling reaction, Step 2, C.
[0404] C. Preparation of 105
[0405] A 1-L 3-neck round bottom flask fitted with a mechanical
stirrer and an addition funnel was charged with solid reagent from
Step 1 (91.3 g, 0.275 mol) and NMP (200 mL) under nitrogen. The
solution was then cooled to -10.degree. C. and stirred at 350 rpm.
A solution of imine (prepared in Step B) in NMP was prepared under
nitrogen and then added over 20 minutes to the above reaction
mixture while the temperature was maintained at -5.degree. C.
(jacket temperature -10.degree. C). The mixture was stirred for an
additional 1.5 hours at -8.degree. C. and one hour at -5.degree. C.
after the addition was complete. After cooling to -10.degree. C. a
mixture of concentrated HCl/saturated solution of NH.sub.4Cl (100
mL), water (100 mL) and brine (100 mL) was added to the solution.
MTBE (200 ml) was added and the mixture was stirred for 15 minutes
at 23.degree. C. at 200 rpm. Stirring was stopped and the layers
separated. The aqueous layer was extracted with MTBE (100 ml). The
two organic layers were combined, washed successively with a
saturated solution of NH.sub.4Cl (100 ml), water (100 ml), and
brine (100 ml). The solution was dried with MgSO.sub.4 (30 g),
filtered and concentrated to afford an orange oil (66.3 g)
(solidifies in standing) containing the desired product as a single
diastereoisomer as determined by proton and carbon nmr. A sample
was purified for analysis by recrystallization from heptane to
afford the product as an off-white solid. Proton and carbon nmr and
IR spectra were consistent with the desired product.
[.alpha.].sup.D.sub.25=+8.7.degree. (c=1.057, MeOH).
Microanalytical: calculated for C.sub.25H.sub.33Cl.sub.2NO.sub.6:
C, 58.77%; H, 6.47%; N, 2.72%; Cl, 13.78% Found: C, 58.22%; H,
6.54%; N, 2.70%; Cl, 13.66%.
[0406] Step 3
[0407] Preparation of 106
[0408] A. A solution of crude ester prepared in Step 2 [17.40 g,
0.033 mole (theory)], and EtOH (250 mL) was charged to a 1-L 3-neck
jacketed reactor. The solution was cooled to 0.degree. C. and
Pb(OAc).sub.4 (14.63 g, 0.033 mole) was added at once. After 2
hours a 15% solution of NaOH (30 mL) was added and ethanol was
removed under reduced pressure. Another portion of 15% NaOH (100
mL) was added and the mixture extracted with MTBE (2.times.100 mL),
washed with H.sub.2O (2.times.100 mL) and brine (50 mL), dried with
Na.sub.2SO.sub.4, filtered on celite and concentrated under reduced
pressure to afford an orange oil (12.46 g) which was homogeneous as
determined by tic. The oil was used without further
purification.
[0409] B. The oil from A, was diluted with EtOH (30 mL) and
paratoluene sulfonic acid (1.3 eq., 0.043 mole, 8.18 g) was added.
The solution was heated to reflux for 8 hours, cooled to ambient
temperature and concentrated under reduced pressure. The residue
was treated with THF (20 mL) and heated to reflux to form a
solution. The solution was cooled to room temperature and the
compound crystallized. Heptane (30 mL) and THF (10 mL) were added
to form a fluid slurry which was filtered. The cake was washed with
THF/heptane (40 mL, 1/1) and vacuum dried for two hours in a
pressure filter under nitrogen to afford a white solid (7.40
g).
[0410] Proton and carbon NMR and IR spectra were consistent with
the desired product as substantially a single enantiomer.
[0411] Microanalytical: calculated for
C.sub.18H.sub.21Cl.sub.2NO.sub.6S, 0.25 C.sub.4H.sub.8O: C, 48.73%;
H, 4.95%; N, 2.99%; Cl, 15.14% Found: C, 48.91%; H, 4.95%; N,
2.90%; Cl, 14.95%.
[0412] Step 4
[0413] Preparation of 107
[0414] To a 500 mL round bottom flask equipped with a magnetic stir
bar and nitrogen bubbler were charged the product from Step 3 (21.7
g, 0.065 mole), N-t-Boc-glycine N-hydroxysuccinimide ester (17.7 g,
0.065 mole) and DMF (200 mL). The reaction mixture was stirred
under nitrogen at room temperature for 3.25 hours and a pale orange
solution formed.
[0415] The reaction mixture was poured into ice-cold ethyl acetate
(1.2 L). The organic solution was washed with 1M HCl (250 mL) and
then with brine (500 Ml), dried (MgSO.sub.4) and concentrated under
vacuum to near dryness to obtain an oil that was subsequently dried
at 50.degree. C. to obtain the product as a colorless oil (28.12 g,
99% yield). Seed crystals were prepared from ethyl acetate/hexanes.
The product (about 28 g) was dissolved in ethyl acetate (35 mL) and
hexanes (125 mL). The solution was seeded with the seed crystals
and precipitate formed. The solids were filtered and dried
overnight under vacuum at 55.degree. C. to yield a colorless solid
(27.0 g, 95% yield).
[0416] .sup.1H-NMR was consistent with the desired product.
[0417] Step 5
[0418] Preparation of 108
[0419] The Boc-protected glycine amide prepared in Step 4 (27.0 g,
0.062 mole) was dried overnight over P.sub.2O.sub.5 and NaOH
pellets. The solid was dissolved in dioxane (40 mL) and the
solution cooled to 0.degree. C. An equivalent volume of 4N
HCl/dioxane (0.062 mole) was added and the reaction was run for 2
hours. At this point the conversion was 80% as determined by
rphplc. The reaction mixture was allowed to warm to room
temperature over 4 hours. The reaction mixture was concentrated at
40.degree. C. to a foam which was triturated with ether (200 mL).
The white solid that formed was filtered and dried over
P.sub.2O.sub.5 to yield the desired glycine beta-amino acid ethyl
ester compound as the HCl salt (20.4%, 88.5% isolated yield.
[0420] .sup.1H-NMR and MS were consistent with the structure.
EXAMPLE H
[0421] Preparation of 109
[0422] Step 1
[0423] Preparation of 110
[0424] Potassium carbonate (powder, oven dried at 100.degree. C.
under vacuum, 22.1 g, 0.16 moles) was added to a solution of
3-chloro-5-bromosalicylaldehyde (35 g, 0.15 moles) in DMF (175 ml)
at room temperature to give a bright yellow slurry. MEMCI (neat,
25.0 g, 0.2 moles) was then added while maintaining the bath
temperature at 20.degree. C. The mixture was then stirred at
22.degree. C. for 6 hours and was poured into DI water (1200 mL) to
precipitate the product. The slurry was filtered on a pressure
filter, the cake washed with DI water (2.times.400 mL) and dried
under N.sub.2/vacuum to afford the product as an off-white solid
(46 g, 95% yield).
[0425] .sup.1H-NMR (CDCl.sub.3, TMS) 3.35 (s, 3H), 3.54 to 3.56 (m,
2H), 3.91 to 3.93 (m, 2H), 5.30 (s, 2H), 7.77 (d, 1H), 7.85 (d,
1H), 10.30 (s, 1H); .sup.13C NMR (CDCl.sub.3, TMS) (ppm): 59.05,
70.11, 71.49, 99.50, 117.93, 129.69, 129.78, 132.37, 138.14,
155.12, 188.22. DSC: 48.24.degree. C. (endo 90.51 J/g);
[0426] Microanalytical: calculated for C.sub.11H.sub.12BrClO.sub.4:
C, 40.82%; H, 3.74%; Cl, 10.95%; Br, 24.69%; Found: C, 40.64%; H,
3.48%; Cl, 10.99%; Br, 24.67%.
[0427] Step 2
[0428] Preparation of 111
[0429] The product obtained in Step 1 (32.35 g, 0.1 mol) was
charged in a 500 ml 3N round bottom flask fitted with a mechanical
stirrer, followed by the addition of THF (160 ml) and
(S)-phenylglycinol (13.71 g, 0.1 mol).
[0430] After 30 minutes at 22.degree. C., MgSO.sub.4 (20 g) was
added. The mixture was stirred for 1 hour at 22.degree. C. and
filtered on a coarse fritted filter. The filtrate was concentrated
under reduced pressure to afford a pale yellow oil (48.0 g)
containing the imine. No further purification was performed and the
crude product was used directly in the coupling reaction.
[0431] Microanalytical: calculated for
C.sub.19H.sub.21BrClNO.sub.4: C, 51.54%; H, 4.78%; N, 3.16%; Br,
18.04%; Cl, 8.00%; Found: C, 51.52%; H, 5.02%; N, 2.82%; Br,
16.31%; Cl, 7.61%.
[0432] Step 3
Preparation of
[0433] 112
[0434] In a 5 L 3N round bottom flask fitted with a mechanical
stirrer, reagent from Step 1 of Example G (332 g, 0.8 mol) was
taken in NMP (660 mL) under nitrogen. The solution was then cooled
to -10.degree. C. A solution of imine produced in Step 2 in NMP
(320 ml) was prepared under nitrogen and then added in 30 minutes
to the above reaction mixture while the temperature was maintained
at -5.degree. C. The mixture was stirred for an additional hour and
then cooled to -10.degree. C. A mixture of concentrated
HCl/saturated solution of NH.sub.4Cl (30 mL/720 mL) was added over
10 minutes. MTBE (760 ml) was added and the mixture was stirred for
1 hour at 23.degree. C. Stirring was stopped and the layers were
separated. The aqueous layer was extracted with MTBE (320 ml). The
two organic layers were combined, washed successively with a
saturated solution of NH.sub.4Cl (320 ml), DI water (320 ml) and
brine (320 ml). The solution was dried with MgSO.sub.4 (60 g),
filtered and concentrated to afford a yellow oil (228 g) containing
the desired product as a single diastereoisomer.
[0435] DSC: 227.54.degree. C. (endo. 61.63 J/g);
[0436] Microanalytical: calculated for
C.sub.25H.sub.33BrClNO.sub.6: C, 53.72%; H, 5.95%; N, 2.50%; Br,
14.29%; Cl, 6.33% Found: C, 53.80%; H, 6.45%; N, 2.23%; Br, 12.85%;
Cl, 6.12%.
[0437] Step 4
[0438] Preparation of 113
[0439] A solution of crude ester from Step 3 (.about.111 g) in
ethanol (1500 mL) was charged under nitrogen atmosphere to a 3 L 3N
round bottom flask fitted with a mechanical stirrer. The reaction
mixture was cooled to 0.degree. C. and lead tetraacetate (88.67 g,
0.2 mol) was added in one portion. The reaction mixture was stirred
for 3 hours at 0.degree. C. and then 15% aqueous NaOH (150 mL) was
added to the reaction mixture below 5.degree. C. Ethanol was
removed under reduced pressure on rotavap. Another 15% aqueous NaOH
(600 mL) was added and the reaction mixture was extracted with
ethyl acetate (2.times.300 mL), MTBE (2.times.200 mL) and ethyl
acetate (2.times.200 mL). The organic layers were combined and
washed with DI water (2.times.200 mL) and brine (2.times.100 mL)
and dried over anhydrous MgSO.sub.4 (30 g). The solution was then
filtered over celite and concentrated under reduced pressure to
give the product as an orange oil (96 g) that was used in the next
step without further purification.
[0440] DSC: 233.60.degree. C. (endo. 67.85 J/g);
[0441] Microanalytical: calculated for
C.sub.24H.sub.29BrClNO.sub.5: C, 54.71%; H, 5.54%; N, 2.65%; Br,
15.16%; Cl, 6.72; Found: C, 52.12%; H, 5.40%; N, 2.47%; Br, 14.77%;
Cl, 6.48.
[0442] Step 5
[0443] Preparation of 114
[0444] The crude product from Step 4 (.about.94 g) was taken up in
absolute ethanol (180 mL) and para toluenesulfonic acid monohydrate
(50.0 g, 0.26 mol) was added. The reaction mixture was then heated
to reflux for 8 hours after which the solvent was removed under
reduced pressure. Residual solid was taken up in THF (100 mL) and
THF was then stripped off under reduced pressure. The residue was
dissolved in ethyl acetate (500 mL) and cooled to -5.degree. C. The
resulting solid was filtered and washed with heptane (2.times.50 m)
to give a white solid. The solid was air dried to give the product
as a white solid (38 g) as a single isomer.
[0445] .sup.1H-NMR (DMSO, TMS) (ppm) 1.12 (t, 3H), 2.29 (s, 3H),
3.0 (m, 2H), 4.05 (q, 2H), 4.88 (t, 1H), 7.11 (d, 2H), 7.48 (d,
2H), 7.55 (d, 1H), 7.68 (1H, d), 8.35 (br, s, 3H); .sup.13C NMR
(DMSO, TMS) (ppm): 13.82, 20.75, 37.13, 45.59, 60.59, 110.53,
122.47, 125.44, 127.87, 128.06, 129.51, 131.95, 137.77, 145.33,
150.14, 168.98; DSC: 69.86.degree. C. (end., 406.5 J/g),
165.72.degree. C. (end. 62.27 J/g), 211.24.degree. C. (exo. 20.56
J/g) [.alpha.].sup.D.sub.25=+4.2.degree. (c=0.960, MeOH); IR (MIR)
(cm-1) 2922, 1726, 1621, 1591, 1494, 1471, 1413, 1376, 1324, 1286,
1237, 1207;
[0446] Microanalytical: calculated for
C.sub.18H.sub.21BrClNO.sub.6S: C, 43.69%; H, 4.27%; N, 2.83%; Br,
16.15%; Cl, 7.16%; S, 6.48%; Found: C, 43.40%; H, 4.24%; N, 2.73%;
Br, 16.40%; Cl, 7.20%; S, 6.54%.
[0447] Step 6
[0448] Preparation of 115
[0449] The above compound was prepared according to the procedures
outlined in Example G, Step 4 and Step 5 where an equivalent
quantity of the intermediate prepared in Step 5 as the free base
was substituted for Example G, Step 4.
[0450] .sup.1H-NMR and MS were consistent with the desired
product.
EXAMPLE I
[0451] Preparation of 116
[0452] Step 1
[0453] Preparation of 117
[0454] The above compound was prepared according to the methodology
of Example G, Step 2A, substituting an equivalent quantity of
2-hydroxy--3,5-dibromobenzaldehyde for
3,5-dichlorosalicylaldehyde.
[0455] Yield: 88%; Pale yellow solid: m.p. 46-47.degree. C;
R.sub.f=0.6 (EtOAc/Hexane 1:1 v/v); .sup.1H-NMR (CDCl.sub.3)
.delta. 3.37 (s, 3H), 3.56 (m, 2H), 3.92 (m, 2H), 5.29 (s, 2H),
7.91 (d, 1H, J=2.4 Hz), 7.94 (d, 1H, J=2.4 Hz), 10.27 (s, 1 H);
FAB-MS m/z 367
[0456] (M+) HR-MS calculated for C.sub.11H.sub.12Br.sub.2O.sub.4:
367.9083 Found: 367.9077.
[0457] .sup.1H-NMR and MS were consistent with the desired
compound.
[0458] Step 2 118
[0459] The above compound was prepared using the procedure of
Example G, Steps 2B and 2C substituting an equivalent quantity of
the compound from Step 1 in the procedure.
[0460] Yield: 90%; Yellow solid; m.p. 57-59.degree. C; R.sub.f=0.46
(EtOAc/Hexane 1:1 v/v);
[0461] .sup.1H-NMR (CDCl.sub.3) .delta. 1.45 (s, 9H); 2.1 (br, 1H,
exchangeable), 2.51 (d, 1H, J. =9.9 Hz, J.sub.2=15.3 Hz), 2.66 (d,
1H, J.sub.1=4.2 Hz, J.sub.2=15.3 Hz), 3.02 (br, 1 H, exchangeable),
3.39 (s, 3H), 3.58-3.62 (m, 4H), 3.81 (m, 1 H), 3.93 (m, 2H), 4.63
(dd, 1H, J=4.2 Hz), 5.15 (s, 2H), 7.17-7.25 (m, 6H), 7.49 (d, 1 H):
FAB-MS m/z 602 (M+H)
[0462] HR-MS calculated for C.sub.25H.sub.34NBr.sub.2O.sub.6:
602.0753 Found: 602.0749.
[0463] .sup.1H-NMR and MS were consistent with the desired
compound.
[0464] Step 3
[0465] Preparation of 119
[0466] The above compound (p-toluenesulfonate salt) was prepared
according to the methodology in Example G, Step 3 substituting an
equivalent quantity of the product in Step 2 in Example G, Step 3A.
Yield: 62%; white solid; .sup.1H-NMR (DMSO-d.sub.6) .delta. 1.09
(t, 3H, J=7.2 Hz), 2.27 (s, 3H), 2.97 (dd, 2H, J. =3.0 Hz,
J.sub.2=7.2 Hz); 4.02 (q, 2H, J=7.2 Hz), 4.87 (t, 1 H, J=7.2 Hz),
7.08 (d, 2H, J=4.8 Hz), 7.45 (m, 3H), 7.57 (d, 1 H, J=2.4 Hz), 8.2
(br, 3H); FAB-MS m/z 365 (M+H)
[0467] HR-MS calculated for C.sub.11H.sub.14NBr.sub.2O.sub.3:
365.9340 Found: 365.9311.
[0468] .sup.1H-NMR and MS were consistent with the desired
product.
[0469] Step 4
[0470] Preparation of 120
[0471] The above compound was prepared using the procedure of
Example G, Step 4 and substituting the compound prepared in Step 3
to produce the BOC protected intermediate. The resulting BOC
protected intermediate was converted to the desired compound using
the procedure of Example G, Step 5.
[0472] .sup.1H-NMR and MS were consistent with the desired
compound.
EXAMPLE J
Preparation of ethyl
.beta.-[(2-aminoacetyl)amino]pyridine-3-propanoate, bis
Hydrochloride Salt
[0473] 121
[0474] Step 1
[0475] To 3-pyridine carboxaldehyde (300 ml) in 2-propanol (3
liters) was added ammonium acetate (297 g) followed by malonic acid
(398 g). The reaction mixture was stirred at reflux for 5 hours.
The precipitate was filtered while hot and washed with hot
isopropanol (2 liters). The resulting white solid was then dried to
yield DL-3-amino-3-(3-pyridyl)pro- pionic acid as a white solid
(220 g).
[0476] NMR and MS were consistent with the desired product.
[0477] Step 2
[0478] DL-3-amino-3-(3-pyridyl)propionic acid (220 g) from Step 1
was slurried in absolute EtOH (3.6 liters). HCl gas (one lecture
bottle- lb) was bubbled into the reaction while stirring over 40
minutes. The slurry was then heated at reflux for 4 hours (a
solution forms after 1 to 1.5 hours). The reaction mixture was
cooled to 5.degree. C. in an ice bath. After stirring at 5.degree.
C. for 1.5 hours, the resulting white precipitate was filtered and
washed thoroughly with ether. After drying under vacuum at
50.degree. C, the desired product, ethyl
DL-3-amino-3-(3-pyridyl)propionate dihydrochloride was obtained as
a white solid (331.3 g).
[0479] NMR and MS were consistent with the desired product.
[0480] Step 3
[0481] To ethyl DL-3-amino-3-(3-pyridyl)propionate dihydrochloride
(220.6 g, 0.83 mole) from Step 2 in anhydrous THF (2 liters) and
triethylamine (167.2 g, 1.65 moles), was added N-t-BOC-glycine
N-hydroxysuccinimide ester (225 g, 0.826 moles) (Sigma) in several
portions at 5-10.degree. C. The reaction mixture was stirred
overnight at room temperature. The resulting precipitate was
filtered and washed with THF. The solvent from the filtrate was
removed under vacuum. The residue was taken up in ethyl acetate
(2.3 liters). The ethyl acetate layer was washed with saturated
sodium bicarbonate (2.times.900 ml) and H.sub.2O (3.times.900 ml),
dried over MgSO.sub.4 and removed under vacuum. The residue was
slurried overnight in 10% ethyl acetate/hexane (2.5 liters). The
precipitate was filtered, washed with 10% ethyl acetate/hexane (1
liter), then hexane, then dried to yield ethyl
.beta.-[[2-[[(1,1-dimethylethoxy)carbonyl]amino-
]acetyl]-amino]-pyridine-3-propanoate as a white solid (233 g).
[0482] NMR and MS were consistent with the desired product.
[0483] Step 4
[0484] Ethyl
.beta.-[[2-[[(1,1-dimethylethoxy)carbonyl]amino]acetyl]amino]-
-pyridine-3-propanoate (from Step 3) (232 g, 0.66 mole) was
dissolved in warm dioxane (1 liter). After cooling to room
temperature, 4M HCl in dioxane (1.6 liters) (Aldrich) was slowly
added. A white precipitate formed after several minutes and then
turned to a thick sticky material. After 2 hours, the solvent was
decanted off. The residue was slurried in ether and the ether
decanted off until a white solid resulted. This was dried under
vacuum to yield ethyl .beta.-[(2-aminoacetyl)amino]pyridine-3-
-propanoate, bis hydrochloride salt as a white hygroscopic solid
(224.2 g).
[0485] NMR and MS were consistent with the desired product.
EXAMPLE K
[0486] Preparation of 2-guanidino-4-carboxy thiazole hydrochloride
122
[0487] Step 1
[0488] To 2-imino-4-thiobiuret (11.1 g, 0.094 mole) (Aldrich) in
absolute EtOH (100 mL) and at reflux was added ethyl bromopyruvate
(20.0 g, 0.102 mole) (Aldrich) portionwise. The solution was
stirred at reflux for 2 hours. Additional ethyl bromopyruvate (2.0
g) was added and the reaction continued at reflux for 2 more hours.
The reaction was cooled to 10.degree. C. and concentrated
NH.sub.4OH was added until pH=10. The resulting precipitate was
filtered, washed with ether and dried to yield
2-guanidino-4-carboxyethylthiazole as a yellow solid (15.1 g).
[0489] MS and .sup.1H-NMR were consistent with the desired
structure.
[0490] Step 2
[0491] To the product of Step 1 (5.0 g, 0.023 mole) slurried in
H.sub.2O (100 mL) and ethanol (40 mL) was added NaOH (0.93 g, 0.023
mole). The solution was stirred overnight at room temperature.
Additional ethanol (20 mL) and NaOH (0.93 g) were added to the
reaction mixture and the solution was stirred at room temperature
for 1 more hour. The pH was lowered to 7 with 1N HCl and the
resultant precipitate was filtered, washed with H.sub.2O and ether,
then dried to yield the product (4.1 g) as the zwitterion.
[0492] The zwitterion was slurried in H.sub.2O and acidified with
concentrated HCl until solution. The solution was frozen and
lyophilized to yield 2-guanidino-4-carboxythiazole hydrochloride as
a light yellow solid (4.33 g).
[0493] MS and .sup.1H-NMR were consistent with the desired
structure.
[0494] Examples L and M were prepared according to the depicted
Schemes, starting from the commercially available
2-amino-6-methylpyridine and 2-amino-4-methyl-pyridine,
respectively.
EXAMPLE L
[0495] Preparation of 2-Aminopyridine-6-carboxylic acid 123
[0496] Step A
[0497] To a solution of 2-acetylamino-6-methylpyridine (10.0 g) in
water (125 mL) at 75.degree. C. was added KMnO.sub.4 (21.0 g) in
portions and heating was continued for 2 hours. The reaction
mixture was cooled, filtered and the residue washed with hot water
(2.times.25 mL). The combined aqueous filtrate and the washings
were washed with dichloromethane (3.times.40 mL), and acidified
with cold 3 N HCl. The resulting precipitate was filtered, washed
with water to neutral pH, and dried under vacuum to afford
2-acetylaminopyridine-6-carboxylic acid (3.8 g, 48% yield). The
dichloromethane extract was concentrated to dryness to give the
unreacted 2-acetylamino-6-methylpyridine (3.5 g).
[0498] .sup.1H-NMR (CD.sub.3OD) .delta. 8.32 (m, 1H), 7.94 (t, 1
H), 7.87 (m, 1H), 2.2 (s, 3H);
[0499] FAB MS m/z 181 (M+H).
[0500] Step B
[0501] A suspension of 2-acetylaminopyridine-6-carboxylic acid (4.1
g) in 2.5 N NaOH (36.5 ml) was heated at 80.degree. C. for 1.5
hours, under nitrogen atmosphere. The resulting solution was cooled
and acidified with cold 3N HCl. The precipitate obtained was
filtered, washed successively with water and acetonitrile. The
resulting white solid was dried under vacuum to afford
2-aminopyridine-6-carboxylic acid (2.4 g, 76% yield).
[0502] .sup.1H-NMR (DMSO-d.sub.6) .delta. 7.57 (t, 1H, J=8.1 Hz),
7.14 (d, 1H, J=7.2 Hz), 6.67 (1H, J=8.1 Hz), 6.51 (br, 2H); FAB MS
m/z 139 (M+H).
[0503] Step C
[0504] A suspension of 2-aminopyridine-6-carboxylic acid (2 g) in
EtOH (10.0 mL) and 4N HCl/dioxane (10.0 mL) was heated to reflux
for 16 hours under anhydrous conditions. The reaction mixture was
then concentrated to dryness and the residue was dried in a
desiccator under vacuum to afford 2-amino-6-carbethoxypyridine
hydrochloride as a white powder (1.6 g).
[0505] .sup.1H-NMR (DMSO-d.sup.6) .delta. 8.3 (br), 7.94 (m, 1 H),
7.37 (d, 1H, J=7.2 Hz), 7.22 (dd, 1 H, J=8.7 Hz), 4.37 (q, 2H,
J=7.2 Hz), 1.32 (t, 3H, J=7.2 Hz); FAB MS m/z 167 (M+H).
EXAMPLE M
Preparation of 2-Aminopyridine-4-carbethoxypyridine
hydrochloride
[0506] 124
[0507] This compound (M) was prepared by a procedure similar to the
procedure for preparing 2-aminopyridine-6-carbethoxypyridine
hydrochloride of Example L starting from
2-acetylamino-4-methyl-pyridine.
[0508] .sup.1H-NMR and MS were consistent with the structure.
EXAMPLE 1
[0509] Preparation of 125
[0510] To the product of Example A (0.5 g, 0.002 mole), the product
of Example E (0.83 g, 0.002 mole), triethylamine (0.2 g, 0.002
mole), and DMAP (24 mg) in anhydrous DMA (5 mL) was added EDCl
(0.38 g, 0.002 mole) at ice bath temperature. The reaction was
stirred at room temperature for 2 days. The ester product was
isolated by reverse phase preparatory HPLC. To the ester in
H.sub.2O (3 mL) and CH.sub.3CN (3 mL) was added LiOH (0.51 g, 0.012
mole). This was stirred at room temperature for 1 hour. The pH was
lowered to 2 with TFA and the product was isolated by reverse phase
preparatory HPLC to yield (after lyophilization) the desired
product as a white solid (350 mg).
[0511] MS and .sup.1H-NMR were consistent with the desired
structure.
EXAMPLE 2
[0512] Preparation of 126
[0513] The titled compound was prepared according to the
methodology of Example 1, substituting an equivalent amount of the
product of Example D for the product of Example E to yield the
desired product as a white solid (210 mg).
[0514] MS and .sup.1H-NMR were consistent with the desired
structure.
EXAMPLE 3
[0515] Preparation of 127
[0516] To the product of Example C (19.5 g, 0.045 mole) and
N-methylmorpholine (9.1 g, 0.09 mole) in anhydrous DMA (85 mL) in a
flame dried flask under N.sub.2 was added isobutylchloroformate
(6.2 g, 0.045 mole) slowly at ice bath temperature. The solution
was stirred at ice bath temperature for 15 minutes. The product of
Example D (15 g, 0.04 mole) was then added at ice bath temperature
followed by slow addition of N-methylmorpholine (4.1 g, 0.04 mole).
The reaction mixture was stirred overnight at room temperature. To
ester in H.sub.2O (50 mL)/CH.sub.3CN (30 mL) was added LiOH (16 g,
0.38 mole). This was stirred for 1 hour at room temperature. The pH
was lowered to 2 with TFA and the product was isolated by reverse
phase preparatory HPLC to yield (after lyopholization) the desired
product as a white solid (13.7 g).
[0517] MS and .sup.1H-NMR were consistent with the desired
structure.
EXAMPLE 4
[0518] Preparation of 128
[0519] The above compound was prepared according to the methodology
of Example 3, substituting an equivalent amount of the product of
Example E for the product of Example D.
[0520] MS and .sup.1H-NMR were consistent with the desired
structure.
EXAMPLE 5
[0521] Preparation of 129
[0522] The above compound was prepared according to the methodology
of Example 3, substituting an equivalent amount of the product of
Example F for the product of Example D.
[0523] MS and .sup.1H-NMR were consistent with the desired
structure.
EXAMPLE 6
[0524] Preparation of 130
[0525] The above compound was prepared according to the methodology
of Example 3, substituting an equivalent amount of the product of
Example B for the product of Example C.
[0526] MS and .sup.1H-NMR were consistent with the desired
structure.
EXAMPLE 7
[0527] Preparation of 131
[0528] To the product of Step 3 of Example 9 (0.6 g, 0.0019 mole)
in anhydrous DMA (4 mL) was added isobutylchloroformate (0.27 g,
0.002 mole) at ice bath temperature followed by N-methylmorpholine
(0.4 g, 0.0038 mole). The solution was stirred for 15 minutes at
ice bath temperature. The product of Example H (0.71 g, 0.0017
mole) was added at ice bath temperature followed by
N-methylmorpholine (0.17 g, 0.0017 mole). The reaction was stirred
overnight at room temperature. HPLC analysis indicated product plus
significant amount of starting material. EDCl (0.38 g, 0.002 mole)
and DMAP (15 mg) were added to the reaction mixture and the
reaction was stirred overnight at room temperature. The ester
product was isolated by reverse phase preparatory HPLC. To the
ester in H.sub.2O (10 mL) and CH.sub.3CN (5 mL) was added LiOH (700
mg, 0.017 mole). This was stirred at room temperature for 1 hour.
The pH was lowered to 2 with TFA and the product was isolated by
reverse phase preparatory HPLC to yield (after lyophilization) the
desired product as a white solid (270 mg).
[0529] MS and .sup.1H-NMR were consistent with the desired
structure.
EXAMPLE 8
[0530] Preparation of 132
[0531] To the product of Example K (0.5 g, 0.0022 mole) and
N-methylmorpholine (0.23 g, 0.0022 mole) in anhydrous DMF (8 mL)
was added isobutylchloroformate (0.31 g, 0.0022 mole) at ice bath
temperature. After stirring for 5 minutes at ice bath temperature,
the product of Example J (0.73 g, 0.0022 mole) and
N-methylmorpholine (0.45 g, 0.0045 mole) in anhydrous DMF (8 mL)
were added at ice bath temperature in one portion. The reaction
mixture was stirred overnight at room temperature. The ester was
isolated by reverse phase preparatory HPLC (530 mg).
[0532] To this ester (400 mg) in H.sub.2O (10 mL) was added LiOH
(91 mg). This was stirred at room temperature for 1 hour. The pH
was lowered to 3 with TFA and the product was isolated by reverse
phase preparatory HPLC to yield (after lyophilization) the desired
product as a white solid (350 mg).
[0533] MS and .sup.1H-NMR were consistent with the desired
structure.
[0534] Guanidations of 2-amino-6-carbethoxypyridine hydrochloride,
and 2-amino-4-carbethoxypyridine hydrochloride, were carried out
using the tris-BOC reagent as illustrated in the depicted schemes
in Examples N and O (Kim. S. K., Qian, L., Tetrahedron Lett. 34,
7677, 1993).
EXAMPLE N
[0535] 133
[0536] To a solution of 2-amino-6-carbethoxypyridine hydrochloride
(0.56 g, 2.8 mmol) and tris-BOC reagent (91.2 g, 2.8 mmol) in
degassed DMF (7.0 mL), mercuric chloride (0.76 g, 2.8 mmol), and
triethylamine (0.79 g, 7.8 mmol) were added. The resulting mixture
was heated at 70.degree. C, under an atmosphere of nitrogen for 24
hours and filtered. DMF was distilled in vacuo, the residue was
triturated with ethyl acetate, and filtered. The orange colored
filtrate was concentrated and the resulting material was purified
by silica gel flash chromatography using ethyl acetate containing
1% triethylamine as the eluent. The appropriate fractions (blue
fluorescent) were combined and concentrated to dryness under
reduced pressure to give a yellow powder. MS analysis [m/z 565
(M+H)] confirmed the formation of the desired tris-BOC product
N.
EXAMPLE O
[0537] 134
[0538] This compound (O) was prepared using a procedure similar to
that of Example N. MS analysis [m/z 565 (M+H)] confirmed the
formation of the desired tris-BOC product O.
[0539] The following compounds P and Q can be prepared following
the conditions set forth in Steps 3-5 of Example 9.
EXAMPLE P
[0540] 135
EXAMPLE Q
[0541] 136
EXAMPLE R
[0542] 137
[0543] The above compound was prepared using the procedures
described in Example G. The reagent 3-bromo-5-chlorosalicylaldehyde
was used in Step 2 instead of 3,5-dichlorosalicylaldehyde. 138
EXAMPLE 9
[0544] Step 1
[0545] To a mechanically stirred suspension of the reagent 1 (18.68
g) in THF (1 L) at 0.degree. C. was added sodium hydride (19 g of
60% suspension in mineral oil) over 30 minutes. After 30 minutes
di-tert-butyl dicarbonate (95 g) was added neat and the reaction
mixture was heated to reflux gently for 16 hours. The mixture was
cooled to 0.degree. C. and quenched with a saturated solution of
NaHCO.sub.3. The mixture was extracted with ethyl acetate. The
organic extract was washed with water, dried (Na.sub.2SO.sub.4) and
concentrated. The residue was rapidly chromatographed using a small
column of silica gel (60 mm.times.180 mm) to give the desired
product 2 as a thick yellow liquid (68 g). NMR was consistent with
the assigned structure.
[0546] Step 2
[0547] A stirred suspension of 3-amino-pyridine-6-carboxylic acid
(25 g) in ethanol (300 mL) at 0.degree. C. was saturated with
gaseous hydrogen chloride. The mixture was allowed to warm to
23.degree. C. and heated to reflux for 2 hours. A clear solution
was obtained. After cooling to 23.degree. C, the mixture was
concentrated in vacuo, neutralized with aqueous NaHCO.sub.3 and
extracted with ethyl acetate. The organic phase was washed with
water, dried over MgSO.sub.4, and concentrated in vacuo to give
ethyl 3-amino-pyridine-6-carboxylate as a pale yellow solid.
[0548] A mixture of the product of Step 1 (40.0 g), HgCl.sub.2
(25.0 g) triethylamine (27 mL) and ethyl
3-amino-pyridine-6-carboxylate (13 g) and DMF (200 mL) was stirred
and heated to 55.degree. C. for 30 hours. The reaction mixture was
cooled to 23.degree. C., diluted with ethyl acetate (500 mL) and
filtered through celite. The filtrate was washed with water
(2.times.), dried over MgSO.sub.4 and concentrated in vacuo. The
residue was chromatographed over silica gel using ethyl acetate in
hexane as eluant to give the desired intermediate 3. NMR was
consistent with the desired structure.
[0549] Step 3
[0550] A suspension of the product of Step 2 (13 g) in 5N
hydrochloric acid (100 mL) was stirred for 16 hours at 230.degree.
C. The mixture was concentrated in vacuo. The residue was
triturated with methanol and the white solid was filtered to
provide the desired product 4. NMR and MS were consistent with the
desired structure.
[0551] Step 4
[0552] The product of Step 3 (0.308 g) was suspended in DMF (10 mL)
and 4-methylmorpholine (0.2 mL) was added to the suspension. The
mixture was stirred at 230.degree. C. for 1 hour. After cooling the
reaction mixture to 0.degree. C., IBCF (0.129 mL) was added. After
1/2 hour, a solution of the product of Example R (0.416 g) and
4-methylmorpholine (0.11 mL) in DMF (3 mL) was added. The mixture
was allowed to warm to 23.degree. C. over 2 hours. Then the mixture
was filtered and the filtrate concentrated in vacuo. The residue
was purified by HPLC to provide 5. Micro-analytical data, NMR and
MS were consistent with the desired structure.
[0553] Step 5 139
[0554] A solution of the product of Step 4 in 3.5N HCl was allowed
to stand at 230.degree. C. for 3 hours, concentrated in vacuo and
the residue purified by HPLC to provide the desired product.
Micro-analytical data, NMR and MS were consistent with the desired
product.
[0555] Analysis calculated for C.sub.21H.sub.22Br Cl
N.sub.6O.sub.6. 2CF.sub.3CO.sub.2H.H.sub.2O: C, 36.80; H, 3.21; N,
10.30 Found: C, 36.52; H, 2.90; N, 9.91.
EXAMPLE 10
[0556] 140
[0557] This compound was prepared using the procedure described in
Example 9, except that the product of Example G was used instead of
the product of Example R in Step 4.
[0558] Analysis calculated for
C.sub.21H.sub.22Cl.sub.2N.sub.6O.sub.6. 2CF.sub.3CO.sub.2H.
H.sub.2O: C, 38.93; H, 3.40; N, 10.89; Found: C, 39.27; H, 3.12; N,
11.09.
EXAMPLE 11
[0559] 141
[0560] The compound was prepared as described for Example 9 using
the product of Example I instead of the product of Example R in
Step 4.
[0561] Analysis calculated for:
C.sub.21H.sub.22Br.sub.2N.sub.6O.sub.6. 2 CF.sub.3COOH. H.sub.2O C,
35.65; H, 2.87; N, 9.98 Found: C, 35.81; H, 2.79; N, 10.14
EXAMPLE 12
[0562] Preparation of
(3S)-N-[[4-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidi-
nyl)amino]-2-thienyl]carbonyl]glycyl-3-(3,5-dichloro-2-hydroxyphenyl)-.bet-
a.-alanine, trifluoroacetate salt 142
[0563] Step 1:
[0564] A solution of 5-bromo-2-thiophene carboxylic acid (5.0 g) in
concentrated sulfuric acid (30 ml) was chilled to -30.degree. C.
and treated dropwise with a solution of 70% nitric acid (7.7 ml)
(d=1.40) in concentrated sulfuric acid (30 ml). The reaction
mixture was stirred for 30 minutes at -25.degree. C. and then
poured over ice water slurry and stirred for a few minutes. The
precipitated solid was filtered, recrystallized from water and
dried to afford a white powder (2.3 g). The .sup.1H-NMR was
consistent with the proposed structure.
[0565] Step 2:
[0566] A solution of the product from Step 1 (1.7 g) in THF (25 ml)
was treated with a catalytic amount of 5% Pd/C under 5 psi
atmosphere of hydrogen at room temperature for 16 hours. The
reaction mixture was filtered and concentrated. The residue was
heated with ethyl acetate and filtered to yield a brown solid (750
mg). .sup.1H-NMR was consistent with the proposed structure.
[0567] Step 3:
[0568] A solution of the product from Step 2 (725 mg) and the
guanylating reagent G1 in THF (15 ml) and dimethylacetamide (10 ml)
was refluxed for 16 hours. The reaction mixture was concentrated
and the residue treated with a solution of TFA (5 ml) and
CH.sub.2Cl.sub.2 (5 ml). After stirring at room temperature for 1
hour, the reaction mixture was concentrated and the residue
purified on reverse phase HPLC using water (0.5% TFA) and
acetonitrile gradient as eluant to afford a light yellow thick
liquid (300 mg). .sup.1H-NMR was consistent with the proposed
structure.
[0569] Step 4:
[0570] In a flame dried flask under N.sub.2 the product from Step 3
(275 mg) was dissolved in 8 ml of dimethylacetamide and
N-methylmorpholine (81 mg). The stirred solution was chilled to
0.degree. C. and treated dropwise with a solution of isobutyl
chloroformate (109 mg) in dimethylacetamide (1 ml).
[0571] The reaction mixture was stirred for 45 minutes at 0.degree.
C. and then treated dropwise with a solution of the product of
Example G (286 mg) and N-methylmorpholine (81 mg) in
dimethylacetamide (2 ml). The reaction mixture was allowed to warm
to room temperature and stirring was continued for 16 hours. The
reaction mixture was concentrated and the residue purified using
reverse phase HPLC as described in Step 3 to afford a thick
colorless liquid (262 mg). .sup.1H-NMR was consistent with the
proposed structure.
[0572] Step 5:
[0573] A solution of the product from Step 4 (250 mg) in methanol
(8 ml) and 1N sodium hydroxide solution (8 ml) was stirred at room
temperature for 16 hours. The reaction was quenched with TFA (0.7
ml) and concentrated. The residue was purified using reverse phase
HPLC as described in Step 3 to give a white solid (144 mg).
.sup.1H-NMR was consistent with the proposed structure.
[0574] Analysis calculated for
C.sub.20H.sub.21N.sub.5O.sub.6Cl.sub.2S.1.5- 0TFA.0.25H.sub.2O: C,
39.13; H, 3.28; N, 9.92; S 4.54; Cl, 10.04; found: C, 38.81; H,
3.17; N, 9.90; S, 4.86; Cl, 10.25.
EXAMPLE 13
[0575] Preparation of N-[[4-[(4,5-dihydro-1
H-imidazol-2-yl)amino]-2-thien-
yl]carbonyl]glycyl-3-(3,5-dichloro-2-hydroxyphenyl)-.beta.-alanine,
trifluoroacetate salt 143
[0576] The above compound was prepared in an analogous sequence of
reactions as used in the preparation of the compound described in
Example 12. The guanylating agent described in Example C (Step 1)
was used instead of G1 in Step 3 of Example 12. Similarly, the
product of Example D was used instead of the product of Example G
in Step 4.
[0577] .sup.1H-NMR was consistent with the proposed structure.
[0578] Analysis calculated for:
C.sub.19H.sub.19N.sub.5O.sub.5Cl.sub.2S. 1.50TFA. 0.50H.sub.2O: C,
38.84; H, 3.18; N, 10.29; S, 4.71; Cl, 10.42. found: C, 38.84; H,
3.01; N, 10.50; S, 5.08; Cl, 11.01. 144
[0579] Step 1:
[0580] (A) was prepared as described in Step 1 of Example 13 using
5-methyl-2-thiophene carboxylic acid (5.2 g). The product was
purified by extraction with dilute sodium hydroxide solution,
acidification with dilute hydrochloric acid and extraction into
ethyl acetate. The organic extract was dried (Na.sub.2SO.sub.4) and
concentrated to afford a yellowish orange solid (2.2 g).
.sup.1H-NMR was consistent with the proposed structure.
[0581] Step 2:
[0582] (B) was prepared using the product of Step 1 (2.2 g) and
following the coupling conditions as described in Step 4 of Example
12. The reaction was concentrated and the residue partitioned
between ethyl acetate and water. The organic extract was washed
with saturated sodium chloride solution, dried (Na.sub.2SO.sub.4)
and concentrated. The residue was recrystallized from ethyl acetate
to afford a tan solid (3.5 g). .sup.1H-NMR was consistent with the
proposed structure.
[0583] Step 3:
[0584] A solution of the product from Step 2 (2.8 g) in THF (25 ml)
was treated dropwise with a solution of tin(II) chloride dihydrate
in concentrated hydrochloric acid (1.0 g/2 ml) at room temperature
until TLC indicated complete disappearance of the starting
material. The organic solvent was removed and the aqueous portion
neutralized with sodium bicarbonate solution. The aqueous portion
was extracted with CH.sub.2Cl.sub.2, dried (Na.sub.2SO.sub.4), and
concentrated to afford a yellow powder (1.1 g). .sup.1H-NMR was
consistent with the proposed structure.
[0585] Step 4:
[0586] To a solution of the product described in Step 3 (375 mg)
and the product of Step 1 of Example 9 (519 mg) in DMF (15 ml),
mercuric chloride (326 mg) and triethylamine (182 mg) were added.
The mixture was heated at 95-100.degree. C. for 3 hours. The
reaction mixture was cooled, treated with ethyl acetate (30 ml),
stirred for 30 minutes and then filtered through a pad of celite.
The filtrate was concentrated and the residue purified using flash
chromatography (eluting with 97.5% CHCl.sub.3-2.5% CH.sub.3OH) to
yield a yellowish brown solid (415 mg). .sup.1H-NMR was consistent
with the proposed structure.
[0587] Step 5:
[0588] A solution of the product from Step 4 (400 mg) in
CH.sub.2Cl.sub.2 (7.5 ml) and TFA (7.5 ml) was stirred at room
temperature for 1 hour. The reaction was concentrated and the
residue was stirred into a solution of CH.sub.3OH (10 ml) and 1N
sodium hydroxide solution (10 ml) at room temperature for 16 hours.
The reaction was quenched with TFA (0.8 ml) and concentrated.
[0589] The residue was purified using reverse phase HPLC as
previously described to produce a white solid (80 mg). .sup.1H-NMR
was consistent with the proposed structure
[0590] Analysis calculated for:
C.sub.21H.sub.23N.sub.5O.sub.6Cl.sub.2. 1.50 TFA.0.50 H.sub.2O: C,
39.79; H, 3.55; N, 9.67; S, 4.43; Cl, 9.79. found: C, 39.50; H,
3.24; N, 9.58; S, 4.71; Cl, 10.22.
EXAMPLE 15
[0591] Preparation of (3S)-N-[[4-(4,5,-dihydro-1
H-imidazol-2-yl)amino]-5--
methyl-2-thienyl]carbonyl]glycyl-3-(3,5-dichloro-2-hydroxyphenyl)-.beta.-a-
lanine, trifluoroacetate salt 145
[0592] The above compound was prepared in an analogous sequence of
reactions as used in the preparation of the compound described in
Example 14, except the guanylating agent described in Example C
(Step 1) was used instead of the reagent used in Step 4 of Example
14. .sup.1H-NMR was consistent with the proposed structure.
[0593] Analysis calculated for:
C.sub.20H.sub.21N.sub.5O.sub.5Cl.sub.2S. 1.50 TFA. 0.25 H.sub.2O.
C, 40.04; H, 3.36; N, 10.15; S, 4.65; Cl, 10.28. found: C, 39.82;
H, 3.19; N, 10.17; S, 4.86; Cl, 10.69. 146
[0594] The title compound was synthesized starting with
2-nitro-5-thiophene-carboxylic acid utilizing the same sequence of
reactions as described in Example 15. For the guanylation reaction,
the conditions described in Step G, Example 17 were followed.
[0595] Analysis calculated for:
C.sub.19H.sub.19N.sub.5O.sub.5Cl.sub.2S. 1.50 TFA. C, 39.36; H,
3.08; N, 10.43; S, 4.78: found: C, 39.05; H, 2.79; N, 10.37; S,
4.90. 147
[0596] Step 1:
[0597] A mixture of 6-hydroxynicotinic acid (20 g) and colorless
fuming nitric acid (60 ml) (d=1.50) was heated to 90-95.degree. C.
for 3 hours. The reaction was cooled to room temperature and poured
onto 1.5 litre of an ice-water slurry with stirring and then
filtered after 15 minutes. The precipitate was washed with water
and dried to afford a light yellow powder (9.3 g). .sup.1H-NMR was
consistent with the proposed structure.
[0598] Analysis calculated for C.sub.6H.sub.4N.sub.2O.sub.5: C,
39.14; H, 2.19; N, 15.22. found: C, 39.08; H, 2.17; N, 15.19.
[0599] Step 2:
[0600] A mixture of the product from Step 1 (5.0 g) and phosphorus
oxychloride (15 ml) was refluxed for 3 hours. The reaction mixture
was cooled to room temperature and added to an ice-water mixture
and stirred for 30 minutes. Additional ice was added to keep the
mixture cold during this period. The reaction mixture was extracted
with a THF-ether (1:2) mixture and the organic extracts washed with
saturated sodium chloride solution, dried (Na.sub.2SO.sub.4) and
concentrated. The residue was recrystallized from 1:1 ether-hexane
to yield a yellow powder (4.0 g). .sup.1H-NMR was consistent with
the proposed structure.
[0601] Step 3:
[0602] A solution of the product from Step 2 (1.6 g) in thionyl
chloride (5.0 ml) was refluxed for 3 hours. The reaction was cooled
to room temperature and evaporated under a stream of nitrogen. The
residue was dried under vaccuum and used without further
purification. In a flame dried flask under nitrogen, the product of
Example D (3.0 g) was dissolved in dimethylacetamide (30 ml) and
N,N-diisopropylethylamine (2.3 g). The solution was chilled in an
ice bath and a solution of the acid chloride (as obtained above) in
THF (20 ml) was added dropwise. The reaction was stirred and
allowed to warm to room temperature and then quenched with water
(25 ml). The mixture was extracted with ethyl acetate and the
organic extracts washed with saturated sodium chloride solution,
dried (Na.sub.2SO.sub.4) and concentrated. The resulting yellow
solid was recrystallized from ethyl acetate to afford a light
yellow powder (3.4 g). .sup.1H-NMR was consistent with the proposed
structure
[0603] Step 4:
[0604] To a suspension of sodium methoxide (2.2 g) in methanol (30
ml) was added dropwise at 0.degree. C. a solution of the product of
Step 3 (4.5 g) in methanol (30 ml). The reaction was stirred for 30
minutes and then quenched with acetic acid (2.3 ml). The reaction
was concentrated and partitioned between ethyl acetate and water.
The organic extracts were dried (Na.sub.2SO.sub.4), concentrated,
and purified on a silica gel column (eluting with 80% ethyl
acetate-20% hexane) to produce a light yellow solid (3.5 g).
.sup.1H-NMR was consistent with the proposed structure.
[0605] Step 5:
[0606] A solution of the product described in Step 4 (1.07 g) in
ethanol (25 ml) was treated with a catalytic amount of 3% Pt/C
poisoned with sulfur under a 5 psi atmosphere of hydrogen at room
temperature for 4 hours. The reaction mixture was filtered and
concentrated to yield a white solid (930 mg) which was used without
further purification. .sup.1H-NMR was consistent with the proposed
structure
[0607] Step 6:
[0608] To a solution of the product of Step 5 (330 mg), G.sub.2
(276 mg) in DMF (10 mL) was added triethylamine (150 mg) and
mercuric chloride (258 mg) and the mixture heated at 85.degree. C.
under nitrogen for 16 hours. The reaction was cooled, treated with
ethyl acetate (25 ml) and filtered. The filtrate was concentrated
and the residue purified on a silica gel column eluting with 98%
CH.sub.2Cl.sub.2-2% methanol to afford white solid (325 mg).
.sup.1H-NMR was consistent with the proposed structure.
[0609] Step 7:
[0610] A solution of the product from Step 6 (114 mg), TFA (8 ml)
and methylene chloride (8 mL) was stirred at room temperature for
90 minutes. The solvent was evaporated and the residue treated with
a solution of 1N sodium hydroxide (8 mL) and methanol (8 mL) at
room temperature for 16 hours. The reaction was quenched with TFA
(1 mL) and concentrated. The residue was purified using reverse
phase HPLC as previously described to afford a white solid (76 mg).
.sup.1H-NMR was consistent with the proposed structure.
[0611] Analysis calculated for:
C.sub.21H.sub.22N.sub.6O.sub.6Cl.sub.2.2TF- A: C, 41.74; H, 3.88;
N, 12.70. found: C, 41.47; H, 3.49; N, 12.85. 148
[0612] Step 1:
[0613] A suspension of the product from Example 17, Step 1 (12.0 g)
in methanol (200 ml) was treated with concentrated sulfuric acid (1
ml) and brought to reflux. After refluxing for 16 hours, the
reaction mixture became a homogenous solution and was allowed to
cool to room temperature. Approximately one half of the solvent was
removed at which point the product crystallized from solution. The
mixture was cooled in an ice bath, filtered and dried to afford a
yellow powder (16.7 g). .sup.1H-NMR was consistent with the
proposed structure.
[0614] Step 2:
[0615] A solution of the product from Step 1 (2.6 g) in DMF (40 ml)
was chilled to 0.degree. C. under N.sub.2 and treated with a 60%
dispersion of sodium hydride in mineral oil (655 mg). The mixture
was stirred at 0.degree. C. for 45 minutes and then treated with
iodomethane (2.8 g) in one portion. The reaction was stirred at
room temperature for 16 hours, and then partitioned between ethyl
acetate and water. The aqueous portion was extracted several times
with additional ethyl acetate and then the combined organic
extracts were washed with saturated sodium chloride solution, dried
(Na.sub.2SO.sub.4) and concentrated. The residue was purified on a
silica gel column (eluting with 2% methanol-98% methylene chloride)
to yield a yellow solid (1.9 g). .sup.1H-NMR was consistent with
the proposed structure.
[0616] Step 3:
[0617] A solution of the product from Step 2 (2.6 g), methanol (60
ml) and 2N sodium hydroxide solution (60 ml) was stirred at room
temperature for 16 hours. The reaction was quenched with glacial
acetic acid (6.9 ml) and concentrated. The residue was dried under
high vacuum. This material was then refluxed with thionyl chloride
(100 ml) under nitrogen for 3 hours. The reaction was cooled,
concentrated and dried thoroughly under high vacuum to afford a tan
solid (2.2 g). .sup.1H-NMR was consistent with the proposed
structure. In a flame dried flask under nitrogen, the product of
Example D (3.5 g) was dissolved in N,N-dimethylacetamide (35 ml)
and diisopropylethylamine (2.9 ml). The solution was chilled to
0.degree. C. and treated with a solution of the acid chloride (1.9
g) (as obtained above) in THF (35 ml). The reaction was stirred for
30 minutes and then concentrated under high vacuum to remove the
solvents. The residue was partitioned between ethyl acetate and
water and the aqueous portion was extracted several times with
additional ethyl acetate. The combined organic extracts were washed
with water several times and then washed with saturated sodium
chloride solution, dried (Na.sub.2SO.sub.4) and concentrated to
produce a yellow solid (1.3 g). .sup.1H-NMR was consistent with the
proposed structure.
[0618] Step 4:
[0619] A solution of the product from Step 3 (1.0 g) in THF (10 ml)
and DMF (10 ml) was treated with a catalytic amount of 5% Pt/C
under a 5 psi atmosphere of hydrogen at room temperature for 4
hours. The reaction mixture was filtered and concentrated. The
residue was taken up in minimal amount of THF and allowed to
crystallize slowly at room temperature. An equal volume of ethyl
acetate was added to the crystallized mixture and digested for 15
minutes. The mixture was cooled, filtered and washed with cold
ethyl acetate. The product was dried to afford a white solid (730
mg). .sup.1H-NMR was consistent with the proposed structure.
[0620] Step 5:
[0621] To a solution of the product from Step 4 (720 mg) and
G.sub.2 (581 mg) in DMF (25 ml), triethylamine (304 mg) and
mercuric chloride (544 mg) were added and the mixture heated at
85.degree. C. under nitrogen for 1 hour. The reaction mixture was
cooled and filtered through a pad of celite. The filtrate was
concentrated and purified on a silica gel column (eluting with 10%
methanol-90% chloroform) to yield a white solid (375 mg).
.sup.1H-NMR was consistent with the proposed structure.
[0622] Step 6:
[0623] The above compound was prepared from the compound prepared
in Step 5 (360 mg) utilizing the procedure described in Example 14
(Step 5). The crude product was purified using reverse phase HPLC
as previously outlined to yield a white solid (223 mg). .sup.1H-NMR
was consistent with the proposed structure.
[0624] Analysis calculated for:
C.sub.21H.sub.22N.sub.6O.sub.6Cl.sub.2.2.5- TFA.0.5H.sub.2O: C,
38.11; H, 3.14; N, 10.26; Cl, 8.65. found: C, 38.18; H, 3.05; N,
10.79; Cl, 9.34.
EXAMPLE 19
N-[[6-chloro-5-[(4,5,-dihydro-1
H-imidazol-2-yl)amino]-3-pyridinyl]carbony-
l]-glycyl-3-(3,5-dichloro-2-hydroxyphenyl)-.beta.-alanine,
(trifluoroacetate) salt, monohydrate
[0625] 149
[0626] Step 1:
[0627] A solution of tin(II) chloride (6.3 g) in concentrated
hydrochloric acid ml) was prepared and was added dropwise to a
solution of the product from Step 3, Example 17 (1.0 g) in THF (15
ml). The reaction was stirred for 15 minutes at which time the
reaction had cooled back to room temperature. The organic solvent
was removed to give a gummy precipitate. The aqueous portion was
decanted and the gummy precipitate partitioned between ethyl
acetate and dilute sodium bicarbonate solution. The aqueous portion
was extracted several times with additional ethyl acetate and the
combined organic extracts were then washed with water and saturated
sodium chloride solution, dried (Na.sub.2SO.sub.4) and
concentrated. The residue was dried under vaccuum to afford a tan
powder (375 mg).
[0628] .sup.1H-NMR was consistent with the proposed structure.
[0629] Step 2:
[0630] The compound described in Step 1 (365 mg) was guanylated
utilizing the methodology outlined in Step 5, Example 18. The crude
product was purified on a silica gel column (eluting with 2%
methanol-98% chloroform) to yield a brownish thick liquid (205 mg).
.sup.1H-NMR was consistent with the proposed structure.
[0631] Step 3:
[0632] The title compound was prepared using the product of Step 2
(200 mg) and following the procedure described in Step 7, Example
17. The crude product was purified using the reverse phase HPLC as
previously described to afford a white solid (53 mg). .sup.1H-NMR
was consistent with the proposed structure.
[0633] Analysis calculated for
C.sub.20H.sub.19N.sub.6O.sub.5Cl.sub.3 .1.7 TFA.1.0 H.sub.2O: C,
37.90; H, 3.09; N, 11.33; Cl, 14.34. found: C, 37.53; H, 2.71; N,
11.33; Cl, 15.01.
EXAMPLE 20
N-[[5-[(4,5,-dihydro-1
H-imidazol-2-yl)amino]-1,6-dihydro-6-oxo-3-pyridiny-
l]-carbonyl]glycyl-3-(3,5-dichloro-2-hydroxyphenyl)-.alpha.-alanine,
(trifluoroacetate) salt
[0634] 150
[0635] The above compound was prepared by dissolving the product
from Example 17, Step 6 (353 mg) in a 6N solution of hydrochloric
acid (50 ml) at room temperature for 48 hours. The reaction was
concentrated and the residue purified using reverse phase HPLC as
previously described to afford a white solid (115 mg). .sup.1H-NMR
was consistent with the proposed structure.
[0636] Analysis calculated for
C.sub.20H.sub.20N.sub.6O.sub.6Cl.sub.2.1.25 TFA: C, 41.33; H, 3.28;
N, 12.85. found: C, 41.57; H, 3.29; N, 12.92. 151
[0637] The starting material used in the preparation of the title
compound was synthesized utilizing the sequence of reactions
described in Example 17 (Steps 1-3). Instead of the product of
Example D the chiral intermediate of Example G was utilized in the
coupling reaction detailed in Step 3.
[0638] Step 1:
[0639] (A) was prepared using the procedure given in Step 4,
Example 17.
[0640] .sup.1H-NMR was consistent with the proposed structure.
[0641] Step 2:
[0642] A solution of the material from Step 1 (2.7 g) in 4N
anhydrous HCl/dioxane (100 ml) was warmed to 45.degree. C. under
N.sub.2 for 72 hours. The reaction was concentrated to dryness to
afford a light brown solid (2.6 g).
[0643] .sup.1H-NMR was consistent with the proposed structure.
[0644] Step 3:
[0645] A solution of the product from Step 2 (1.85 g) in ethanol
(50 ml) was treated with a catalytic amount of 5% Pt/C under a 5
psi atmosphere of hydrogen at room temperature for 2 hours. The
reaction mixture was filtered and concentrated and the residue
purified using reverse phase HPLC to yield a white solid (507 mg).
.sup.1H-NMR was consistent with the proposed structure.
[0646] Step 4:
[0647] To a solution of the product from Step 3 (500 mg) and the
product of Step 1 of Example 4 (650 mg) in DMF (15 ml),
triethylamine (304 mg) and mercuric chloride (408 mg) were added
and the mixture heated to 100.degree. C. for 2 hours under
nitrogen. The reaction mixture was cooled to room temperature and
stirred with ethyl acetate (30 ml) for 15 minutes and then
filtered. The filtrate was concentrated and the residue treated
with a solution of TFA (7 ml) and CH.sub.2Cl.sub.2 (7 ml) at room
temperature for one hour. The mixture was concentrated and the
residue purified using reverse phase HPLC as previously described
to afford a white solid (400 mg). .sup.1H-NMR was consistent with
the proposed structure.
[0648] Step 5:
[0649] A solution of the product from Step 4 (200 mg), 1N sodium
hydroxide (8 ml) and methanol (8 ml) was stirred at room
temperature for 16 hours. The reaction was quenched with TFA (1 ml)
and concentrated. The residue was purified using reverse phase HPLC
as previously described to yield a white solid (79 mg). .sup.1H-NMR
was consistent with the proposed structure.
[0650] Analysis calculated for
C.sub.21H.sub.22N.sub.6O.sub.7Cl.sub.2.1.5 TFA: C, 40.46; H, 3.32;
N, 11.80. found: C, 40.12; H, 3.57; N, 12.26. 152
[0651] Step 1:
[0652] To a solution of 2-hydroxynicotinic acid (10.0 g, 71.9 mmol)
in concentrated sulfuric acid (28.6 ml), was added fuming nitric
acid (7.1 ml) in a dropwise fashion. The reaction mixture was
heated at 55.degree. C. for 4 hours. The cooled reaction mixture
was poured onto ice-water. The product precipitated as a yellow
solid. The precipitated solid was collected by filtration, washed
with water, and air dried to yield the desired product (7.2 g, 54%
yield). NMR was consistent with the proposed structure.
[0653] Step 2:
[0654] A solution of the product of Step 1 (5.0 g, 27.2 mmol) in
phosphorus oxychloride (13.5 g) was refluxed for 4.5 hours. The
cooled reaction mixture was poured onto ice water (200 g). The
resulting mixture was stirred for 30 minutes and extracted with
tetrahydrofuran/ethyl acetate (2/1). The organic layer was washed
with brine, dried over Na.sub.2SO.sub.4, and filtered. The filtrate
was concentrated to give an oil. The oil was treated with a mixture
of hexane/ether (4/1) to give the desired product as a fine yellow
powder (5.0 g, 91% yield). NMR was consistent with the proposed
structure.
[0655] Step 3:
[0656] A solution of the product of Step 2 (3.1 g, 15.3 mmol) in
thionyl chloride (8.1 ml) was refluxed for 4.5 hours. The remaining
thionyl chloride was removed from the reaction mixture under
reduced pressure to give a pale brown oil. This oil was dried under
vacuum to give the product as a yellow solid (2.7 g, 79% yield).
NMR was consistent with the proposed structure.
[0657] Step 4:
[0658] Diisopropylethylamine (3.7 g, 4.9 ml) was added to a
solution of the product of Example D (5.5 g, 14.8 mmol) in
N,N-dimethylacetamide (40 ml) and tetrahydrofuran (15 ml) and the
reaction mixture cooled to -5.degree. C. A solution of the product
of Step 3 (3.1 g, 14.1 mmol) in tetrahydrofuran (25 ml) was added
to the reaction over 15 minutes. The reaction was stirred at
-5.degree. C. for 30 minutes and allowed to warm to room
temperature. After 3 hours, tetrahydrofuran was removed from the
reaction mixture under reduced pressure. The reaction mixture was
poured onto ice-water. The precipitated solid was collected by
filtration, washed with water, and dried in air to give the product
as a yellow solid (6.2 g, 85% yield). NMR was consistent with the
proposed structure.
[0659] Step 5:
[0660] A solution of the product of Step 4 (4.0 g, 7.7 mmol) and
sodium methoxide (1.67 g, 30.8 mmol) in methanol (45 ml) was
stirred at 0.degree. C. for 4 hours. The reaction was neutralized
with acetic acid. Methanol was removed from the reaction mixture
and the crude mixture was purified by chromatography (silica gel,
ethyl acetate-toluene, 6/4) to give the desired product as a yellow
solid (2.5 g, 67% yield). NMR was consistent with the proposed
structure.
[0661] Step 6:
[0662] A mixture of the product of Step 5 (0.99 g, 1.9 mmol), 3%
platinum on carbon, and methanol was treated with H.sub.2 gas under
5 psi at room temperature for 16 hours. Platinum catalyst was
removed by filtration. Methanol was removed under reduced pressure
to give the desired product as a yellow solid (0.62 g, 70% yield).
This was used in the next reaction without further purification.
NMR was consistent with the proposed structure.
[0663] Step 7:
[0664] A mixture of the product of Step 6 (0.269, 0.54 mmol),
G.sub.2 (0.18 g, 0.59 mmol), triethylamine (0.25 g, 1.78 mmol),
mercury(II) chloride (0.16 g, 0.59 mmol), and N,N-dimethylformamide
(15 ml) was heated at 90-5.degree. C. for 16 hours. The cooled
reaction mixture was filtered through a short celite column with
ethyl acetate (40 ml) and then dichloromethane (30 ml). The crude
mixture was chromatographed (silica gel,
CH.sub.2Cl.sub.2--CH.sub.3OH--NH.sub.4OH, 95/5/0.5) to give the
product as a yellow solid (0.31 g, 76% yield). NMR was consistent
with the proposed structure.
[0665] Step 8:
[0666] A solution of the product of Step 7 (0.31 g, 0.41 mmol),
trifluoroacetic acid (3.5 ml), and dichloromethane (7.0 ml) was
stirred at room temperature for 2 hours. Trifluoroacetic acid and
dichloromethane were removed under reduced pressure and the crude
mixture was treated with methanol (5 ml) and sodium hydroxide
solution (2N, 2.5 ml) for 18 hours at room temperature. Acetic acid
was added to netrualize sodium hydroxide. Methanol was removed to
give a crude mixture. The crude mixture was purified using reverse
phase HPLC to give the above compound as a white solid (0.10 g, 36%
yield).
[0667] Analysis calculated for
C.sub.21H.sub.22N.sub.6O.sub.6Cl.sub.21.3CF-
.sub.3COOH.0.25H.sub.2O:
[0668] C, 41.80; H, 3.54; N, 12.39; Cl, 10.46; Found: C, 42.12; H,
3.84; N, 11.87; Cl, 10.99.
EXAMPLE 23
[0669] Preparation of
N-[[5-(4,5,-dihydro-1H-imidazol-2-yl)amino]-1,2-dihy-
dro-2-oxo-3-pyridinyl]-carbonyl]glycyl-3-(3,5-dichloro-2-hydroxyphenyl)-.b-
eta.-alanine, (trifluoroacetate) salt 153
[0670] A solution of the product (0.21 g, 0.28 mmol) of Step 7,
Example 22, in dioxane (4 ml) was treated with 6N HCl (6 ml) at
room temperature for 72 hours. The solvent was removed under
reduced pressure and the crude mixture purified on a reverse phase
HPLC using acetonirtile-water as eluent to give the desired
compound as an off white solid (0.052 g, 27% yield).
[0671] Analysis calculated for
C.sub.20H.sub.20N.sub.6O.sub.6Cl.sub.2.1.6C- F.sub.3COOH: C, 40.17;
H, 3.14; N, 12.11; found: C, 40.10; H, 3.22; N, 11.84. 154
[0672] The Steps 1 and 2 in the synthesis of the target compound
were carried out following the literature procedures (Justus
Liebigs. Ann. Chem, 512, 97, 1934 and J. Heterocyclic Chem. 21,
737, 1994 respectively).
[0673] Step 3:
[0674] To a solution of the product of Step 2 (0.9 g, 5.3 mmol) and
G.sub.2 (1.9 g, 5.9 mmol) in DMF (25 ml), triethylamine (2.5 ml,
17.6 mmol) and mercuric chloride (1.6 g, 5.9 mmol) were added.
After heating the mixture at 80-85.degree. C. for 18 hours, the
reaction mixture was cooled and filtered through a celite column.
The residue was washed with methylene chloride and the combined
fractions concentrated. The residue was redissolved in methylene
chloride and washed with water and brine. After drying over sodium
sulfate, the mixture was filtered and concentrated. The crude
orange solid (1.8 g) was purified using silica gel chromatography
(hexane/ethyl acetate 1/1) to give the N-Boc protected product as
an off-white solid (1.4 g).
[0675] Step 4:
[0676] To a solution of the product of Step 3 (2.4 g, 5.5 mmol) in
ethanol (50 ml), aqueous lithium hydroxide (526 mg in 5 ml water)
was added. The reaction mixture was stirred at room temperature for
24 hours. Acetic acid (22 ml) was added to the reaction and the
mixture stirred for 15 miniutes. After removal of the solvent under
reduced pressure, the crude mixture was purified on a reverse phase
HPLC (acetonitrile/water containing trifluoroacetic acid) to give
the product as a TFA salt as a thick white liquid. The residue was
treated with hydrogen chloride (4M solution in dioxane) and stirred
for 10 minutes. The reaction was concentrated to remove the solvent
and the process repeated twice to give the desired product as a
white solid (3.9 g). The product was used in the next Step without
further purification.
[0677] Step 5:
[0678] To a solution of the of the product of Step 4 (0.9 g, 3.7
mmol) in DMF (15 ml) at 0.degree. C., N-methylmorpholine (605 ml,
5.5 mmol) and isobutyl chloroformate (475 ml, 3.7 mmol) were added
sequentially. After stirring for 5 minutes, a solution of the
product of Step D in DMF (10 ml) containing N-methylmorpholine (605
ml, 5.5 mmol) was injected into the reaction. The mixture was
allowed to stir at 0.degree. C. for 1 hour and at room temperature
for 36 hours. The solvent was removed under reduced pressure and
the residue purified on a reverse phase HPLC (acetonitrile/water
containing trifluoroacetic acid) to give the product (525 mg) as a
TFA salt.
[0679] Step 6:
[0680] To a solution of the product of Step 5 (540 mg, 1 mmol) in
ethanol (50 ml), aqueous lithium hydroxide (144 mg in 10 ml water)
was added. The reaction mixture was stirred at room temperature for
24 hours. Acetic acid (305 ml) was added to the reaction and the
mixture stirred for 15 minutes. After removal of the solvent under
reduced pressure, the crude mixture was purified on a reverse phase
HPLC (acetonitrile/water containing trifluoroacetic acid) to give
the desired product (486 mg, 75% yield) as a TFA salt.
[0681] Analysis calculated for
C.sub.19H.sub.21N.sub.7O.sub.5Cl.sub.2.1.5C- F.sub.3CO.sub.2H: C,
39.48; H, 3.39; N, 14.65. Found: C, 39.29; H, 3.14; N, 14.72.
[0682] NMR and MS were consistent with the desired structure.
EXAMPLE 25
[0683] Preparation of
N-[[5-[(4,5-dihydro-1H-imidazol-2-yl)amino]--1H-pyra-
zol-3-yl]carbonyl]-glycyl-3-(3,5-dichloro-2-hydroxyphenyl)-.beta.-alanine,
(trifluoroacetate) salt 155
[0684] The compound was synthesized as in the Example 24 utilizing
benzylhydrazine instead of methylhydrazine in Step 2. The resulting
N-benzyl pyrazole compound was deprotected in the last Step using
catalytic hydrogenation conditions (5% Pd/C, 20 psi, room
temperature, 26 hours). This reaction was carried out using acetic
acid-trifluoroacetic acid (4/1) as the solvent.
[0685] Analysis calculated for
C.sub.18H.sub.19N.sub.7O.sub.5Cl.sub.2.1.75- CF.sub.3CO.sub.2H.
1.25H.sub.2O: C, 36.56; H, 3.32; N, 13.88. found: C, 36.35; H,
2.96; N, 14.28.
[0686] NMR and MS were consistent with the desired structure.
EXAMPLE 26
[0687] 156
[0688] The above compound was prepared as described in Example 9
except the product of Example S was used instead of the product of
Example R in Step 4.
[0689] Analysis calculated for C.sub.21H.sub.22BrIN.sub.6O.sub.6. 2
CF.sub.3COOH. 0.25 H.sub.2O C, 33.60; H, 2.76; N, 9.40 Found C,
34.23; H, 2.35; N, 9.72 Example 27 157
[0690] The starting material needed in this preparation was
synthesized utilizing the procedure of Example 21, Step 1.
[0691] Step 1
[0692] A solution of the starting material (1.4 g) in ethanol (50
ml) was treated with a catalytic amount of 5% Pt/C under 5 psi
pressure of hydrogen at room temperature for 5 hours. The reaction
mixture was filtered, concentrated, and dried to afford a white
solid (1.1 g). .sup.1H-NMR was consistent with the proposed
structure.
[0693] Step 2
[0694] The compound 2 was prepared by following the experimental
procedure given in Step 4 of Example 21. .sup.1H-NMR was consistent
with the proposed structure.
[0695] Step 3
[0696] The ester group of compound 2 was hydrolyzed following the
experimental procedure given in Step 5 of Example 21. .sup.1H-NMR
was consistent with the proposed structure.
[0697] Analysis calculated for
C.sub.22H.sub.24N.sub.6O.sub.7Cl.sub.2.1.50 TFA. 0.25 H.sub.2O: C,
41.08; H, 3.59; N, 11.50. Found: C, 41.03; H, 3.69; N, 11.45.
158
[0698] The starting material needed in this preparation was
prepared as described in Step 1, Example 18.
[0699] Step 1
[0700] The compound 1 was prepared following the procedure given in
Step 2 of Example 18 except that 2-methoxyethoxymethyl chloride was
used as the alkylating agent instead of iodomethane. .sup.1H-NMR
was consistent with the proposed structure.
[0701] Step 2
[0702] A solution of the product described in Step 1 (4.6 g) in
methanol (50 ml) was treated with a catalytic amount of 5% Pt/C
under 5 psi pressure of hydrogen at room temperature for 2 hours.
The reaction mixture was filtered, concentrated and dried to afford
a viscous oil (4.3 g). .sup.1H-NMR was consistent with the proposed
structure.
[0703] Step 3
[0704] A portion of the product of Step 2 (2.0 g) was guanylated
using the reaction conditions described in Step 4 of Example 21 to
afford the product 3 as a viscous golden oil (890 mg). .sup.1H-NMR
was consistent with the proposed structure.
[0705] Step 4
[0706] The ester group from the product 3 was hydrolyzed using the
experimental procedure given in Step 5 of Example 21. .sup.1H-NMR
was consistent with the proposed structure.
[0707] Step 5
[0708] The product of Step 4 was coupled to the product of Example
I following the procedure given in Step 4 of Example 12.
.sup.1H-NMR was consistent with the proposed structure.
[0709] Step. 6
[0710] The ester group from the product of Step 5 was hydrolyzed
following the procedure given in Step 5 of Example 21. .sup.1H-NMR
was consistent with the proposed structure.
[0711] Analysis calculated for
C.sub.25H.sub.31N.sub.6O.sub.9Br.sub.2 1.75TFA 0.25 H.sub.2O: C,
37.07; H, 3.63; N, 9.10. Found: C, 36.86; H, 3.66; N, 9.39.
EXAMPLE 29
[0712] 159
[0713] The product of Step 5 of Example 28 was used as the starting
material in this procedure.
[0714] Step 1
[0715] A portion (425 mg) of the starting material was treated with
saturated anhydrous HCl in ethanol (10 ml) at room temperature for
four hours. The reaction mixture was concentrated to dryness and
the product was used in the next step without purification.
[0716] Step 2
[0717] The ester group from the crude product of Step 1 was
hydrolyzed following the procedure in Step 5 of Example 21.
.sup.1H-NMR was consistent with the proposed structure.
[0718] Analysis calculated for
C.sub.21H.sub.22N.sub.6O.sub.7Br.sub.2 1.75TFA 0.25 H.sub.2O: C,
35.27; H, 2.93; N, 10.07. Found: C, 35.21; H, 3.16; N, 10.27.
EXAMPLE S
[0719] 160
[0720] The above compound was prepared following the procedures
described for Example G. In step 2A, 3-iodo-5-bromosalicylaldehyde
was used instead of 3,5-dichlorosalicylaldehyde.
EXAMPLE T
[0721] 161
[0722] The above compound was prepared following the procedures
described for Example G. In step 2A,
3-bromo-5-chlorosalicylaldehyde was used instead of
3,5-dichlorosalicylaldehyde. Similarly, in step 2B,
R-phenylglycinol was used instead of S-phenylglycinol.
EXAMPLE U
[0723] 162
[0724] The above compound was prepared following the procedures
described for Example D. The racemic mixture obtained in step 2 was
resolved as described below. 163
[0725] Step 1:
[0726] To the racemic amino ester hydrochloride (50.0 g, 158.9
mmol) obtained from Step 2, example D, in CH.sub.2Cl.sub.2 (500 mL)
and water (380 mL) was added NaHCO.sub.3 (38.2 g, 454.5 mmol). The
mixture was stirred at room temperature for 10 minutes with
vigorous gas evolution. A solution of benzyl chloroformate (43.4 g,
222.8 mmol) in CH.sub.2Cl.sub.2 (435 mL) was added over 20 minutes
with rapid stirring. After 40 minutes, the reaction mixture was
poured into a separatory funnel and the organic solution collected.
The aqueous phase was washed with CH.sub.2Cl.sub.2 (170 mL). The
combined organic solution was dried (MgSO.sub.4) and concentrated
in vacuo. The resulting gummy solid was triturated with hexane and
collected by filtration. The tan solid was dried in vacuo to give
the desired racemic product,
[0727] (62.9 g, 96%. yield). This material was subjected to reverse
phase HPLC using a chiral column to give each pure enantiomer, A
and B. The column employed was a Whelk-O(R,R), 10 micron particle
size using a 90:10 heptane:ethanol mobile phase. Optical purity was
determined to be >98% using analytical HPLC with similar solvent
and conditions. .sup.1H NMR was consistent with proposed
structure.
[0728] Step 2A 164
[0729] To a solution of Enantiomer A, Step 1 (57.9 g, 140.4 mmol)
in CH.sub.2Cl.sub.2 (600 mL) was added trimethylsilyl iodide (33.7
g, 168.5 mmol) in CH.sub.2Cl.sub.2 (125 mL) via canula. The orange
solution was stirred at room temperature for 1 hour. Methanol (27.3
mL, 674.1 mmol) was added dropwise and the solution stirred for 15
minutes. The reaction solution was concentrated in vacuo to give an
orange oil. The residue was dissolved in methyl t-butyl ether (670
mL) and extracted with 1M HCl (420 mL) and water (1.times.230 mL,
1.times.130 mL). The aqueous extracts were back washed with MTBE
(130 mL). To the aqueous solution was added solid NaHCO.sub.3 (52.9
g, 630 mmol) in small portions. The basified aqueous mixture was
extracted with MTBE (1.times.1.2 L, 2.times.265 mL). The combined
organic solution was washed with brine and concentrated in vacuo to
give the desired product, (28.6 g, 73% yield). .sup.1H NMR was
consistent with proposed structure.
[0730] Step 2B 165
[0731] To a solution of the Enantiomer B, Step 1, the compound of
Example 1 (38.5 g, 93.4 mmol) in CH.sub.2Cl.sub.2 (380 mL) was
added trimethylsilyl iodide (25.0 g, 125.0 mmol) in
CH.sub.2Cl.sub.2 (80 mL) via canula. The orange solution was
stirred at room temperature for 1.5 hours. Methanol (20.0 mL, 500.0
mmol) was added dropwise and the solution stirred for 20 minutes.
The reaction solution was concentrated in vacuo to give an orange
oil. The residue was dissolved in diethyl ether (450 mL) and
extracted with 1M HCl (320 mL) and water (1.times.200 mL,
1.times.100 mL). The aqueous extracts were back washed with diethyl
ether (100 mL). To the aqueous solution was added solid NaHCO.sub.3
(40.1 g, 478 mmol) in small portions. The basified aqueous mixture
was extracted with diethyl ether (1.times.1.0 L, 2.times.200 mL).
The combined organic solution was washed with brine and
concentrated in vacuo to give the desired product (20.8 g, 80%
yield).
[0732] Anal. calculated for C.sub.11H.sub.13Cl.sub.2NO.sub.3: C,
47.50; H, 4.71; N, 5.04. Found: C, 47.11; H, 4.66; N, 4.93.
[0733] The product of step 2B was converted to the target
intermediate by using the reagents and conditions described in
steps 4 and 5 of example G.
EXAMPLE V
[0734] 166
[0735] The above compound was prepared following the procedures
described in Example G. In step 2A, 5-bromo-3-iodobenzaldehyde was
used instead of 3, 5-dichlorosalicylaldehyde.
EXAMPLE 30
[0736] 167
[0737] Step 1.
[0738] Preparation of 168
[0739] To a stirred solution of methyl 4-methoxy-2-aminopicolinate
(602 mg, 3.3 mmol) (JACS,78, 4130,1956) in CH.sub.2Cl.sub.2 (20
ml), was added benzoylisothiocyanate (1 ml, Aldrich), and the
reaction mixture was stirred at room temperature for 90 minutes.
The mixture was diluted with ether (20 ml). The mixture was cooled
in an ice bath and solid was filtered and washed with ether and
dried to give the desired compound (828 mg, 73.27% yield) as white
solid: .sup.1H NMR: 300 MHz was consistent with proposed
structure
[0740] Step 2.
Preparation of
[0741] 169
[0742] To a stirred solution of the product of Step 1 (750 mg, 2.17
mmol) in methanol (30 ml), under nitrogen atmosphere was added
NaOMe (538 mg). The reaction mixture was stirred at room
temperature for 2 hours. The mixture was quenched with glacial
acetic acid (0.575 ml), and was stirred at room temperature for 15
minutes. The solid was filtered under vacuum, washed with cold
methanol and dried to give the desired compound (385 mg, 73% yield)
as white solid: .sup.1H NMR: 300 MHz was consistent with proposed
structure.
[0743] Step 3
[0744] Preparation of 170
[0745] To a stirred solution of the product of Step 2 (364 mg, 1.5
mmol) in methanol (20 ml), was added iodomethane (0.25 ml). The
reaction mixture was heated to reflux for 2 hours. The mixture was
cooled to room temperature and was concentrated to give the desired
compound (560 mg) as white solid: .sup.1H NMR: 300 MHz was
consistent with proposed structure.
[0746] Step 4
[0747] Preparation of 171
[0748] To a stirred solution of the product of Step 3 (500 mg, 1.30
mmol) in N,N-dimethylacetamide (10 ml), was added
1,3-diamino-2-hydroxypropane (123 mg, 1.37 mmol). The reaction
mixture was heated to 90.degree. C. for 2 hours. The mixture was
concentrated in vacuo to give the crude product which was purified
by reverse phase HPLC to give the desired compound (228 mg) as
white solid. .sup.1H-NMR: 300 MHz was consistent with proposed
structure.
[0749] Step 5
Preparation of
[0750] 172
[0751] To a stirred solution of the product of Step 4 (200 mg) in
methanol (3 ml), and THF (3 ml), was added 1N NaOH solution (3 ml).
The reaction mixture was stirred at room temperature for 1 hour.
The mixture was concentrated in vacuo to yield an oily gum which
was taken up in water (2 ml), and was neutralized with 1N HCl (3
ml). The mixture was concentrated in vacuo to give the crude
product which was purified by reverse phase HPLC to give the
desired compound (228 mg) as white solid. .sup.1H NMR: 300 MHz was
consistent with the proposed structure.
[0752] Step 6
[0753] Preparation of 173
[0754] To a stirred solution of the product of Step 5 (151.25 mg,
0.5 mmol) in N,N-dimethylacetamide (5 ml) was added
4-methylmorpholine (202 mg, 2 mmol), and 1-hydroxybenzotriazole (67
mg, 0.5 mmol), and, the amino ester product of Example R (208.5 mg,
0.5 mmol). The mixture was stirred at room temperature for 5
minutes. The reaction mixture was treated with
1-13-(dimethylamino)propyl-3-ethylcarbodiimide (96 mg, 0.5 mmol),
and 4-(dimethylamino)pyridine (10 mg). The reaction mixture was
stirred at room temperature under nitrogen atmosphere for 72 hours.
The reaction mixture was quenched with water (1 ml) and
concentrated in vacuo to give the crude product which was purified
by reverse phase HPLC to give the desired compound (42 mg) as white
solid. .sup.1H NMR: 400 MHz was consistent with the proposed
structure.
[0755] Step 7
[0756] Preparation of 174
[0757] To a stirred solution of the product of Step 6 (35 mg) in
methanol (3 ml), and THF (3 ml), was added 1N NaOH solution (3 ml).
The reaction mixture was stirred at room temperature for 1 hour.
The mixture was concentrated in vacuo to yield an oily gum which
was taken up in water (2 ml), and neutralized with 1N HCl (3 ml).
The mixture was concentrated in vacuo to give the crude product
which was purified by reverse phase HPLC to give the desired
compound (22 mg) as a white solid. .sup.1H NMR: 400 MHz was
consistent with the proposed structure.
[0758] Analysis Calculated for: C.sub.22H.sub.24N.sub.6O.sub.7BrCl
2TFA,0.5H.sub.2O: C, 37.22; H, 3.25; N, 10.04 Found: C, 36.91; H,
3.17; N, .sub.10.02
EXAMPLE 31
[0759] 175
[0760] Step 1
[0761] Preparation of 176
[0762] To a stirred solution of the product of Step 4 of Example 30
(900 mg) in glacial acetic acid (10 ml) was added 48% HBr (10 ml).
The reaction mixture was heated to reflux for 3 hours The mixture
was cooled to room temperature and stirred at room temperature for
18 hours. The mixture was concentrated in vacuo to give the crude
product which was purified by reverse phase HPLC to give the
desired compound (720 mg) as an oily gum. .sup.1H NMR: 300 MHz was
consistent with the proposed structure.
[0763] Step 2
[0764] Preparation of 177
[0765] To a stirred solution of the product of Step 1 (720 mg, 1.7
mmol) in N,N-dimethylacetamide (10 ml) was added 4-methylmorpholine
(520 mg, 5.2 mmol), and 1-hydroxybenzotriazole (221 mg, 1.71 mmol),
and the amino ester product of Example R (710 mg, 1.71 mmol). The
mixture was stirred at room temperature for 5 minutes. The reaction
mixture was treated with
1-13-(dimethylamino)propyl-3-ethylcarbodiimide (211 mg, 1.7 mmol),
and 4-(dimethylamino)pyrdine (10 mg). The reaction mixture was
stirred at room temperature under nitrogen atmosphere for 72 hours.
The reaction mixture was quenched with water (1 ml) and
concentrated in vacuo to give the crude product which was purified
by reverse phase HPLC to give the desired compound (182 mg) as
white solid. .sup.1H NMR: 300 MHz was consistent with the proposed
structure.
[0766] Step 3
[0767] Preparation of 178
[0768] To a stirred solution of the product of Step 2 (100 mg) in
methanol (3 ml), and THF (3 ml), was added 1N NaOH solution (3 ml).
The reaction mixture was stirred at room temperature for 1 hour.
The mixture was concentrated in vacuo to yield an oily gum which
was taken up in water (2 ml), and neutralized with 1N HCl (3 ml).
The mixture was concentrated in vacuo to give the crude product
which was purified by reverse phase HPLC to give the desired
compound (42 mg) as a white solid. .sup.1H NMR: 300 MHz was
consistent with the proposed structure.
[0769] Analysis Calculated for
C.sub.21H.sub.22N.sub.6O.sub.7BrCl1.5TFA,0.- 5H.sub.2O: C, 37.64;
H, 3.22; N, 10.97 Found: C, 37.56; H, 3.05; N, 10.99
EXAMPLE 32
[0770] 179
[0771] To a solution of the product of Step 3, Example 9 (860
mg.sub.1 2.45 mmol) and the product of Example T (1.0 g, 2.41 mmol)
in dimethylacetamide (24 mL) at 0.degree. C. was added HOBT (358
mg, 2.64 mmol) followed by N-methylmorpholine (0.6 mL, 5.15 mmol).
The reaction solution was stirred for 15 minutes and EDC (470 mg,
2.45 mmol) was added. The mixture was warmed to room temperature
overnight. The mixture was concentrated in vacuo and the residue
partitioned between ethyl acetate and water. The aqueous solution
was extracted with ethyl acetate and the combined organic layers
were dried (Na.sub.2SO.sub.4) and concentrated. The residue was
purified by RP HPLC (90:10 water/TFA:MeCN starting gradient,
retention time 22.5 min) to give the desired coupled product along
with recovered Compound B (480 mg). This material (compound B) was
treated with 1M aqueous NaOH (6 mL) and stirred for 3 hours. The
solution was acidified to pH 4 with TFA. The mixture was purified
by RP HPLC (95:5 water/TFA:MeCN starting gradient, retention time
24.5 min) to give the desired product (160 mg, 8% yield for the two
steps).
[0772] Analysis calculated for:
C.sub.21H.sub.22BrClN.sub.5O.sub.6+2.4 TFA: C, 36.74; H, 2.92; N,
9.96. Found: C, 36.83; H, 3.07; N, 9.88.
[0773] .sup.1H NMR was consistent with the proposed structure.
EXAMPLE 33
[0774] 180
[0775] Step 1
[0776] A solution of the material from Step 2, Example 18 (5.72 g)
in THF (80 ml) was treated with a catalytic amount of 5% Pd/C under
a 5 psi atmosphere of hydrogen at room temperature for 2 hours. The
reaction mixture was filtered and the residue washed with DMF (250
ml). The filtrate was concentrated and the residue treated with
ether, filtered, and air dried to afford a brown powder (4.9 g)
which was used directly in the next step without further
purification. .sup.1H-NMR was consistent with the proposed
structure.
[0777] Step 2
[0778] The material from Step 1 (500 mg) was guanylated using the
tris boc reagent and the conditions described in Step 4 of Example
21 to afford the desired product (128 mg) as a golden glass.
.sup.1H-NMR was consistent with the proposed structure.
[0779] Step 3
[0780] The ester group from the product of Step 2 was hydrolyzed
using the experimental procedure given in Step 5 of Example 21.
.sup.1H-NMR was consistent with the proposed structure.
[0781] Analysis calculated for:
C.sub.11H.sub.14N.sub.4O.sub.4.1.5TFA C, 38.45; H, 3.57; N, 12.81.
Found: C, 38.32; H, 3.77; N, 12.80.
[0782] Step 4
[0783] The desired compound was prepared utilizing the same
methodology as described in Step 4, Example 12 by coupling the
product described in Step 3 with the product of Example R.
.sup.1H-NMR was consistent with the proposed structure.
[0784] Step 5
[0785] The ester group from the product in Step 4 was hydrolyzed
utilizing the same procedure as described in Step 5 of Example 12.
.sup.1H-NMR was consistent for the proposed structure.
[0786] Analysis calculated for:
C.sub.21H.sub.22N.sub.6O.sub.7BrCl.1.5TFA.- 0.25H.sub.2O C, 37.86;
H, 3.18; N, 11.04; Cl, 4.66; Br, 10.50. Found: C, 37.60; H, 3.26;
N, 11.20; Cl, 4.79; Br, 10.19
EXAMPLE 34
[0787] 181
[0788] The above compound was prepared utilizing the methodology
described in Example 33. In Step 4, the product of Example H was
used instead of the product of Example R.
[0789] Analysis calculated for:
C.sub.21H.sub.22N.sub.6O.sub.7BrCl.2.0TFA.- 0.5H.sub.2O C, 36.49;
H, 3.06; N, 10.21 Found C, 36.10, H, 2.83; N, 10.29
EXAMPLE 35
[0790] 182
[0791] The above compound was prepared utilizing the methodology
described in Example 33. In Step 4, the product of Example V was
used instead of the product of Example R.
[0792] Analysis calculated for:
C.sub.21H.sub.22N.sub.6O.sub.6Br.sub.2 1.75TFA. C, 35.76; H, 3.03;
N, 10.21. Found: C, 35.58; H, 3.07; N, 10.61.
EXAMPLE 36
[0793] 183
[0794] Step 1
[0795] The product from Step 1 of Example 33 (261 mg) was
guanylated using the bis-boc reagent G.sub.2 and the reaction
conditions described in Step 5 of Example 18 to afford the product
as a white solid (207 mg). This material was then saponified using
the experimental conditions described in Step 5, Example 21. The
.sup.1H-NMR was consistent with the proposed structure.
[0796] Step 2
[0797] The desired compound was prepared utilizing the same
methodology as described in Step 4 of Example 12. The product
described in Step 1 was coupled with the product of Example I.
.sup.1H-NMR was consistent with the proposed structure.
[0798] Step 3
[0799] The ester group from the product in Step 2 was hydrolyzed
utilizing the same procedure as described in Step 5 of Example 12.
.sup.1H-NMR was consistent with the proposed structure.
[0800] Analysis calculated for
C.sub.20H.sub.20N.sub.6O.sub.6Br.sub.2 1.75TFA 0.25H.sub.2O C,
35.10; H, 2.79; N, 10.45 Found: C, 34.85; H, 2.59; N, 10.62.
EXAMPLE 37
[0801] 184
[0802] Step 1
[0803] 2-nitrothiophene-4-carboxaldehyde (5.0 g) was suspended in
water (100 ml) at room temperature and a solution of sodium
hydroxide (5.2 g) in water (50 ml) was added in one portion. The
black reaction mixture was stirred at room temperature for 1 hour
and then filtered through a pad of celite. The filtrate was
acidified with 1N HCl solution and then extracted with ethyl
acetate. The combined organic extracts were washed with saturated
sodium chloride solution, dried (Na.sub.2SO.sub.4) and concentrated
to afford a light yellow solid (5.0 g) which was used without
further purification. .sup.1H-NMR was consistent with the proposed
structure.
[0804] Step 2
[0805] The product from Step 1 (2.5 g) was stirred with potassium
carbonate (2.0 g) and methyl iodide (2.2 g) in DMF (30 ml) at room
temperature for 16 hours. The reaction mixture was partitioned
between ethyl acetate and water and the layers separated. The
aqueous portion was extracted with additional ethyl acetate and
then the combined organic extracts were washed with water,
saturated sodium chloride solution, dried (Na.sub.2SO.sub.4) and
concentrated. The dark colored residue was purified on a silica gel
column with 15% ethyl acetate-85% hexane to yield a yellow solid
(950 mg). .sup.1H-NMR was consistent with the proposed
structure.
[0806] Step 3
[0807] The product obtained in Step 2 (2.0 g) was dissolved in
methanol (50 ml) and treated with a catalytic amount of 5% Pd/C
under a 50 psi atmosphere of hydrogen at 60.degree. C. for 32
hours. The reaction was cooled and filtered and the filtrate was
concentrated. The residue was purified on a silica gel column
eluting with 25% ethyl acetate-75% hexane to afford a light yellow
solid (920 mg). .sup.1H-NMR was consistent with the proposed
structure.
[0808] Step 4
[0809] A solution of the product from Step 3 (900 mg) was dissolved
in ethyl acetate (20 ml) and treated with benzoyl isothiocyanate
(947 mg) in one portion at room temperature. The reaction was
stirred for 30 minutes and the precipitate filtered, washed with
ethyl acetate and air dried to yield a light yellow solid (1.51 g).
.sup.1H-NMR was consistent with the proposed structure.
[0810] Step 5
[0811] The product obtained in Step 4 of Example 35 was dissolved
in methanol (70 ml) and treated with sodium methoxide (1.3 g)
portionwise at room temperature. The reaction was stirred for 30
minutes and then quenched with glacial acetic acid (1.4 g). The
reaction was concentrated and the residue was partitioned between
ethyl acetate and water. The aqueous portion was extracted with
additional ethyl acetate and the combined organic extracts were
washed with saturated sodium chloride solution, dried
(Na.sub.2SO.sub.4) and concetrated to yield a light yellow powder
(900 mg). .sup.1H-NMR was consistent with the proposed
structure.
[0812] Step 6
[0813] The product from Step 5 (900 mg) was dissolved in methanol
(20 ml) and treated with methyl iodide (1.4 g). The reaction was
refluxed for 2 hours and then cooled and concentrated. The residue
was treated with ether, filtered and air dried to produce a white
solid (1.27 g). .sup.1H-NMR was consistent with the proposed
structure.
[0814] Step 7
[0815] The product from Step 6 (1.2 g) was heated at 95-100.degree.
C. with 1,3-diamino-2-hydroxypropane (469 mg) and DMA (20 ml) for 8
hours. The reaction was cooled and the solvent removed under high
vacuum. The residue was purified via reverse phase HPLC eluting
with a water (0.5% TFA)-acetonitrile gradient to afford the desired
product (255 mg). 'N-NMR was consistent with the proposed
structure.
[0816] Step 8
[0817] The desired compound was prepared as using the material
produced in Step 7 using the conditions described in Step 5,
Example 21. .sup.1H-NMR was consistent with the proposed
structure.
[0818] Step 9
[0819] The desired compound was prepared utilizing the same
methodology as described in Step 4 of Example 12 by coupling the
product from Step 8 with the material from Example G. .sup.1H-NMR
was consistent with the proposed structure.
[0820] Step 10
[0821] The ester group from the product Step 9 was hydrolyzed
utilizing the same procedure as described in Step 5 of Example 12.
.sup.1H-NMR was consistent with the proposed structure.
[0822] Analysis calculated for
C.sub.20H.sub.21N.sub.5O.sub.6C.sub.12S. 1.75TFA. C, 38.43; H,
3.19; N, 9.54; S, 4.37 Found: C, 38.43; H, 3.39; N, 9.73;
S.4.27
EXAMPLE 38
[0823] 185
[0824] Step 1
[0825] Acetic anhydride (20 ml) was treated with 70% nitric acid (4
ml) at room temperature. This solution was then added drop wise to
a stirred mixture of N-methylpyrrole-2-carboxylic acid (5.09) in
acetic anhydride (30 ml) at 30.degree.. The reaction was stirred
and allowed to warm to room temperature for 30 minutes. The
reaction was then re-chilled to -25.degree. and filtered through a
cold filter, washed with cold hexane and air dried to afford yellow
powder (1.5 g). .sup.1H-NMR was consistent with the proposed
structure.
[0826] Step 2
[0827] The desired compound was prepared utilizing the procedure
described in Step 2, Example 37 using the product prepared in Step
1. The crude product was purified by chromatography on a silica gel
column eluting with 40% ethyl acetate-hexane. .sup.1H-NMR was
consistent with the proposed structure.
[0828] Step 3
[0829] The product from Step 2 (1.0 g) was dissolved in methanol
(25 ml) and treated with a catalytic amount of 5% Pd/C under a 5
psi atmosphere of hydrogen at room temperature for 3 hours. The
reaction was filtered and concentrated to afford a deep red liquid
(1.0 g) which was used without further purification, .sup.1H-NMR
was consistent with the proposed structure.
[0830] Step 4
[0831] The desired compound was prepared using the product
described in Step 3 utilizing the sequence of Steps 4-8 described
in Example 37. .sup.1H-NMR was consistent with the proposed
structure.
[0832] Step 5
[0833] A solution of the product from Step 4 (425 mg),
2-chloro-4,6-dimethoxytriazine (201 mg) and N-methylmorpholine (263
mg) in DMA (10 ml) was stirred in an ice bath under nitrogen. The
reaction was allowed to warm to room temperature and stirring was
continued for 3 hours. A solution of the product of Example G (386
mg) and N-methylmorpholine (105 mg) in DMA (5 ml) was prepared and
added to the reaction at room temperature in one portion. The
reaction was stirred for 15 hours, quenched with TFA (1.5 ml) and
then concentrated under high vacuum. The residue was purified via
reverse phase HPLC eluting with a water (0.5% TFA)-acetonitrile
gradient to afford a white solid (706 mg). .sup.1H-NMR was
consistent with the proposed structure.
[0834] Step 6
[0835] The ester group from the product in Step 5 was hydrolyzed
utilizing the same procedure described in Step 5 of Example 12.
.sup.1H-NMR was consistent with the proposed structure.
[0836] Analysis calculated for:
C.sub.21H.sub.24N.sub.6O.sub.6Cl.sub.2 1.5TFA0.5H.sub.2O C, 40.75;
H, 3.78; N, 11.88; Cl, 10.02. Found: C, 40.40; H, 3.68; N, 12.10;
Cl, 10.20.
EXAMPLE 39
[0837] 186
[0838] Step 1
[0839] A mixture of 3-bromo-4-methyl thiophene, (10 g) copper (1)
cyanide (11.3 g) and HMPA (15 ml) was heated at 130-140.degree. for
18 hours. The mixture was cooled and poured into a stirred solution
of sodium cyanide (18.8 g) in water (28 ml) and stirred for 1 hour.
The thick brown mixture was diluted with some additional water and
extracted with ether. The combined ethereal extracts were washed
with water, saturated sodium chloride solution, dried
(Na.sub.2SO.sub.4) and concentrated. The residue was purified on a
silica gel column eluting with 90% hexan-10% ethyl acetate to
afford a pale yellow liquid (5.2 g). .sup.1H-NMR was consistent
with the proposed structure.
[0840] Step 2
[0841] A mixture of the nitrile prepared in Step 1 (1.5 g) and 2N
sodium hydroxide solution (150 ml) was refluxed for 1 hour. The
reaction was cooled and acidified with 2N hydrochloric acid until
pH-2 and extracted with ether. The combined ethereal extracts were
dried (Na.sub.2SO.sub.4) and concentrated to afford a white solid
(16.4 g) which was used without further purification. .sup.1H-NMR
was consistent with the proposed structure.
[0842] Step 3
[0843] The product from Step 2 (16.4 g) was esterified as described
in Step 2 of Example 37 to afford the desired product (13.6 g)
after purification on a silica gel column eluting with 10% ethyl
acetate-90% hexane. .sup.1H-NMR was consistent with the proposed
structure.
[0844] Step 4
[0845] A mixture of N-bromosuccinimide (6.3 g) and dibenzoyl
peroxide (100 mg) in carbon tetrachloride (25 ml) was added over a
period of 90 minutes to a refluxing solution of the product from
Step 3 (5.0 g) and dibenzoyl peroxide (100 mg) in CCl.sub.4 (25
ml). After refluxing for 2 hours the reaction mixture was cooled,
filtered and concentrated and the residue purified on a silica gel
column eluting with 10% ethyl acetate-90% hexane to afford the
desired compound (4.3 g). .sup.1H-NMR was consistent with the
proposed structure.
[0846] Step 5
[0847] A mixture of the product described in Step 4 (4.2 g), sodium
azide (2.9 g) and DMF (50 ml) was heated at 550 under nitrogen for
5 hours. The reaction mixture was cooled and partitioned between
water and ethyl acetate. The layers were separated and the aqueous
portion was extracted with additional ethyl acetate. The combined
organic extracts were washed with saturated sodium chloride
solution, dried (Na.sub.2SO.sub.4) and concentrated to afford a
golden oil (3.5 g) which was used without further purification.
.sup.1H-NMR was consistent with the proposed structure.
[0848] Step 6
[0849] A solution of the product described in Step 5 (1.0 g) 1N
sodium hydroxide solution (15 ml) and methanol (15 mL) was stirred
at room temperature for 16 hours. The reaction was treated with
glacial acetic acid (2 ml) and concentrated. The residue was
partitioned between water and ethyl acetate. The layers were
separated and the aqueous portion was extracted with additional
ethyl acetate.
[0850] The combined organic extracts were washed with water,
saturated sodium chloride solution, dried (Na.sub.2SO.sub.4) and
concentrated. The residue was dried at 61.degree. for 2 hours under
high vacuum to afford a white solid (860 mg). .sup.1H-NMR was
consistent with the proposed structure.
[0851] Step 7
[0852] A solution of the product described in Step 6 (850 mg) in
methylene chloride (10 ml) was chilled in an ice bath and treated
with a 2N solution of oxalyl chloride (5 ml) in methylene chloride
in one portion followed by 2 drops of DMF. The reaction was stirred
for 2 hours while allowing to warm to room temperature.
[0853] The solution was concentrated and dried under high vacuum at
room temperature for 16 hours to afford a yellow brown solid (785
mg). .sup.1H-NMR was consistent with the proposed structure.
[0854] Step 8
[0855] In a flame dried flask under nitrogen was placed a solution
of diisopropylethylamine (1.3 ml), the product of Example G (1.4 g)
and DMA (10 ml). The solution was chilled in an ice bath and a
solution of the acid chloride from Step 7 (770 mg) in DMA (5 ml)
was added dropwise. The reaction was stirred for 30 minutes after
the addition was completed and then partitioned between ethyl
acetate and water. The layers were separated and the aqueous
portion was extracted with additional ethyl acetate. The combined
organic extracts were purified on a silica gel column eluting with
50% ethyl acetate-50% hexane to afford white solid (1.0 g).
.sup.1H-NMR was consistent with the proposed structure.
[0856] Step 9
[0857] A solution of the product from Step 8 (806 mg) in ethanol
(20 ml) was heated with a catalytic amount of 5% Pt/C under a 5 psi
atmosphere of hydrogen at room temperature for 21 hours. The
reaction was filtered and concentrated and the residue was purified
via reverse phase HPLC eluting with a water (0.5% TFA)-acetonitrile
gradient to afford a white solid (480 mg). .sup.1H-NMR was
consistent with the proposed structure.
[0858] Step 10
[0859] The product described in Step 9 (550 mg) was guanylated and
purified using the conditions described in Step 4 of Example 21 to
afford a white solid (206 mg). .sup.1H-NMR was consistent with the
proposed structure.
[0860] Step 11
[0861] The ester group from the product in Step 10 was hydrolyzed
utilizing the same procedure set forth in Step 5 of Example 12.
.sup.1H-NMR was consistent with the proposed structure.
[0862] Analysis calculated for:
C.sub.21H.sub.23N.sub.5O.sub.5Cl.sub.2S.1.- 5TFA, 0.5H.sub.2O C,
39.79; H, 3.55; N, 9.67; Cl, 9.79; S, 4.43 Found: C, 39.91; H,
3.58; N, 9.94; Cl, 10.06; S, 4.52
EXAMPLE 40
[0863] 187
[0864] Step 1
[0865] The product prepared in Step 3 of Example 33 (1.09) was
coupled with glycine ethyl ester hydrochloride utilizing the
procedure described in Step 5 of Example 38 to afford a yellow
solid (1.19) after a similar purification .sup.1H-NMR was
consistent with the proposed structure,
[0866] Step 2
[0867] The produce described in Step 1 (1.0 g) was hydrolyzed using
the procedure described in Step 5 of Example 21 to afford a white
solid (910 mg).
[0868] .sup.1H-NMR was consistent with proposed structure.
[0869] Step 3
[0870] The product from Step 2 was coupled with
3-amino-4,4,4-trifluoro-bu- tyric acid ethyl ester hydrochloride
utilizing the protocol described in Step 5 of Example 38.
.sup.1H-NMR was consistent with the proposed structure.
[0871] Step 4
[0872] The ester group from the product in Step 3 was hydrolyzed
utilizing the procedure described in Step 5 of Example 12.
.sup.1H-NMR was consistent with the proposed structure.
[0873] Analysis calculated for:
C.sub.17H.sub.20N.sub.5O.sub.6F.sub.3.1.5T- FA C, 38.01; H, 3.67;
N, 11.08. Found C, 37.88; H, 3.64; N, 1102
EXAMPLE 41
[0874] 188
[0875] Step 1
[0876] The product of Step 3, Example 33 (527 mg, 1.3 mmol) and
CDMT (244 mg, 1.4 mmol) was dissolved in DMAC (8 ml) under argon.
The solution was cooled to 0.degree. for 3 hours NMM (0.15 ml, 1.3
mmol) was added dropwise. The solution was stirred at 0.degree. for
3 hours and then the product of Example U and NMM (0.15 ml) in DMAC
(10 ml) was added. The reaction was allowed to warm to room
temperature and stirred at room temperature overnight. The reaction
was quenched with TFA (2 ml) and concentrated in vacuo. The crude
yellow solid was purified by RP-HPLC using a gradient elution of
90:10 H.sub.2O/TFA:CH.sub.3CN (.lambda.=254 nm). The product was
isolated as a white solid (725 mg, 75% yield).
[0877] Analysis Calculated for
C.sub.23H.sub.26N.sub.6O.sub.7Cl.sub.2 1.5 TFA: C, 42.12; H, 3.74;
N, 11.35 Found C, 42.26; H, 3.87; N, 11.45
[0878] H.R.M.S. M+1 calculated for
C.sub.23H.sub.27N.sub.6O.sub.7Cl.sub.2 569.1318. Found
569.1323.
[0879] Step 2
[0880] The product from Step 1 (725 mg, 0.98 mmol) was dissolved in
THF(5 ml)/1 CH.sub.3OH) and 1M NaOH (6.5 ml) was added. The
reaction was stirred at room temperature overnight and then 1M HCl
(6.5 ml) was added. After concentrating in vacuo, the crude yellow
solid was purified by RP-HPLC using a gradient elution of 95:5
H.sub.2O/TFA:CH.sub.3CN (.lambda.=254 nm). The product was isolated
as a white solid (589 mg, 79% yield).
[0881] Analysis Calculated for: Anal. calcd for
C.sub.21H.sub.22N.sub.6O.s- ub.7Cl.sub.2 1.9 TFA: C, 39.30; H,
3.18; N, 11.09. Found C, 39.22; H, 3.16; N, 11.39.
[0882] H.R.M.S. M+1 calculated for
C.sub.21H.sub.23N.sub.6O.sub.7Cl.sub.2 541.1005. Found
541.1000.
EXAMPLE 42
[0883] 189
[0884] Step 1
[0885] 2-methoxy-6-chloropyridine carboxylic acid (10 g; 0.053 mol)
was dissolved in an excess of concentrated aqueous ammonium
hydroxide in a high pressure reactor and heated to 175.degree. C.
for 24 hours to obtain a pressure of 500 psi. The solution was
evaporated to dryness under reduced pressure and converted to the
acid by treatment with 2N HCl at 25.degree. C. for 2 days and then
evaporated to dryness under high vacuum, while heating to
60.degree. C. After 12 hours, the residual water was azeotropically
removed with absolute ethanol and the resulting residue was treated
with methanol and evaporated under reduced pressure three times.
The resulting residue was dissolved in methanol (250 ml) and 4N HCl
in dioxane (25 mol) was added to this solution and then refluxed
for 2.5 days. The solvent was removed by evaporating under reduced
pressure and the resulting crude residue was purified by reverse
phase HPLC (gradient, 95/5 0.1% TFA in
H.sub.2O/CH.sub.3CN-60/400.1% TFA in H.sub.2O/CH.sub.3CN). The
desired product was dissolved in methanol and treated with solid
sodium bicarbonate, filtered, and the solvent evaporated. The
resulting solid was suspended in 50/50 ethylacetate/hexane and the
solid was collected by filtration to obtain of the desired brown
solid (1.7 g, 20% yield).
[0886] Step 2
[0887] The compound (300 mg; 1.8 mmol) from Step 1 was dissolved in
DMF (7.1 ml) and the product of Step 1, Example 9 (927 mg; 2.1
mmol) was added followed by triethylamine (0.44 ml, 325 mg; 3.2
mmol) and mercuric chloride (326 mg; 1.2 mmol). The reaction
mixture was stirred at 25.degree. C. for 3.5 hours then heated to
60.degree. C. for 16 hours. Ethyl acetate (7 ml) was added to the
reaction after cooling to room temperature and the heterogeneous
solution was filtered through celite. The celite was washed
thoroughly with 97/3 ethylacetate/ethanol. The solvents were
removed under reduced pressure and the resulting crude red oil was
dissolved in methylene chloride (30 ml) and treated with
trifluoroacetic acid (2.77 ml) and refluxed for 1 hour. The
reaction was cooled and the solvent was removed under reduced
pressure to give a brown oil. The sample was purified by reverse
phase HPLC (C18, gradient 90/10 0.1% TFA/H.sub.2O) to give an
impure compound which was dissolved in methanol (2 ml) and treated
with 1N NaOH (0.15 ml) and stripped to dryness to give a dark brown
oil. This oil was purified by reverse phase HPLC (C18, gradient
99/1 0.1% TFA/H.sub.2O/CH.sub.3CN) to give a tan solid (36 mg).
[0888] Step 3
[0889] The compound (74 mg; 0.18 mmol) from the previous step was
dried in the vacuum oven overnight and dissolved in DMF (1 ml)
(stored over molecular sieves) and cooled to 0.degree. C. Then
N-methylpiperidine (27 ml; 22 mg; 0.22 mmol) was added followed by
isobutylchloroformate (47 ml; 49 mg; 0.36 mmol) and stirred for 5
minutes. A solution (0.2 mL) of the product of Example G in DMF was
added and the residual .beta.-aminoester was washed with additional
DMF (0.2 ml). Next N-methylpiperidine (22 ml; 18 mg; 0.18 mmol) was
added. The reaction mixture was allowed to slowly warm to room
temperature. After stirring at 25.degree. C. for 12 hours the
solvent was removed under high vacuum to give a red-brown oil which
was purified by reverse phase HPLC (C18, gradient 80/20 0.1%
TFA/H.sub.2O/CH.sub.3CN) to give the coupled product (22 mg) and
the coupled product with an isobutylformyl group incorporated on
the pyridone oxygen atom (47 mg). These products were combined and
dissolved in methanol (2 ml) to which 1N aqueous sodium hydroxide
(240 ml) was added. The reaction was stirred at 25.degree. C.
overnight and trifluoroacetic acid (84.7 ml) was added. The solvent
was removed under reduced pressure and purified by reverse phase
HPLC (C18, gradient 95/5 0.1% TFA/H.sub.2O/CH.sub.3CN) to give the
desired product (37 mg).
[0890] Microanalytical calcd. for
C.sub.21H.sub.22N.sub.6O.sub.7Cl.sub.2. 2.1TFA. 0.2 H.sub.2O C,
38.58; H, 3.15; N, 10.71. Found 38.12; H, 3.36; N, 10.71
EXAMPLE 43
[0891] 190
[0892] The above compound was prepared following the procedure
described in Step 3, Example 42 by reacting the product of Step 2,
Example 42 with the product of Example R.
[0893] Microanalytical calculated for:
C.sub.21H.sub.22N.sub.6O.sub.7ClBr.- 1.8TFA: C, 37.35; H, 3.03; N,
10.62. Found C, 37.31; H, 3.23; N, 10.65
EXAMPLE 44
[0894] 191
[0895] Step 1
[0896] The product of Step 3, Example 17 (3.0 g; 5.77 mmol) was
dissolved in isopropanol (25 ml) and to this solution was added
concentrated ammonium hydroxide (45 ml). After stirring at
25.degree. C. for 3 hours, the solution was evaporated to dryness
under reduced pressure.
[0897] The crude sample was hydrogenated in a Parr shaker in
ethanol (3A) (50 ml) over 5% platinum on carbon at 5 psi at
25.degree. C. for 2.5 hours. The sample was filtered and the
filtrates were concentrated to dryness under reduced pressure. The
compound was purified by reverse phase chromatography (C18, 80/20
CH.sub.3CN/H.sub.2O gradient) to yield the desired product (1.5 g,
39% yield),
[0898] Step 2
[0899] The product of step 1 (200 mg) was dissolved in methanol (2
ml) and sodium bicarbonate (133 mg) was added. The solution was
stirred for 30 minutes at 25.degree. C, filtered and the resulting
solution evaporated to dryness. The resulting sample (205 mg; 0.43
mmol) was dissolved in DMF (1.72 ml) and then the product of Step
1, Example 9 (282.8 mg; 0.65) was added, followed by triethylamine
(99 mg; 0.97 mmol, 0.14 ml) then mercuric chloride (177 mg; 0.65
mmol). The solution was heated to 60.degree. C. for 30 minutes then
to 90.degree. C. for 12 hours. The reaction mixture was cooled then
diluted with ethyl acetate (1.7 ml) and filtered through celite.
The resulting filtrate was evaporated to dryness. The crude sample
was purified by flash chromatography to remove unreacted starting
material. This material was treated with 50/50 TFA/CH.sub.2Cl.sub.2
to give the impure desired product. This material was dissolved in
methanol (2 ml) and 1N sodium hydroxide (2 ml). After stirring at
25.degree. C. for 12 hours, the solution was neutralized with TFA
(77 ml), then evaporated to dryness under reduced pressure. The
crude product was purified by reverse phase chromatography (C18,
95/5 H.sub.2O/CH.sub.3CN) to give the desired product (6.8 mg).
[0900] Microanalytical calcd for
C.sub.21H.sub.23N.sub.7O.sub.6Cl.sub.2.3.- 3TFA: C, 36.17; H, 2.89;
N, 10.70. Found C, 36.57; H, 3.21; N, 10.37.
EXAMPLE 45
[0901] 192
[0902] Step 1:
[0903] To a mixture of 3-methyl-2-thiophenecarboxylic acid (1.0 g,
7.0 mmol), N,N-dimethylformamide (4.0 ml), and potassium carbonate
(1.93 g, 14 mmol), was added iodomethane (1.49 g, 10.5 mmol). The
reaction was stirred at room temperature for 80 hours, and diluted
with ethyl acetate (150 ml), and washed with H.sub.2O (100 ml), and
brine (100 ml). The organic layer was dried (Mg.sub.2SO.sub.4) and
concentrated to a clean product as a pale brown oil (0.87 g, 81%
yield). .sup.1H NMR was consistent with the proposed structure.
[0904] Step 2:
[0905] To a solution of the product of Step 1 (5.0 g, 32.0 mmol),
dibenzoyl peroxide (0.08 g), and carbon tetrachloride (20 ml), was
added a mixture of N-bromosuccinimide (6.3 g, 35.3 mmol), dibenzoyl
peroxide (0.08 g), and carbon tetrachloride (20 ml) at reflux over
30 minutes. The resulting reaction mixture was heated at reflux for
18 hours. The solid was filtered and washed with carbon
tetrachloride (2.times.10 ml). The filtrate was concentrated to
give a mixture of oil and solid (8.1 g, 80% yield). .sup.1H NMR was
consistent with the proposed structure
[0906] Step 3:
[0907] A mixture of the product of Step 2 (8.1 g, 34.7 mmol),
sodium azide (5.6 g, 87 mmol), and N,N-dimethylformamide (25 ml)
was heated at 58.degree. C. for 2.5 hours. The reaction was diluted
with ethyl acetate (800 ml), and washed with H.sub.2O (500 ml). The
aqueous layer was extracted with ethyl acetate (100 ml). The
combined organic layer was dried (MgSO.sub.4) and concentrated to
give a pale brown oil (6.0 g, 85% yield). .sup.1H NMR was
consistent with the proposed structure
[0908] Step 4:
[0909] A solution of the product of Step 3 (6.0 g, 25.9-mmol), NaOH
(1N, 50 ml), and MeOH (50 ml) was stirred overnight. The reaction
was treated with acetic acid (2.5 ml). The product was extracted
with ethyl acetate (300 ml). The organic layer was dried with
Na.sub.2SO.sub.4, and concentrated to give a yellow oil. A yellow
solid (2.0 g, 42% yield) was obtained under vacuum. .sup.1H NMR was
consistent with the proposed structure.
[0910] Step 5:
[0911] A mixture of the product of Step 4 (0.5 g, 2.7 mmol), oxalyl
chloride (2 M in dichloromethane, 2.7 ml, 5.4 mmol), and
dichloromethane (20 ml) was stirred at room temperature for 2.5
hours. The solvent was removed from the reaction to give the
product as brown oil (0.51 g, 85% yield). .sup.1H NMR was
consistent with the proposed structure
[0912] Step 6:
[0913] A solution of the product of Example G (0.91 g, 2.43 mmol),
diisopropylethylamine (0.63 g, 4.86 mmol), and
N,N-dimethylacetamide (20 ml) was added to a mixture of the product
of Step 5 (0.46 g, 2.43 mmol) and THF (10 ml) at 0.degree. C. The
reaction mixture was stirred at 0.degree. C. for 10 minutes and
allowed to warm to room temperature. After 16 hours, the solvents
were removed from the reaction under vacuum. The product was
extracted with ethyl acetate (300 ml). The organic solution was
washed with saturated NaHCO.sub.3 solution (100 ml), H.sub.2O (100
ml), dried with Na.sub.2S, O.sub.4, and concentrated to give the
crude product. The crude product was purified by column
chromatography (on silica gel, CH.sub.2Cl.sub.2/MeOH/NH.sub.4OH,
98/2/0.2) to give clean product as a gummy solid (0.7 g, 58%
yield). .sup.1H NMR was consistent with the proposed structure.
[0914] Step 7:
[0915] At room temperature, a mixture of the product of Step 6
(0.78 g, 1.56 mmol), 5% Pt/C, and EtOH was stirred under 5 psi for
20 hours. The catalyst was filtered. The filtrate was treated with
trifloroacetic acid (0.6 ml) and concentrated to give the crude
product. The crude product was purified by HPLC to give a white
solid (0.4 g, 54% yield). .sup.1H NMR was consistent with the
proposed structure.
[0916] Step 8:
[0917] Mercury (II) chloride (0.51 g, 1.87 mmol) was added to a
mixture of the product of Step 7 (0.55 g, 1.25 mmol), product of
Step 1, Example 9 (0.81 g, 1.87 mmol), triethylamine (0.38 g, 3,75
mmol), and N,N-dimethylforamide (15 ml) at room temperature. The
reaction was heated at 95-100.degree. C. for 16 hours. The cooled
reaction was filtered through a bed of celite (2"), and washed with
ethyl acetate. The solvent was removed from the filtrate under
vacuum to give a oil. This oil was diluted with
CH.sub.2Cl.sub.2trifloroacetic acid (10 ml/10 ml) and stirred at
room temperature for 1 hour. The solid formed was collected by
filtration. The filtrate was concentrated and treated with
CH.sub.2Cl.sub.2/trifloroacetic acid (15 ml/15 ml) for 1.5 hours.
The solvent was removed under reduced pressure to give a brown oil.
This oil was purified by HPLC to give a mixture of the desired
product and its ethyl ester. The desired compound was
recrystallized from acetonitrile as a white solid (0.068 g). The
ester product was treated with NaOH/Ethanol (7.0 ml/7.0 ml) for 18
hours, and purified by HPLC to give additional (0.055 g)
compound.
[0918] Calculated for C.sub.21H.sub.23N.sub.5O.sub.6Cl.sub.2 S.2.0
CF.sub.3COOH: C, 38.87; H, 3.26; N, 9.07; Found: C, 38.78; H, 3.6;
N, 9.16. 193
[0919] Step 1:
[0920] Benzoylisothiocyanate (3.34 g, 21.3 mmol) was added to a
solution of the product of Step 1, Example 33 (3.5 g, 20.8 mmol)
and N,N-dimethylformamide (45 ml) at room temperature. The reaction
was stirred for 2 hours, and poured into ether (300 ml). The
resulting mixture was stirred for 15 minutes. The product was
collected by filtration, washed with ether (2.times.40 ml), and
air-dried as a yellow solid (6.95 g, 100% yield). .sup.1H NMR was
consistent with the proposed structure.
[0921] Step 2:
[0922] Sodium methoxide (2.64 g, 48.9 mmol) was added to a
suspension of the product of step 1 (6.90 g, 20.8 mmol) and
methanol (200 ml) in small portions at room temperature. Upon
completion of the addition, the reaction was stirred for 1 hour.
Acetic acid (2.8 ml, 48.9 mmol) was added to the reaction. The
resulting mixture was stirred for 15 minutes. The product was
collected by filtration, washed with methanol (2.times.30 ml), and
dried under reduced pressure to yield an off white solid (3.8 g,
81% yield).
[0923] .sup.1H NMR was consistent with the proposed structure.
[0924] Step 3:
[0925] A mixture of the product of Step 2 (1.90 g, 8.4 mmol),
methyl iodide (3.56, 25.1 mmol) and methanol (60 ml) was heated at
reflux for 3.5 hours, and cooled to room temperature. The solvent
was removed from the reaction solution under reduced pressure to
give a yellow oil. The oil residue was treated with ether to give a
clean product as a yellow solid (3.1 g, 100% yield). .sup.1H NMR
was consistent with the proposed structure.
[0926] Step 4
[0927] A solution of the product of Step 3 (0.5 g, 1.36 mmol),
2-methoxyethylamine (0.12 ml, 1.36 mmol) and N,N-dimethylacetamide
(5.0 ml) was heated at 85.degree. C. for 2.5 hours. An additional
2-methoxyethylamine (0.12 ml, 1.36 mmol) was added. The reaction
was heated at 85.degree. C. for 2 hours. N,N-dimethylacetamide was
removed from the cooled reaction under reduced pressure to give a
crude product. The crude product was purified by reverse phase HPLC
to yield the desired clean product (0.38 g, 76% yield). .sup.1H NMR
spectra was consistent for the proposed structure
[0928] Step 5
[0929] A solution of the product of Step 1 (0.38 g, 1.42 mmol),
NaOH solution (1N, 15 ml), and MeOH (15 ml) was stirred at room
temperature for 16 hours, and then treated with trifluoroacetic
acid (1.2 ml). The solvent was removed from the reaction solution
under reduced pressure to give a crude product. The crude product
was purified by HPLC to yield the desired product as a white solid
(0.55 g, 100% yield). .sup.1H NMR was consistent with the proposed
structure
[0930] Step 6
[0931] N-methylmorpholine (0.1 ml, 1.42 mmol) was added to a
solution of the product of Step 5 (0.54 g 1.42 mmol) in
N,N-dimethylacetamide (16 ml). At -5.degree. C, isobutyl
chloroformate (0.18 g, 1.35 mmol) was added to the reaction over 5
minutes, and stirred for 15 minutes. A solution of the product of
Example G (0.396 g, 1.07 mmol) and N-methyl morpholine (0.075 ml,
1.07 mmol) and N,N-dimethylacetamide (10 ml) was added to the
reaction. The resulting reaction solution was allowed to warm to
room temperature and stirred for 16 hours. The solvent was removed
from the reaction solution under reduced pressure to give a crude
product. The crude product was purified by HPLC to yield the
desired product as a white solid (0.145 g, 14% yield). .sup.1H NMR
was consistent with the proposed structure
[0932] Step 7
[0933] A solution of the product of Step 6 (0.145 g, 0.20 mmol),
NaOH (1N, 25 ml), and MeOH (25 ml) was stirred for 16 hours. The
solvent was removed from the reaction mixture under reduced
pressure to give a crude product. The crude product was treated
with trifloroacetic acid (2 ml) and purified by HPLC to give the
desired product as a off white solid (0.11 g, (70% yield).
Calculated for C.sub.21H.sub.24N.sub.6O.sub.7Cl.sub-
.2.2CF.sub.3COOH: C, 38.93; H, 3.40; N, 10.89; Found: C, 39.29; H,
3.47: N, 11.15.
EXAMPLE 47
[0934] 194
[0935] Step 1:
[0936] A mixture of the product of Step 3, Example 46 (1.56 g, 4.22
mmol), 2,2-dimethyl-1,3-propanediamine (0.45 g, 4.40 mmol), and
N,N-dimethylacetamide (15 ml) was heated at 92.degree.
C.-95.degree. C. for 6.5 hours and then allowed to cool to room
temperature. A solid was formed overnight. The product was
collected by filtration, and washed with N,N-dimethylacetamide (5
ml), and ether (5 ml) to give a clean product as a white solid
(0.50 g, 43% yield). .sup.1H NMR was consistent with the proposed
structure.
[0937] Step 2:
[0938] A solution of the product of Step 1 (0.48 g, 1.7 mmol), NaOH
(1N, ml), and MeOH (10 ml) was stirred at room temperature
overnight. The solvent was removed from the reaction mixture under
reduced pressure to give a crude product. The crude product was
treated with triflouroacetic acid (2 ml) and purified by HPLC to
give a white solid as the desired product (0.38 g, 58% yield).
[0939] Step 3:
[0940] A solution of 4-methyl morpholine (0.14 g, 1.41 mmol) in
N,N-dimethylacetamide (1.5 ml) was added to a solution of the
product of Step 2 (0.36 g, 0.94 mmol),
2-chloro-4,6-dimethoxytriazine (0.18 g, 1.03 mmol) and
N,N-dimethylacetamide (10 ml) at 0.degree. C. The resulting bright
orange solution was allowed to warm to room temperature, and
stirred for 3 hours.
[0941] A solution of the product of Example G (0.350 g, 0.94 mmol),
4-methyl morpholine (0.93 g, 0.94 mmol), and N,N-dimethylacetamide
(4 ml) was added to the reaction solution. The resulting solution
was stirred at room temperature overnight, and treated with
trifloroacetic acid (1.0 ml). The solvent was removed from the
reaction solution under reduced pressure to give a crude product.
The crude product was purified by HPLC to give a yellow solid as
the desired product (0.35 g, 54% yield).
[0942] Step 4:
[0943] A solution of the product of Step 3 (0.33 g, 0.47 mmol),
NaOH (1N, 9 ml), and MeOH (9 ml) was stirred 18 hours. The reaction
was treated with trifloroacetic acid (1.0 ml). The solvent was
removed from the reaction solution under reduced pressure to give a
crude product. The crude product was purified by HPLC to give the
desired compound as a pale yellow solid (0.285 g, 84% yield).
[0944] Calculated for
C.sub.23H.sub.26N.sub.6O.sub.6Cl.sub.2.1.25CF.sub.3C-
OOH.1.0H.sub.2O: C, 42.90; H, 4.13; N, 11.77; Found: C, 43.03; H,
4.03; N, 11.26.
EXAMPLE 48
[0945] 195
[0946] The above compound was synthesized using the methodology
described in Example 47. In Step 1 ethylenediamine was used instead
of 2,2-dimethyl-1,3-diaminopropanediamine. In Step 3 the product of
Example U was used instead of the product of Example G.
[0947] Calculated for
C.sub.20H.sub.20N.sub.6O.sub.6Cl.sub.2.1.25CF.sub.3C-
OOH.0.5H.sub.2O: C, 40.77; H, 3.38; N, 12.68; Found: C, 40.98; H,
3.17; N, 12.57.
EXAMPLE X
[0948] Preparation of 5-Bromo-3-iodosalicylaldehyde 196
[0949] The above compound was prepared by iodination of
5-bromosalicylaldehyde as described in literature (J. Org. Chem.
1990, 55, 5287-5291).
EXAMPLES Y & Z
Scheme A1
[0950] 197
[0951] Step 1
[0952] Preparation of 198
[0953] A mixture of 5-aminonicotinc acid (10.0 g, 0.072 mole),
benzoylisothiocyanate (11.8 g, 0.072 mole), and DMAP (catalytic
amount) in anhydrous acetonitrile (250 mL) was heated to reflux
overnight under anhydrous conditions with vigorous stirring (Scheme
A1). The resulting yellow suspension was cooled and filtered. The
residue was washed with water, followed by acetonitrile, and dried
in vacuo overnight to yield the desired product as a pale yellow
solid (21.4 g, 98% yield).
[0954] MS and .sup.1H-NMR were consistent with the desired
structure.
[0955] Step 2
[0956] Preparation of 199
[0957] To the suspension of the product from Step 1 (11.1 g, 0.037
mole) in anhydrous MeOH (230 mL), was added NaOMe (25 wt % solution
in methanol, 21.1 mL, 0.092 mole), at which point the reactant went
into solution to give an orange-brown solution (Scheme A1). This
solution was stirred at room temperature for 3 hours, cooled in an
ice bath, and methyliodide (3.45 mL, 0.055 mole added). The
resulting mixture was stirred at 10.degree. C. for 30 minutes and
1.5 hours at room temperature. The reaction mixture was then
quenched with acetic acid (2 mL), cooled in an ice bath, and
filtered. The solids were washed with cold MeOH and dried in vacuo
to afford the desired product as a beige solid (2.66 g, 37%
yield).
[0958] MS and .sup.1H-NMR were consistent with the desired
structure.
[0959] Step 3
[0960] Preparation of Examples Y & Z.
[0961] To a solution of 1,3-diamino-2-hydroxypropane (11.2 g, 0.124
mole) in anhydrous DMF (80 mL), was added the product from Step 2
(8.7 g, 0.041 mole). This mixture was heated at 85.degree. C. under
anhydrous conditions for 3 hours (Scheme A1). After 1-2 hours of
heating, the solution became turbid and turbidity increased during
the course of heating. The reaction mixture was then cooled in an
ice bath and filtered. The solids were washed with acetonitrile,
water, acetonitrile, and dried in vacuo to yield the desired
product (Example Y) as a beige solid (3.7 g, 38% yield).
[0962] MS and .sup.1H-NMR were consistent with the desired
structure.
[0963] Example Z was synthesized using the methodology described
for Example Y substituting 4 equivalents of
2,2-dimethyl-1,3-propanediamine for
1,3-diamino,2-hydroxypropane.
[0964] Each of the products from Step 3 were converted to their
respective TFA or HCl salts by stirring 1 hour at 10.degree. C. in
a solution of anhydrous THF (10 mL for 1.0 g substrate) and TFA (1
eqivalent) or 4N HCl/dioxane (2 eqivalents).
EXAMPLE 49
[0965] Preparation of 200 201
[0966] To a suspension of Example Y (0.40 g, 0.00125 mole, Scheme
A2) in anhydrous DMF (10 mL) at -20.degree. C. was added
isobutylchloroformate (0.17 g, 0.00125 mole), followed by the
dropwise addition of N-methylmorpholine (0.14 g, 0.00137 mole).
After stirring this mixture under argon atmosphere for 20 minutes
at -20.degree. C., an additional amount of N-methylmorpholine (0.14
g, 0.00137 mole) was added, followed by the addition of product
from Example G (0.46 g, 0.00125 mole). The resulting mixture was
stirred at -20 C. for 15 minutes, and then stirred at room
temperature for 2 hours. DMF was distilled in vacuo and the residue
was purified by reverse phase HPLC to yield (after lyophilization)
the desired ester as a white solid (0.20 g, 21% yield).
[0967] MS and .sup.1H-NMR were consistent with the desired
structure. This ester (0.2 g) was stirred with 1M LiOH (2 mL) for 1
hour at room temperature. The pH was adjusted to 2 with
trifluoroacetic acid and the product was purified by reverse phase
HPLC to provide (after lyophilization) the desired acid as a white
solid (0.11 g).
[0968] MS and .sup.1H-NMR were consistent with the desired
structure.
EXAMPLE 50
Preparation of
[0969] 202
[0970] The above compound was prepared (Scheme A2) using the
procedure described in Example 49 substituting an equivalent amount
of Example R for the Example G.
[0971] MS and .sup.1H-NMR were consistent with the desired
structure(s). The ester (0.19 g, 0.00023 mole) was stirred with 1M
LiOH (2 mL) for 1 hour at room temperature. The pH was adjusted to
2 with trifluoroacetic acid and the product was purified by reverse
phase HPLC to provide (after lyophilization) the desired acid as a
white solid (0.13 g, 72% yield).
[0972] MS and .sup.1H-NMR were consistent with the desired
structure.
EXAMPLE 51
[0973] Preparation of 203 204
[0974] Step 1
[0975] Preparation of
bis-N-benzyloxycarbonyl-2-hydoxy-1,3-diaminopropane. 205
[0976] To a suspension of 2-hydroxy-1,3 diaminopropane (5.8 g,
0.064 mol) in dichloromethane (150 mL) containing
N-methylmorpholine (14 mL) at 10.degree. C., was added
benzyloxycarbonylsuccinimide (32 g, 0.129 mol) in portions (Scheme
B). The reaction mixture was stirred at room temperature for 16
hours, and resulting clear solution was diluted with
dichloromethane (100 mL), washed successively with 10% citric acid
(2.times.50 mL), water and dried (Na.sub.2SO.sub.4). Following
filtration, the solvent was removed under reduced pressure, and
resulting white solid was crystallized from dichloromethane to
afford desired compound (20.0 g, 87%).
[0977] .sup.1H-NMR and MS were consistent with the structure.
[0978] Step 2
[0979] Preparation of
bis-N-benzyloxycarbonyl-1,3-diaminopropane-2-one. 206
[0980] To a suspension of product from Step 1 (21.0 g, 0.058 mol)
and EDC (33.0 g) in dichloromethane (120 mL) containing DMSO (24.0
mL), was added dropwise a solution of pyridiniumtrifluoroacetate
(33.0 g) in dichloromethane (50 mL) over a period of 30 minutes and
stirred at 10.degree. C. After the addition, a clear yellow
solution was obtained. Upon stirring at room temperature for 3
hours, a white solid separated from the reaction mixture. It was
cooled, filtered, and the solid was washed with cold
dichloromethane and water. The white solid obtained was dried in a
desiccator in vacuo to afford the desired product (15.5 g, 74%
yield). .sup.1H-NMR and MS were consistent with the structure.
[0981] Step 3
[0982] Preparation of 207
[0983] A mixture of product from Step 2 (2.5 g, 0.007 mol),
p-toluenesulfonic acid (0.3 g, 0.0016 mol), and DMSO (1.0 mL) in
dichloroethane (25 mL) containing ethyleneglycol (2.0 mL) was
heated to reflux under anhydrous conditions (Scheme B). After 24
hours, the reaction mixture was cooled, diluted with
dichloromethane (25 mL) and washed successively with 10% sodium
bicarbonate, water and dried (Na.sub.2SO.sub.4). After removal of
the solvent under reduced pressure, the residue was crystallized
from dichloromethane/hexane to give the desired compound (2.5 g,
89% yield). .sup.1H-NMR and MS were consistent with the
structure.
[0984] Step 4
[0985] The product from Step 3 (3.0 g, 0.0075 mol) was dissolved in
a solvent mixture of ethanol (50.0 mL) and ethyl acetate (50.0 mL),
and hydrogenated at 50 psi in the presence of Pd/C (5%, 1.5 g) for
16 hours at room temperature (Scheme B). The catalyst was removed
by filtration, was washed with 40% water in ethanol (50 mL) and
filtered. The combined filtrate and aqueous washings were
concentrated to dryness under reduced pressure to afford a syrup.
This material was dissolved in DMF (10.0 mL), the product from Step
2 of Example 1 (1.0 g, 0.0047 mol), was added with triethylamine
(0.7 mL), and DMAP (0.05 g). The resulting mixture was heated at
90.degree. C. under anhydrous conditions. After 3 hours, DMF was
distilled in vacuo, the residue was triturated with water, and
filtered. It was washed with water, acetonitrile, and dried in a
desiccator in vacuo to obtain Example 5 (0.4 g, 30%) as a powder.
This material was used without further purification in step B.
.sup.1H-NMR and MS were consistent with the structure.
EXAMPLE 52
[0986] Preparation of 208 209
[0987] The compound of Example 51 (0.38 g, 0.0014 mol) was
suspended in dry THF (5.0 mL) and trifluoroacetic acid (0.1 mL) was
added and stirred at 10.degree. C. under anhydrous conditions
(Scheme C). After 30 minutes, the THF was distilled under reduced
pressure and the residue was dried in vacuo for 3 hours. The
resulting material was dissolved in dry DMF (4.0 mL), cooled to
-15.degree. C., and isobutylchloroformate (0.18 mL) was added,
followed by the addition of N-methylmorpholine (0.17 mL). The
solution was stirred for 30 minutes under an argon atmosphere. To
the mixture was added a solution of amine generated by the addition
of N-methylmorpholine (0.17 mL) to a solution of Example R (0.51 g)
in DMF (3.0 mL) at 0.degree. C. The resulting mixture was stirred
at -15.degree. C. for 30 minutes, and then at room temperature for
16 hours. The solvents were then removed by distillation in vacuo,
and the residue was purified by reverse-phase HPLC using 10-90%
acetonitrile/water gradient (40 minutes) at a flow rate of 70
mL/min.
[0988] The appropriate fractions were combined and freeze dried to
afford the desired ester (0.4 g) as a fluffy white powder. This
material was stirred with lithium hydroxide (1M, 2.0 mL) at room
temperature. After 45 minutes, the reaction mixture was cooled,
diluted with water, acidified with trifluoroacetic acid, and the
desired acid (0.25 g) was isolated by reverse-phase HPLC using
10-90% acetonitrile/water as described above. .sup.1H-NMR and MS
were consistent with the structure.
EXAMPLE 53
[0989] Preparation of 210 211
[0990] Preparation of
bis-N-benzyloxycarbonyl-2-fluoro-1,3-diaminopropane. 212
[0991] To a stirred suspension of
bis-N-benzyloxycarbonyl-2-hydoxy-1,3-dia- minopropane (6.0 g, 0.017
mol) in dichloromethane (50 mL) and pyridine (2.7 mL) at
-50.degree. C., was added dropwise a solution of DAST (2.5 mL) in
dichloromethane (7.5 mL, Scheme D). The reaction mixture was
gradually allowed to warm to room temperature over a period of 16
hours under an atmosphere of argon. A clear yellow solution was
obtained. The solution was cooled and poured into a mixture of ice,
water (100 mL), and dichloromethane (50 mL). The organic phase was
washed with water (2.times.50 mL), and dried (Na.sub.2SO.sub.4).
After removal of the solvent, the residue was purified by silica
gel flash chromatography using 30% EtOAc in hexane. The appropriate
fractions were combined, concentrated to dryness and the product
was crystallized from dichloromethane/hexane to afford the desired
fluoro intermediate as a white fluffy powder (2.0 g). .sup.1H-NMR
and MS were consistent with the structure.
[0992] Step 2
[0993] A solution of
bis-N-benzyloxycarbonyl-2-fluoro-1,3-diaminopropane (3.3 g, 0.0092
mol) obtained from Step 1, in EtOAc (30 mL), and EtOH (30 mL) was
hydrogenated at 50 psi in the presence of Pd/C (10%, 2.7 g) for 16
hours at room temperature (Scheme D). Following filtration, the
catalyst was stirred with EtOH containing 40% water (50 mL) and
filtered again. The filtrate was concentrated to dryness to afford
a syrup (0.7 g). The syrup was suspended in DMF (8.0 mL). The
product from Step 2 of Example 1 (0.7 g, 0.0033 mol), catalytic
amount of DMAP (0.01 g), were added and heated at 90.degree. C. for
3 hours under anhydrous conditions. DMF was distilled in vacuo, the
residue was suspended in water (25 mL) and the pH was adjusted to
4.5 by the addition of 1N HCl. The resulting mixture was cooled.
The solid that separated was filtered and washed thoroughly with
water, acetonitrile and dried in a desiccator in vacuo to provide
the desired compound as brown powder (0.24 g). .sup.1H-NMR and MS
were consistent with the structure.
EXAMPLE 54
[0994] Preparation of 213 214
[0995] The compound of Example 53 (0.22 g) as obtained above was
suspended in dry THF (4.0 mL). Trifluoroacetic acid (0.1 mL), was
added and the solution was stirred at 10.degree. C. for 30 minutes,
and concentrated under reduced pressure. The residue was dried in a
desiccator in vacuo. The material obtained was suspended in dry DMF
(5 mL). Isobutylchloroformate (0.12 mL) was added, followed by the
addition of N-methylmorpholine (0.11 mL). The solution was stirred
-15.degree. C. under an argon atmosphere (Scheme E). After 30
minutes, a solution of amine generated by the addition of
N-methylmorpholine (0.095 mL) to a solution of the product of
Example R (0.37 g) in DMF (3.0 mL) was added. The resulting mixture
was stirred at -15.degree. C. for 30 minutes, and at room
temperature for 16 hours. DMF was distilled in vacuo and the
residue was purified by reverse-phase HPLC using 10-90%
acetonitrile/water. The appropriate fractions were combined and
freeze dried to afford the desired ester product as a pale yellow
powder (0.35 g). .sup.1H-NMR and MS were consistent with the
structure.
[0996] The resulting product (0.3 g, Scheme E) was stirred with 1M
LiOH (3.0 mL) at room temperature. After 1 hour, the solution was
diluted with water (3.0 mL), cooled and acidified with
trifluoroacetic acid. The resulting mixture was then purified by
reverse-phase HPLC using 10-90% acetonitrile/water (30 minute
gradient) at flow rate of 70 mL/min. The appropriate fractions were
combined and freeze dried to provide the desired compound as a
white powder (0.22 g). .sup.1H-NMR and MS were consistent with the
structure.
EXAMPLE 55
Preparation of 0 OH
[0997] 215 216
[0998] Step 1
[0999] Preparation of 217
[1000] To a solution of 1,4-diamino-2,3-dihydroxybutane
dihydrochloride [2.21 g, 0.012 mole] [synthesized from
dimethyl-L-tartrate as described in J. Carbohydrate Chemistry, 5,
(2), 183-197, [1986], in water (6 mL) and anhydrous DMF (10 mL),
was added sodium carbonate (1.83 g, 0.017 mole). To this mixture,
the product from Step 2 of Example 1 (1.21 g, 0.006 mole) was added
and the mixture was heated at 85.degree. C. for 3 hours. After
cooling in an ice bath, DMF was distilled in vacuo and, the
resulting residue was suspended in water. The pH was adjusted to
-5.6. The solution was lyophilized to afford the desired product
(0.907 g, 59% yield). MS was consistent with the desired structure
(M+H 267).
[1001] The compound obtained was converted to its HCl salt by
stirring with 4N HCl/dioxane (2 equivalents) in THF (10 mL) at
10.degree. C. for 1 hour.
[1002] Step 2
[1003] To a suspension of the product from Step 1 (0.11 g, 0.00023
mole) in anhydrous DMF (10 mL) at -20.degree. C., was added
isobutylchloroformate (0.016 g, 0.00012 mole), followed by the
dropwise addition of N-methylmorpholine (0.013 g, 0.00013 mole,
Scheme F). After stirring this mixture under argon atmosphere for
20 minutes at -20.degree. C, an additional amount of
N-methylmorpholine (0.013 g, 0.00013 mole) was added followed by
the addition of the product from Example R (0.048 g, 0.00012 mole).
The resulting mixture was stirred at -20.degree. C. for 15 minutes.
After stirring at room temperature for 2 hours, DMF was distilled
in vacuo and the residue was purified by reverse-phase HPLC to
yield (after lyophilization) the desired ester as a white solid
(0.03 g, 33% yield).
[1004] MS (M+H 627 M+H 629) and .sup.1H-NMR were consistent with
the desired structure.
[1005] .sup.1H-NMR (400 MHz, Cd.sub.3Od): .delta. 8.8 (s, 1H)
.delta. 8.5 (s, 1H), 8.1 (s, 1H), 7.4 (s, 1H), 7.2 (s, 1H) 5.6 (m,
1H), 4.1 (m, 4H), 3.7 (m, 2H), 3.6 (m, 2H), 3.3 (m, 2H), 2.9 (m,
2H), 1.2 (m, 3H)
[1006] The resulting ester (0.03 g, 0.000035 mole) was stirred with
1M LiOH (2 mL). After stirring for 1 hour at room temperature, the
pH was adjusted to 2 with trifluoroacetic acid, and the product was
isolated by reverse-phase HPLC to provide (after lyophilization)
the desired acid as a white solid (0.001 g, 3.5% yield).
[1007] MS (M+H 599 M+H 601) and .sup.1H-NMR were consistent with
the desired structure.
[1008] .sup.1H-NMR (400 MHz, CD.sub.3OD): .delta. 8.8 (s, 1H), 8.5
(s, 1H), 8.0 (s, 1H), 7.4 (s, 1H), 7.2 (s, 1H) 5.6 (m, 1H), 4.1 (m,
2H), 3.8 (m, 2H), 3.5 (m, 2H), 3.3 (m, 2H), 2.8 (m, 2H)
EXAMPLE 56
[1009] The difluoro analog is prepared according to the synthetic
sequence outlined in Scheme 1 below. 218
[1010] The carbobenzoxy-protected ketone is converted to the
corresponding difluoro intermediate using DAST diethylaminosulfur
trifluoride. Subsequent removal of the carbobenzoxy groups (Z) by
catalytic hydrogenation and coupling of the resulting diamine with
the S-methylisothiourea derivative of 5-aminonicotinic acid
derivative, provides the corresponding difluoro-substituted
guanidine containing nicotinic acid precursor. This compound is
reacted with a glycine-beta amino acid-ester, followed by
hydrolysis and acidification to yield the final desired
compound.
EXAMPLE 57
[1011] Compounds containing seven-membered fluoro/hydroxy
substituted guanidines are prepared according to the following
Scheme starting from the known diisopropyl-L-tartrate (J. Am. Chem.
Soc. 1988, 110, 7538). 219
[1012] The monosilylated intermediate is synthesized by amidation,
silylation and N-desilylation. The diborane reduction of this
monosilyl derivative provides the corresponding diamine
dihydrochloride. Subsequent condensation of the free-diamine with
the S-methylisothiourea 5-aminonicotinic acid derivative, provides
the corresponding seven-membered guanidine derivative. Further
reaction of this guaniidine with the glycine-beta-amino acid-ester,
followed by hydrolysis and acidification yields the final desired
compound.
EXAMPLE 58
[1013] The dialkyl/diol substituted seven-membered cyclic guanidine
compounds are prepared according to reactions outlined in the
following Scheme. Starting from the known carbobenzoxy-protected
diamines (J. Med. Chem. 1996, 39, 2156), the corresponding
seven-membered cyclic guanidine is synthesized by reacting the
free-diamine precursor with the S-methylisothiourea
5-aminonicotinic acid derivative. The condensation of the resulting
guanidine-carboxylic acid with a glycine-beta-amino acid-ester,
followed by hydrolysis and acidification yields the final desired
compound. 220
EXAMPLE 59
[1014] The dihydroxy compounds are prepared by the acid catalysed
cleavage of the cyclic ketal precursor as shown in the following
Scheme. 221
EXAMPLE 60
[1015] Compounds containing the seven-membered diol substituted
cyclic guanidines starting from D or meso-tartarate derivatives are
prepared as outlined in Scheme F.
[1016] The activity of the compounds of the present invention was
tested in the following assays. The results of testing in the
assays are tabulated in Table 1.
Vitronectin Adhesion Assay
[1017] Materials
[1018] Human vitronectin receptor (.alpha..sub.V.beta..sub.3) was
purified from human placenta as previously described [Pytela et
al., Methods in Enzymology, 144:475-489 (1987)]. Human vitronectin
was purified from fresh frozen plasma as previously described
[Yatohgo et al., Cell Structure and Function, 13:281-292 (1988)].
Biotinylated human vitronectin was prepared by coupling NHS-biotin
from Pierce Chemical Company (Rockford, Ill.) to purified
vitronectin as previously described [Charo et al., J. Biol. Chem.,
266(3):1415-1421 (1991)]. Assay buffer, OPD substrate tablets, and
RIA grade BSA were obtained from Sigma (St. Louis, Mo.).
Anti-biotin antibody was obtained from Calbiochem (La Jolla,
Calif.). Linbro microtiter plates were obtained from Flow Labs
(McLean, Va.). ADP reagent was obtained from Sigma (St. Louis,
Mo.).
Methods
Solid Phase Receptor Assays
[1019] This assay was essentially the same as previously reported
[Niiya et al., Blood, 70:475-483 (1987)]. The purified human
vitronectin receptor (.alpha..sub.V.beta..sub.3) was diluted from
stock solutions to 1.0 .mu.g/mL in Tris-buffered saline containing
1.0 mM Ca.sup.++, Mg.sup.++, and Mn.sup.++, pH 7.4 (TBS.sup.+++).
The diluted receptor was immediately transferred to Linbro
microtiter plates at 100 .mu.L/well (100 ng receptor/well). The
plates were sealed and incubated overnight at 4.degree. C. to allow
the receptor to bind to the wells. All remaining steps were at room
temperature. The assay plates were emptied and 200 .mu.L of 1% RIA
grade BSA in TBS.sup.+++ (TBS.sup.+++/BSA) were added to block
exposed plastic surfaces. Following a 2 hour incubation, the assay
plates were washed with TBS.sup.+++ using a 96 well plate washer.
Logarithmic serial dilution of the test compound and controls were
made starting at a stock concentration of 2 mM and using 2 nM
biotinylated vitronectin in TBS.sup.+++/BSA as the diluent. This
premixing of labeled ligand with test (or control) ligand, and
subsequent transfer of 50 .mu.L aliquots to the assay plate was
carried out with a CETUS Propette robot; the final concentration of
the labeled ligand was 1 nM and the highest concentration of test
compound was 1.0.times.10-4 M. The competition occurred for two
hours after which all wells were washed with a plate washer as
before. Affinity purified horseradish peroxidase labeled goat
anti-biotin antibody was diluted 1:3000 in TBS.sup.+++/BSA and 125
.mu.L were added to each well. After 30 minutes, the plates were
washed and incubated with OPD/H.sub.2O.sub.2 substrate in 100 mM/L
Citrate buffer, pH 5.0. The plate was read with a microtiter plate
reader at a wavelength of 450 nm and when the maximum-binding
control wells reached an absorbance of about 1.0, the final
A.sub.450 were recorded for analysis. The data were analyzed using
a macro written for use with the EXCELJ spreadsheet program. The
mean, standard deviation, and % CV were determined for duplicate
concentrations. The mean A.sub.450 values were normalized to the
mean of four maximum-binding controls (no competitor added)(B-MAX).
The normalized values were subjected to a four parameter curve fit
algorithm [Rodbard et al., Int. Atomic Energy Agency Vienna, pp 469
(1977)], plotted on a semi-log scale, and the computed
concentration corresponding to inhibition of 50% of the maximum
binding of biotinylated vitronectin (IC.sub.50) and corresponding
R.sup.2 was reported for those compounds exhibiting greater than
50% inhibition at the highest concentration tested; otherwise the
IC.sub.50 is reported as being greater than the highest
concentration tested. .beta.-[[2-[[5-[(aminoimin-
omethyl)amino]-1-oxopentyl]amino]-1-oxoethyl]amino]-3-pyridinepropanoic
acid [U.S. Ser. No. 08/375,338, Example 1] which is a potent
.alpha..sub.V.beta..sub.3 antagonist (IC.sub.50 in the range 3-10
nM) was included on each plate as a positive control.
Purified IIb/IIIa Receptor Assay
[1020] Materials
[1021] Human fibrinogen receptor (.alpha..sub.V.beta..sub.3) was
purified from outdated platelets. (Pytela, R., Pierschbacher, M.
D., Argraves, S., Suzuki, S., and Rouslahti, E.
"Arginine-Glycine-Aspartic acid adhesion receptors", Methods in
Enzymology 144(1987):475-489.) Human vitronectin was purified from
fresh frozen plasma as described in Yatohgo, T., Izumi, M.,
Kashiwagi, H., and Hayashi, M., "Novel purification of vitronectin
from human plasma by heparin affinity chromatography," Cell
Structure and Function 13(1988):281-292. Biotinylated human
vitronectin was prepared by coupling NHS-biotin from Pierce
Chemical Company (Rockford, Ill.) to purified vitronectin as
previously described. (Charo, I. F., Nannizzi, L., Phillips, D. R.,
Hsu, M. A., Scarborough, R. M., "Inhibition of fibrinogen binding
to GP IIb/IIIa by a GP IIIa peptide", J. Biol. Chem. 266(3)(1991):
1415-1421.) Assay buffer, OPD substrate tablets, and RIA grade BSA
were obtained from Sigma (St. Louis, Mo.). Anti-biotin antibody was
obtained from Calbiochem (La Jolla, Calif.). Linbro microtiter
plates were obtained from Flow Labs (McLean, Va.). ADP reagent was
obtained from Sigma (St. Louis, Mo.).
[1022] Methods
[1023] Solid Phase Receptor Assays
[1024] This assay is essentially the same reported in Niiya, K.,
Hodson, E., Bader, R., Byers-Ward, V. Koziol, J. A., Plow, E. F.
and Ruggeri, Z. M., "Increased surface expression of the membrane
glycoprotein IIb/IIIa complex induced by platelet activation:
Relationships to the binding of fibrinogen and platelet
aggregation", Blood 70(1987):475-483. The purified human fibrinogen
receptor (.alpha..sub.V.beta..sub.3) was diluted from stock
solutions to 1.0 .mu.g/mL in Tris-buffered saline containing 1.0 mM
Ca.sup.++, Mg.sup.++, and Mn.sup.++, pH 7.4 (TBS.sup.+++). The
diluted receptor was immediately transferred to Linbro microtiter
plates at 100 .mu.L/well (100 ng receptor/well). The plates were
sealed and incubated overnight at 4.degree. C. to allow the
receptor to bind to the wells. All remaining Steps were at room
temperature. The assay plates were emptied and 200 .mu.L of 1% RIA
grade BSA in TBS.sup.+++(TBS.sup.+++/BSA) were added to block
exposed plastic surfaces. Following a 2 hour incubation, the assay
plates were washed with TBS.sup.+++using a 96 well plate washer.
Logarithmic serial dilution of the test compound and controls were
made starting at a stock concentration of 2 mM and using 2 nM
biotinylated vitronectin in TBS.sup.+++/BSA as the diluent. This
premixing of labeled ligand with test (or control) ligand, and
subsequent transfer of 50 .mu.L aliquots to the assay plate was
carried out with a CETUS Propette robot; the final concentration of
the labeled ligand was 1 nM and the highest concentration of test
compound was 1.0.times.10-4 M. The competition occurred for two
hours after which all wells were washed with a plate washer as
before. Affinity purified horseradish peroxidase labeled goat
anti-biotin antibody was diluted 1:3000 in TBS.sup.+++/BSA and 125
.mu.L were added to each well. After 30 minutes, the plates were
washed and incubated with ODD/H.sub.2O.sub.2 substrate in 100 mM/L
citrate buffer, pH 5.0. The plate was read with a microtiter plate
reader at a wavelength of 450 nm and when the maximum-binding
control wells reached an absorbance of about 1.0, the final
A.sub.450 were recorded for analysis. The data were analyzed using
a macro written for use with the EXCELJ spreadsheet program. The
mean, standard deviation, and % CV were determined for duplicate
concentrations. The mean A.sub.450 values were normalized to the
mean of four maximum-binding controls (no competitor added)(B-MAX).
The normalized values were subjected to a four parameter curve fit
algorithm, [Robard et al., Int. Atomic Energy Agency. Vienna, pp
469 (1977)], plotted on a semi-log scale, and the computed
concentration corresponding to inhibition of 50% of the maximum
binding of biotinylated vitronectin (IC.sub.50) and corresponding
R.sup.2 was reported for those compounds exhibiting greater than
50% inhibition at the highest concentration tested; otherwise the
IC.sub.50 is reported as being greater than the highest
concentration tested.
.beta.-[[2-[[5-[(aminoiminomethyl)amino]-1-oxopentyl]amino]-1-oxoethyl]am-
ino]-3-pyridinepropanoic acid [U.S. Ser. No. 08/375,338, Example 1]
which is a potent .alpha..sub.V.beta..sub.3 antagonist (IC.sub.50
in the range 3-10 nM) was included on each plate as a positive
control.
Human Platelet Rich Plasma Assays
[1025] Healthy aspirin free donors were selected from a pool of
volunteers. The harvesting of platelet rich plasma and subsequent
ADP induced platelet aggregation assays were performed as described
in Zucker, M. B., "Platelet Aggregation Measured by the Photometric
Method", Methods in Enzymology 169(1989):117-133. Standard
venipuncture techniques using a butterfly allowed the withdrawal of
45 mL of whole blood into a 60 mL syringe containing 5 mL of 3.8%
trisodium citrate. Following thorough mixing in the syringe, the
anti-coagulated whole blood was transferred to a 50 mL conical
polyethylene tube. The blood was centrifuged at room temperature
for 12 minutes at 200.times.g to sediment non-platelet cells.
Platelet rich plasma was removed to a polyethylene tube and stored
at room temperature until used. Platelet poor plasma was obtained
from a second centrifugation of the remaining blood at 2000.times.g
for 15 minutes. Platelet counts are typically 300,000 to 500,000
per microliter. Platelet rich plasma (0.45 mL) was aliquoted into
siliconized cuvettes and stirred (1100 rpm) at 370.degree. C. for 1
minute prior to adding 50 .mu.L of pre-diluted test compound. After
1 minute of mixing, aggregation was initiated by the addition of 50
.mu.L of 200 .mu.M ADP. Aggregation was recorded for 3 minutes in a
Payton dual channel aggregometer (Payton Scientific, Buffalo,
N.Y.). The percent inhibition of maximal response (saline control)
for a series of test compound dilutions was used to determine a
dose response curve. All compounds were tested in duplicate and the
concentration of half-maximal inhibition (IC.sub.50) was calculated
graphically from the dose response curve for those compounds which
exhibited 50% or greater inhibition at the highest concentration
tested; otherwise, the IC.sub.50 is reported as being greater than
the highest concentration tested.
1 EXAMPLE NO. .alpha..sub.v.beta..sub.3 (IC.sub.50, nm) IIb/IIIa
(IC.sub.50, nm) 1 1.58 313 2 1.32 272 3 0.41 298 4 0.74 581 5 0.42
884 6 0.27 1260 7 0.21 361 8 95.1 857 9 0.18 244 10 0.14 161 11
0.34 462 12 4.5 442 13 9.32 780 14 12.4 772 15 25.4 1040 16 22000
6180 17 0.46 724 18 0.43 798 19 2.96 2490 20 0.32 2020 21 0.2 551
22 6.96 1710 23 3600 10100 24 91200 15800 25 1870 3910 26 0.71 831
27 0.26 482 28 0.43 984 29 0.46 1385 30 155 29.5 31 3942 1803 32
2.1 49 33 0.2 520 34 0.34 1203 35 0.14 340 36 1.13 970 37 63.8 267
38 278 115 39 1917 2458 40 1.5 20630 41 10.2 35400 42 3.1 5954 43
6.5 7527 44 42.1 1061 45 1094 1678 46 1.97 2693 47 0.99 6709 48 4.3
27910
* * * * *